THERMODYNAIMIC STUDY OF NUCLEIC ACIDS RECOGNITION BY AMINOGLYCOSIDES by Xi, Hongjuan
Clemson University
TigerPrints
All Dissertations Dissertations
12-2007
THERMODYNAIMIC STUDY OF NUCLEIC
ACIDS RECOGNITION BY
AMINOGLYCOSIDES
Hongjuan Xi
Clemson University, hxi@clemson.edu
Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations
Part of the Analytical Chemistry Commons
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by
an authorized administrator of TigerPrints. For more information, please contact kokeefe@clemson.edu.
Recommended Citation
Xi, Hongjuan, "THERMODYNAIMIC STUDY OF NUCLEIC ACIDS RECOGNITION BY AMINOGLYCOSIDES " (2007). All
Dissertations. 156.
https://tigerprints.clemson.edu/all_dissertations/156
i 
 
 
 
 
 
 
 
THERMODYNAIMIC STUDY OF NUCLEIC ACIDS RECOGNITION BY 
AMINOGLYCOSIDES   
 
 
A Dissertation 
Presented to 
the Graduate School of 
Clemson University 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 
Chemistry  
 
 
by 
Hongjuan Xi 
December 2007 
 
 
Accepted by: 
Dr. Dev P. Arya, Committee Chair 
Dr. Stephen E. Creager 
Dr. Jason D. McNeill 
    Dr. Jeffrey T. Petty  
 
 ii 
ABSTRACT 
 
 
Since the origin of first aminoglycosides antibiotics, streptomycin, isolated by 
Selman Waksman about 60 years ago, a number of aminoglycosides antibiotics were 
discovered to treat different infections. Neomycin class aminoglycosides were found to 
originally target the A site 16S rRNA in the 30S subunit of the ribosome within the 
Gram-negative bacteria. In addition to its antibacterial effect, aminoglycosides were also 
found to binding to various other viral RNA structures such as TAR and RRE of HIV, 
Group I introns and hammerhead ribozyme, implying its potential to be used as antiviral 
reagent. 
Furthermore, previous studies in our laboratory discovered a new class of targets, 
triple helix nucleic acids for aminolgycosides. Aminoglycosides, especially neomycin, 
shows potent stabilization effect of poly(dA)•2poly(dT), poly(rA)•2poly(rU), short-
mixed-base oligomers, an intramolecular 12-mer triplex, DNA/RNA hybrid 
duplexes/triplexes and even G-tetraplex. The binding infidelity of aminoglycosides 
induces a variety of problems such as drug resistance and adverse side effects, thereby 
diminishing their therapeutic application. Increase of aminoglycoside antibiotics binding 
selectivity has become imperative. Chemical derivatization, either modifying a specific 
functional group or conjugating them with other ligands, has developed quickly in the 
past decade to improve aminoglycosides selectivity and expand them for a new 
therapeutic application. Aminoglycosides dimer, intercalator-neomycin conjugate and 
minor groove binder-neomycin conjugate were synthesized and studied by our 
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laboratory. Primary study showed that the binding selectivity was achieved, for example, 
a neomycin dimer favors an AT-rich duplex at nanomolar scale. 
However, in order to understand better the aminoglycosides binding selectivity and 
achieve the different therapeutic applications, a comprehensive picture of 
aminoglycosides binding to a variety of nucleic acids is a requirement. Unfortunately, 
this study is still in lack. This work considers the neomycin class aminoglycosides, 
especially neomycin which has the most amino groups (6) relative to other 
aminoglycosides. The binding to a broad range of nucleic acids will be considered, and 
these targets include single strand RNA, AT/GC rich duplexes, TAT DNA triplex 
oligomer and polymer, AU rich RNA duplex and triplex, hybrid duplexes, G-tetraplex, 
polydC intercalating tetraplex, and A site 16S rRNA. The common thread of those 
structures that neomycin favorably binds to lies in their propensity toward an A-type 
conformation. The more A like the conformation is, the more favorably neomycin binds 
to it. The complete thermodynamic and kinetic studies of aminoglycosides interaction 
with various nucleic acids were conducted mainly via techniques including UV thermal 
denaturation, circular dichroism, fluorescence, differential scanning calorimetry, 
isothermal titration calorimetry, and surface plasmon resonance.  
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CHAPTER 1 
NUCLEIC ACIDS AND THEIR INTERACTION WITH SMALL LIGANDS 
 
Nucleic Acid Binding Ligands 
Introduction 
Ligands that can bind to nucleic acids have been the subject of much research   
for the past 50 years for two reasons: (1) DNA or RNA has been presumed to be the 
intracellular targets for various small ligands having diverse chemical structures; (2) 
The ligand-nucleic acid interaction creates the potential for regulating gene expression, 
replication, transcription and translation, resulting in therapeutic treatment for tumors, 
and viral and bacterial diseases. For both natural and synthetic ligands, however, these 
therapeutic applications also include, for example, side effects, drug resistances, and 
allergies, among others.  To understand the cause of these side effects, knowledge 
about how the ligands take effect in the organism is needed. The initial research in this 
area began with the discovery of the double helical DNA structure by Watson and 
Crick (1), a milestone in biochemistry which led to the study of the ligand-nucleic acid 
interaction at the molecular level. Understanding of the ligand-nucleic acid complex 
structure was attained with the help of such powerful structural or computational 
techniques as X-ray crystallography, multidimensional nuclear magnetic resonance, and 
computer modeling. These structural studies not only explain how nucleic acids interact 
with currently used drug molecules, but also help in the rational design of new ones.  
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 Small ligands, because of their biological, chemical and medical potential as 
chemotherapeutic agents, have increasingly become the focus in many labs. These 
small ligands that interact with nucleic acids can be divided into two main categories 
based on their binding modes: (1) Groove binders, which bind to either the major or 
minor grooves of nucleic acids via noncovalent interaction; (2) Intercalaters, which 
intercalate into the DNA base pairs via pi-pi stacking interaction. Most of the past 
research on small ligands has focused on these two fields. In this study, we will primary 
focus on the groove binders.  
 
Groove Binders 
 Groove binders are subdivided into minor or major groove binders, based on the 
binding site of the ligands, with their shape and size differing significantly. For 
example for a typical B form DNA, the major groove is wide and deep, while the minor 
groove is narrow and shallow. The significant difference of the dimensions of the two 
grooves attracts the very different-shaped targeting species, the major grooves being 
primarily the targets of proteins, specifically enzymes, due to their large approachable 
groove size. While most of the groove binders target specifically the minor grooves of 
the nucleic acids.  
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Minor groove binders 
 The classic minor groove binders include netropsin, distamycin, Hoechst 33258, 
berenil, DAPI and DODC. The common structural features for most minor groove 
binders include a crescent shape, positive charges and the linked rather than fused 
aromatic rings. They bind  predominantly to AT-rich sequences because the exocyclic 
NH2 amino group (N2) of the guanine hinders the efficient contact of the drug to the 
inner surface of the groove (2, 3). Several crystallographic and NMR studies of the 
complexes of a number of drugs such as berenil (4, 5) and netropsin (6, 7) have found 
that the drug molecules are stabilized by the hydrogen bonds formed between drug and 
the N3 atoms of adenines or O2 atom of thymines, as well as the close van der Waals 
interaction with the walls and floor of the groove itself. In addition, the greater negative 
electrostatic potential of the AT-rich regions compared to the GC-rich regions forms an 
efficient electrostatic interaction with drugs bearing multiple positive charges. 
Furthermore, the concave curvature of the inner surface of the drug molecules and the 
convex surface of the floor of the DNA minor groove itself promotes binding. This 
surface matching, referred as isohelicity (8), can be used to design novel groove 
binders.  
 Figure 1.1 shows the structures of representative minor groove binders. The 
resulting forces in the complexes are noncovalent, including the hydrogen bonds, van 
der Waals, the hydrophobic interaction and the electrostatic interaction. The shape and 
charge complementarities are the two most important factors responsible for AT 
preferring interaction of these minor groove binders.   
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Figure 1.1. Structures of representative minor groove binders. 
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Major groove binders  
Major grooves are believed to be the binding sites of proteins, and this 
recognition is responsible for the transcription. Blocking of major grooves of DNA and 
RNA by small molecules or other species, thus, can be potentially applied to prevent 
the occurrence of transcription. However, few small molecules bind to major grooves, 
most probably because of the lack of size complementarities between drug molecules 
and major grooves. Carbohydrates represent a class of DNA major groove binders 
because of their size and the intricate distribution of the hydrophobic and hydrophilic 
interaction within their molecular structure. But to date only a limited number of 
carbohydrates have been found to interact with DNA major grooves. Representative 
examples of these compounds include neocarzinostatin (9), altromycin B (10), 
hedamycin (11), respinomycin (12), rebeccamycin (13), nogalamycin (14), NB 506 
derivatives (13) and aminoglycosides (15) (Figure 1.2). These carbohydrates, upon 
binding to a major groove, display such characteristics as DNA cleavage 
(neocarzinostatin), alkylation (altromycin B), and intercalative-groove binding 
(nogalamycin).  
 Neocarzinostatin is used here in order to explain the binding of a ligand-major 
groove interaction more specifically. The spirolactone cumulene intermediate formed 
by the base-catalyzed intramolecular attack within neocarzinostatin will experience a 
Bergman-type arrangement, and then induce a bulge in the DNA upon binding. The 
computer model clearly shows that the neocarzinostatin molecule acts as a “wedge” 
within the groove, with the two fused rings closely stacked in the DNA helix and  the 
 6 
carbohydrate portion of the molecule sitting on the floor of the major groove of the A-T 
step in the DNA 5’-d(CCCGATGC-L-GCAATTCGGG)-3’. Here ‘L’ denotes the 
triethylene glycol linker (16).  
 In looking for the new major groove binders, aminoglycosides antibiotics, a new 
class of ligands, have shown their preference to the major grooves of either DNA or 
RNA in the past decade. Here we will introduce these ligands in detail.  
Altromycin
Neocarzinostatin Hedamycin
NB-506
NogalamycinRebeccamycin
 
Figure 1.2. Structures of some representative major groove binders . 
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Aminoglycoside antibiotics 
Aminoglycoside antibiotics, another class of major groove binders, have been 
studied extensively over the past twenty years, although their application began 
approximately a half century ago. This class of compounds represents the naturally 
occurring pseudo-oligosaccharides containing highly positive charges. The common 
structural feature of most aminoglycosides is 2-deoxystreptamine (2-DOS),  its linkage 
with hexoses and pentoses via glycosidic bonds at the 4 and 5 or the 4 and 6 positions 
generating most aminoglycosides (Figure 1.3).  One important property of the 
aminoglycoside structure is that it contains multiple amine groups on different sugar 
rings, a situation contributing to their effective binding with nucleic acids.  
The first aminoglycoside antibiotic, streptomycin, isolated from Streptomyces 
Griseus by Selman Waksman in 1944, became the second antibiotic (after penicillin) in 
the clinical treatment of tuberculosis (17). However, its bactericidal properties were not 
explained until 1964. The landmark work done by Davies and others showed that the 
binding site of streptomycin is within the 30S unit of the 79S ribosome (18).  The 
function of this drug is to inhibit the fidelity of translation between ribosome and 
mRNA, inducing inefficient protein production resulting in consequent cellular death.  
Since the first discovery of aminoglycosides, a number of molecules in the 
aminoglycosides family have also been found to be effective antibiotics. Neomycin 
(19), which was isolated from streptomyces fradiae, was originally used to treat 
infections caused by aerobic gram-negative bacteria, as was Gentamicin, isolated from 
Micromonospora Purpurea in 1963.  Amikacin, a semisynthetic derivative of 
 8 
kanamycin, is currently used to treat infections caused by pseudomonas aeruginosa, 
acinetobacter, and enterobacter.  
Other aminoglycosides include netromycin, tobramycin, butirosin, isepamicin, 
kanamycin and spectinomycin which were also discovered subsequently, some of 
which are used clinically today. Most aminoglycosides work by binding to the 16S A 
site within the 30S ribosomal subunit, inducing a conformational change of the A site 
that leads to the displacement of two adenine residues (A1492 and A 1493) toward the 
minor groove, where they interference the anticodon-codon interaction, thereby causing 
a mistranslation, making the bacterium unable to synthesize the proteins vital to its 
growth (20).  
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Figure 1.3. Representative chemical structures of aminoglycosides antibiotics and pKa 
values for some well studied structures.  
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However, the exact mechanism of this action is not yet fully known. The current 
therapeutic application of aminoglycosides has been reduced because of the 
development of drug resistance coupled with the adverse side effects of renal toxicity 
and ototoxicity. There are three type of aminoglycosides resistance recognized today, 
namely ribosome  alternation (21), decreased permeability(22), and the inactivation of 
the drugs by aminoglycoside-modifying enzymes (23-25). Ribosome alternation, which 
induces a high-level resistance to streptomycin and spectinomycin, is causes bya single-
step mutation in chromosomal genes encoding the rebosomal proteins (26). Decreased 
permeability results from an alternation in the aminoglycoside transport system such as 
inadequate membrane potential or modification in the lipopolysacchaccarides 
phenotype. This type of alternation may induce a cross resistance to all 
aminoglycosides. The inactivation of aminoglycosides is caused by enzymes which 
modify the structure of the drug molecule, resulting in its subsequent disfunction.  Such 
enzymes include ACC (acetyltransferases) (27-30), ANT (nucleotidyltransferases) (31, 
32), and APH (phosphotransferases) (33).  
Several methods have been to proposed to reduce the nephrotoxity and 
ototoxity, both of which can lead to the renal and vestibular failure associated with 
aminoglyosides (34). One of the methods,  the population pharmacokinetic program, is 
used to control the aminoglycoside serum concentration and  to predict the efficady, but 
the estimation of the drug concentration is not completely reliable.  Another approach is 
to combine the molecular modeling and analog synthesis to develop less toxic 
aminoglycosides, but this approach is expensive and time-consuming. A third method, 
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co-administration of polyaspartic acid and defferoxamine, appears to be a protective 
approach showing promise  in clinical practice (34).  
When investigating the binding property of aminoglycosides in organisms, it is 
first necessary to analyze their structures. The common feature of neomycin-class 
aminoglycosides is that they all contain several amino groups, with different pKa 
values. Those amino groups play important roles either in forming either hydrogen 
bonds or in electrostatic interaction. The difference in the pKa values can be attributed 
to the steric effect of the spatial arrangement and the hydrogen bonds from the 
neighboring hydroxyl and amino groups on the sugar rings. The pKa values of 
neomycin B, paromomycin I, and lividomycin A sulfate have been determined by Pilch 
using pH-dependent 15N NMR spectroscopy, the results ranging from 6.92 to 9.51 (35). 
These values are higher in magnitude than those observed in pKa associated with the 
free base form (36). These higher pKa values in the sulfate form of neomycin are due to 
the interaction of drug with sulfate anions at the high drug concentration used in the 15N 
NMR studies (35). It has been reported that the binding of aminoglycosides to A site 
16S rRNA oligonucleotide involves the protonation of amino groups in drugs (37). The 
protonation of aminoglycosides is driven by binding with the number of protons 
transferred in the interaction being system dependent. To date, the binding of 
aminoglycosides to their natural target A site 16S rRNA has induced the highest 
protonation of the amino groups at physiological pH, 1.42 for neomycin, 1.55 for 
paromomycin, and 1.11 for ribostamycin (37).  In addition, the protonation of amino 
groups is position and temperature dependent. The number of protons taken by the 
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aminoglycosides can be obtained using the buffer-dependent approach, which is 
accomplished through isothermal titration calorimetry (ITC) (37). 
Even though aminoglycosides were found effective in treating gram-negative 
bacteria much earlier, their exact binding site was not identified until 1996. Moazed and 
Noller initially found that neomycin and related aminoglycosides bind directly to the 
conserved sequences of 16S rRNA, partially forming aminoacyl-tRNA (A site) and 
peptidyl-tRNA (P site) within the 30S ribosomal subunit (38). Later it was learned that 
the neomycin-class aminoglycosides bind to the asymmetric internal loop of the A-site 
16S rRNA duplex rather than the P site in the 30S subunit (39, 40). Currently, it is 
known that most neomycin-class aminoglycosides bind to the 16S rRNA.  In addition 
to the natural target A site 16S rRNA, aminoglycosides have also been found to bind to 
other nucleic acids with strong binding. Patel and co-workers found that tobramycin 
binds to a RNA aptamer in a manner such that the drug is centered at the hairpin loop-
stem junction site (41). NMR studies of both A site 16S rRNA and RNA aptamer 
demonstrated that aminoglycosides bind to RNA major grooves that are distorted by the 
either a loop or a bulge (41), and an NMR study conducted by Shafer and Kuntz 
showed that aminoglycosides are also directed to the major groove of a normal RNA 
duplex (42).  In addition to A-form RNA duplexes, aminoglycosides have shown their 
capability to bind to the major groove of a 34mer DNA d(A2G15C15T2)2  by converting 
the DNA conformation from B to A (43), with the cationic ligands interacting with 
bases on the floor of DNA major groove.  
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However, even though aminoglycosides have been shown to bind to the DNA 
duplex, those sequences are limited to the GC-rich duplexes. The binding preference of 
aminoglycosides for AT-rich duplexes has not been found under physiological 
conditions. Recent work conducted in Arya’s laboratories provided the evidence for 
neomycin-class aminoglycosides recognition by AT-rich duplexes in a nanomolar 
range. Dual groove-binding ligands, such as neomycin-Hoechst 33258 conjugate (15) 
and neomycin-neomycin dimer (44), were developed and studied for their binding 
affinity to B form AT-rich duplexes. This study was conducted using UV thermal 
denaturation technique. A poly(dA).2poly(dT) triplex was formed in the physiological 
condition (pH 7.2 and 150 mM KCl) in the absence of ligands, observed as a 
hyperchromic transition in the UV melting profile. However, in the presence of ligands, 
the triplex transition disappeared. This phenomenon can be explained as the neomycin 
inhibition of the third poly(dT) strand from binding to the major groove of the 
poly(dA)•poly(dT).  The molecular modeling of the neomycin-Hochest 33258 
conjugate interacting with d(CGCAAATTTGCG)2 showed that the neomycin binds 
within the major groove at multiple contacts and Hochest 33258 binds to the central 
A3T3 region (15) (Figure 1.4). The binding affinity of neomycin-Hochest 33258 to AT-
rich B form duplex, approximately 108 M-1, is comparable to Hochest 33258 alone (15).  
 Another important function of aminoglycosides, found in Arya’s laboratories, 
involves stabilizing the higher order nucleic acids such as DNA and RNA triplex (45, 
46). Among the aminoglycosides antibiotics studied, neomycin has been found to 
stabilize the triplexes significantly (46). The binding of neomycin to triplex is selective 
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since it shows no binding to duplexes at physiological pH. The binding site is within 
the major groove, specifically, the Watson-Hoogsteen groove formed by the association 
of the third strand with the duplex (47). This finding prompted the exploration of 
additional nucleic acid structures to which aminoglycosides could potentially bind, 
leading to the conclusion that aminoglycosides bound structures do not end with 
triplexes. It was found using competition dialysis and ITC studies that neomycin binds 
to 16S A site rRNA and RNA strongly. In addition, non-RNA structures, such as 
poly(dG)•poly(dC), DNA triplex, tetraplex, DNA/RNA hybrids, were shown to bind 
neomycin as well (48). A close investigation of these unexpected structures revealed 
that all possess A-like conformation, a finding unraveling the ties that hold nucleic acid 
structures together as the specific sites for aminoglycosides recognition: it is the A-like 
conformation of nucleic acids, not only the RNA, that drives the binding of such 
aminoglycosides as neomycin.  
 
Figure 1.4. Computer model of neomycin-Hoechst 33258 conjugate docked into 
duplex d(CGCAAATTTGCG)2 (15). 
 15 
Intercalators 
 DNA-intercalating ligands have received great attention because intercalation 
was the first binding mode used to explain the biological activity of a compound (49). 
These ligands, namely intercalators, possess planar aromatic ring systems (typically 
two or three six-membered rings in size) able to insert themselves between adjacent 
base pairs in DNA, resulting in the elongation of DNA (3.4 A per bound drug 
molecule) and the partially unwinding of the intercalating area (changing the helical 
twist of the base pairs). The complex formed is reversible. Lerman, the first one to 
hypothesize the intercalation mode, suggested that the planar drug chromophore is 
stabilized by the pi-pi stacking interaction and the van der Waals dispersion interaction 
between its planar group and the base pair surrounding it (49). In contrast to minor 
groove binders, intercalators are typically characterized by a rather low affinity for 
DNA due to the local rearrangement and significant distortion of the DNA. The classic 
intercalators include ethidium bromide, acridine orange, proflavine, nogalamycin, 
actinomycin, anthracyclines, lymphoma, and daunomycin, etc (some representative 
structures are shown in Figure 1.5). Some of them, such as actinomycin and 
daunomycin, have been clinically used as antitumor drugs. The intercalator-base pair 
recognition does not exhibit much sequence selectivity, with only a very small 
preference for the pyrimidine- 3’, 5’-purine sequences (50). However, attaching 
additional groups such as side-chains, sugar rings, or peptide units can improve the 
direct sequence-specific readout. In these complexes, thee attached groups reside in the 
DNA groove to form the van der Waals interaction and hydrogen bonds with adjacent 
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base pairs, while the fused ring moiety will intercalate as usual (51). The dual binding 
mode improves the selectivity and the binding affinity of the intercalator to DNA. 
Some groups also synthesized the bis-intercalators such that two chromophores 
intercalate into two separate base pairs, signigicantly increasing the binding affinity. 
For example, bis-methidium exhibits a binding constant to calf thymus DNA of 4×109 
M-1, much higher than to its parent compound ethidium bromide 3×105 M-1 (52). Tri-
recognition intercalator, such as nogalamycin, has also been synthesized to combines 
both intercalation and groove binding modes. (14). The aglycone group of the 
nogalamycin molecule holds in the minor groove and amino sugar sits in the major 
groove, with its drug chromophore itself intercalating into the GC base pairs as 
expected, thereby providing simultaneous major-minor groove directed binding and 
intercalation (14). Arya laboratories have developed intercalator-groove binder 
conjugates with the aim of achieving dual recognition. BQQ-neomycin, pyrene-
neomycin, anthraquinone-neomycin, and naphthalenediimide-neomycin were 
synthesized and found to show significant preference for the poly(dA)•2poly(dT) 
triplex while having much less effect on the duplex poly(dA)•poly(dT) (unpublished 
data). Methidium-neomycin, which was synthesized recently in the same laboratory 
(unpublished data), was found to exhibit selective binding to hybrid duplex 
poly(dA)•poly(rU), with a high binding affinity in the nanomolar range. Computer 
modeling depicted the possible binding of conjugates to those nucleic acids structures, 
with the intercalator portion stacking into the base pairs and the neomycin portion  
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Figure 1.5. Chemical structures of some representative intercalator structures.  
  
binding within the major grooves. Such dual recognition ligands open the door for the 
design of more selective and potent compounds for targeting specific sequences. 
 This class of compounds is important in cancer chemotherapy. Even though the 
exact mechanism is still being studied, topoisomerases, a strand that temporary cuts one 
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strand of DNA during replication to help unwind the double helix, is suggested as the 
mechanism of action for such clinically useful intercalators such as adriamycin. 
Intercalator drugs prevent the topoisomerares from reattaching the cut ends, thereby 
stopping cell division (53), causing the  death of any dividing cells. Since most human 
cells are not dividing all the time, these drugs preferentially kill cancer cells. However, 
some types of quick dividing human cells such as bone marrow, gastrointestional tract 
and hair follicles, which divide rapidly, are also killed by chemotherapy drugs, 
explaining the side effects caused by cancer drugs.  
 19 
Adenine guanine
Thymine Cytosine Uracil
Pyrimidine
O
OHOH
base
HO
Ribose sugar in RNA
O
OH
base
HO
Deoxyribose sugar in DNA
Purine
 
  
Figure 1.6. DNA and RNA nucleobases and the sugar structures.  
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Nucleic Acids and Their Interaction with Ligands 
Introduction 
 Currently, there are two categories of nucleic acids: deoxyribonucleic acid 
(DNA) and ribonucleic acid (RNA). The base unit of nucleic acids, called the 
nucleotide, contains a sugar, a phosphate and a nitrogen-containing base. Four different 
types of bases are found in nucleic acids: Adenosine (A), Guanosine (G), Cytidine (C), 
and Thymidine (T) for DNA or Uridine (U) for RNA (Figure 1.6). DNA is a double-
stranded molecule twisted into a helix. The recognition of one stand by another one is 
governed by a base-base hydrogen bonding, called Watson-Crick, on opposite strands, 
usually A paired to T or U and G paired to C. All living organisms (except viruses) 
contain DNA, the genetic material for organism development and growth. Nucleic acid, 
one of three important biological macromolecules, carries the code for the synthesis of 
specific proteins, with different triplet combinations of bases responsible for one amino 
acid. It also contains two intertwined strands, usually only one of the two codes for a 
specific DNA. A length of DNA sequence that codes for an entire protein is called 
gene.  Replication of DNA itself also needs the current DNA as a template. RNA, 
different from DNA, contains only one strand and is generally smaller than DNA. The 
sugar in RNA is also slightly different from DNA, accounting for their names. RNA, 
the primary genetic material in viruses, is also responsible for the protein synthesis in 
the living organisms other than viruses. Based on the different functions RNA serves in 
organisms, RNA can be categorized as messenger RNA (mRNA), transfer RNA 
(tRNA), and ribosomal RNA (rRNA). In the protein synthesis, the genetic information 
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of DNA is first copied into mRNA (a process called transcription); then mRNA carries 
information along with tRNA to the ribosome to synthesize the amino acids (a process 
called translation) that make a protein (Figure 1.7), the material essential for cellular 
function and subsequent cell growth.  
 
DNA  replication
Transcription
Translation
 
Figure 1.7.  Three important biological processes for synthesis of genetic information. 
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Minor groove binding Intercalation
Triplex Tetraplex
 
 
Figure 1.8. Two main binding modes by small molecules (groove binding and 
intercalation) to duplex DNA (7, 54), and structures of two high order nucleic acids 
(triplex (55) and tetraplex (56)).  
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 Even though both nucleic acid and protein are linear polymers formed from a 
monomeric unit, the nature of the linkage between these monomers is quite different. 
The phosphate backbone of nucleic acids carries a permanent negative charge and 
displays a relatively large degree of freedom, whereas the rigid planar peptide linkage 
in the protein is neutral and affords less freedom as compared to nucleic acid. Even 
though these properties make the structure of nucleic acids relatively flexible and less 
able to form extensively folded structures, however, they can form structures includeing 
single, double, triple and even quadruple strands, all of which exist naturally or are 
induced by ligands.  
 One approach of chemotherapy is to target different structures of nucleic acids 
(single strand, duplexes, triplexes and G-quadruplexes) (See structures of higher order 
DNA in Figure 1.8), thus interfering with their function and inhibiting cell growth. 
Figure 1.7 illustrates the important biological process involved in cell replication. 
Targeting the DNA duplex with a small ligand or a triplex forming third strand can 
inhibit the replication of DNA itself and subsequent transcription. A DNA/RNA hybrid 
is formed during the transcription process. By targeting and stabilizing the resulting 
DNA/RNA hybrid, either the transcription or the reverse-transcription is inhibited. 
Single-strand RNA can be targeted by small ligands to form secondary physiologically 
stable structures or by other strands to form a duplex or a triplex, thus potentially 
stopping the transcription and translation. This approach has seen initial success in 
treating the diseases such as cancers and other tumors. However, since those anti-
cancer drugs also attack normal cells unexpectedly, they can cause severe side effects. 
 24 
Increasing the drug selectivity, important in the treatment of various malignant 
diseases, has been the long focus in the chemotherapy research. In achieving this 
purpose, nucleic acid biophysics has served as the fundamental basis in relating the 
structural information to the thermodynamic stability and functional properties of those 
complexes formed between drug and nucleic acid.  Thermodynamic stability is 
concerned exclusively with the difference in free energy between the final 
conformational state and the original free component state.  In general, the denaturation 
of high ordered, compact nucleic acid to a less compact and more flexible state is 
expected to be associated with an increase in both entropy and heat capacity 
change (∆Cp). The term ∆Cp is fundamental in understanding the origins of both the 
stabilized nucleic acid structures and their interactions with ligands. Thus, the studies of 
the thermodynamics of small molecule-nucleic acid interactions provide important 
insight into the forces that drive bimolecular interactions.  
 
Single Stranded Nucleic Acids 
 Single strand nucleic acids do not form unique structure  but rather partially 
stacked helixes or random coils(57, 58), with the degree of stacking being strongly 
temperature, ion-strength or pH dependent (57, 58). Among those single nucleic acids, 
poly(A) and poly(U) have attracted much attention due to their ability to form higher 
order or other secondary nucleic acid structures, and the importance of their biological 
functions in cell growth. It has been demonstrated that the poly (rA) can form A-A 
duplex with parallel strands and protonated adenine bases under acidic conditions (57, 
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59, 60). However in the neutral condition, it exists as a flexible and irregular helix, the 
two chains being held together at low pH via hydrogen bonds between adenine 
residues. Different from the standard double stranded nucleic acid, the 
poly(rA).poly(rA) duplex is hypothesized to be an interrupted helical model (57). 
 It is known that poly(A) structure play an important role in gene expression in 
eukaryotic cells. All mRNAs in eukaryotic cells contain a poly(A) tail at the 3’ end that 
is important for the maturation and stability of mRNA and for the initiation of 
translation (61, 62). Post-translational polyadenylation of mRNA is catalyzed by the 
enzyme poly(A) polymerase. Recent studies have found that neoPAP, a human 
polyadenylic polymerase, is significantly over-expressed in human cancer cells (63, 
64). Thus, the new cancer therapeutic agents can be developed, ones that bind to the 
poly(A) tail of mRNA and thereafter interfering with mRNA processing by PAP. 
However, very few molecules are known to bind to a poly(A) single structure or to 
stabilize the poly(A)•poly(A) duplex at neutral pH. Of this small number of ligands, 
berberine (65), coralyne (66), and palmatine (67) have been studied. Berberine binds to 
single strand poly(A) through a mechanism of partial intercalation rather than inducing 
a corresponding duplex.  Coralyne also induces a secondary structure when binding to 
single strand poly(A), with a melting temperature at 60oC. Coralyne is unique in its 
selective recognition of poly(dA) and poly(A) (66, 68), its exact binding mode not yet 
clear. Research on the interaction of neomycin with poly(A) has found that a secondary 
structure, but not a duplex conformation, is formed. 
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 It has been reported that poly(U) does not possess any specific structure at 
ambient temperatures, indicating a lack of stacking interaction between uridine bases, 
thereby leading to a random-coiled conformation (69). However, poly(U) can form an 
antiparallel duplex structure held by hydrogen bonds between base pairs at low 
temperatures (<10oC). The ligands capable of binding to poly(U) are rare. Neomycin 
was found to increase the stability of the poly(U)•poly(U) duplex of approximately 10 
oC. Under physiological conditions, however, poly(U) displays only as a random coil, 
strongly suggesting its possibility of associating with single strand poly(A) to form 
poly(A).poly(U) duplex.  The formation of poly(A).poly(U) duplex was demonstrated 
to be capable of increasing the number of antibody–forming cells four or five times 
(70). The formed poly(A)•poly(U) was then tested in human beings as an adjunct for 
surgery  for breast cancer, the treatment increasing the survival rate from 57% to 71% 
in the control group (71, 72). Since no significant toxicity was observed using this 
poly(A).poly(U) treatment, this approach is undergoing further testing in clinical trials.  
 
Double Stranded Nucleic Acids 
 Double stranded nucleic acids, specifically DNA, are the dominant nucleic acid 
structure in the organisms. First discovered 1860s in the nuclei of human blood cells by 
Johann Friedrich Miescher in (73), its 3-dimentional structure was not fully understood 
until Fames Watson and Francis Crick described it using the results from X-ray fiber 
diffraction in 1953 (1), proposing DNA as a right-handed double helix (Figure 1.8). 
The five-membered-ring sugars are linked by a phosphate group, peripheral to the 
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structure, while the base pairs are buried deep inside the structure. This structural 
property of DNA protects the base pairs from chemical modification by the 
physiological environment, thereby retaining unchanged the genetic information stored 
in it. As shown in Figure 1.9, the purines (A and G) and pyrimidines (C, T or U) are 
connected to the anomeric carbon of the furanose ring at N9 position on the purines and 
at N-1 on the pyrimidines via a β-glycosidic linkage.  
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Figure 1.9. Hydrogen bonds between nucleic acid base pair and the phosphodiester 
backbone.  
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 The two strands of DNA are oriented antiparallel to each other.  Using the two 
ways to link to the sugar of the backbone; 3’ and 5’, the convention for describing the 
orientation of DNA sequence is to proceed along the chain in the 5’ to 3’ direction. In a 
typical sequence, the 3’-sugar carbon of one nucleotide is linked via a phosphate to the 
5’-sugar carbon of the adjacent one. The bond formed between these two nucleotides, 
termed as 3’-5’ phosphodiester bond, always remains deprotonated, carrying a negative 
charge under physiological conditions (Figure 1.9).  
 Hydrogen bonds formed between the Watson-Crick base pairs are different 
between A-T and G-C pairs (Figure 1.9). Adenine pairs with thymine via two hydrogen 
bonds and guanine forms three hydrogen bonds with cytosine. The more hydrogen 
bonds formed in the G-C pairs explain the high melting temperature and the melting 
enthalpy associated with GC-rich DNA sequences. The specific base paring of DNA 
ensures fidelity in genetic information transferring processes such as transcription and 
translation. In addition to the Watson-Crick base pairing, other possible base pairing 
modes have also been discovered, including C-C, A-A, U-U, A-T Hoogsteen, and A-T 
reverse Hoogsteen. However, most of their formations need specific conditions such as 
temperature and pH.  
 In addition to hydrogen bonding, another important factor contributing to the 
stability of the double helix is the pi-pi base stacking. The aromatic and planar base 
structures stack on top of one another and rotate slightly relative to one another. The 
base pair reside in a plane that is perpendicular to the double helix axis. The 
arrangement of the backbone of two single stands constructs two grooves, the major 
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and the minor grooves. Based on the width and depth of the two grooves, the duplex 
conformation can be divided into three main categories: A-form, B-form and Z-form 
(Figure 1.10). In addition, there are two primary sugar pucker conformations: C2’-endo 
(anti) and C3’-endo (syn). Particular conformation adopts specific sugar pucker 
conformations. A-form and B-form nucleic acids adopt a C3’-endo and C2’-endo, 
respectively, while the Z-form structure takes a combination of C3’-endo and C2’-endo 
alternatively.  In the C2’-endo sugar conformation, the C2 and N3 face of the 
pyrimidines and the N1 and C2 face of the purines are away from the sugar ring; 
therefore, the hydrogen atoms attached to the C8 of the purine and the C6 of the 
pyrimidine lie over the sugar ring. In the case of the syn conformation, the orientations 
are reversed.  
 These different sugar pucker conformations directly affect the conformation of 
the helix structure. The diameter for A-form DNA is 26 Å, while in the B-form DNA it 
is only 20 Å. In every helical turn in the A-form, there are 11 residues, one more than 
that for the B-form. The major groove of the A-form structure is deeper and narrower 
than of the B-form one, while the minor groove is wider but shallower in the A-form 
than for the B-form. Z-form DNA, first solved by Alexander Rich and co-workers in 
1979, was found to have a zigzag, left-handed DNA structure (74). In general, 
formation of this structure is not favorable, although certain conditions such as 
alternating purine-pyrimidine sequence, DNA supercoiling or high salt solutions can 
induce it. While the definitive biological significance of this DNA conformation has not 
yet been found, it is known that it provides supercoiling as DNA transcription occurs. 
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 In contrast to the DNA duplex, RNA tends to adopt only the A- and Z-forms 
(75). In general, the DNA duplex tends to form B-form, while the RNA duplex prefers 
to adopt the A-form structure. This difference is primarily due to the sugar C2’-OH 
group. This hydroxyl group renders the RNA minor groove more hydrophilic than the 
deoxyriboses, tending to force the formation of a C3’-endo ribose, an energetically 
stable state in the A-form.  
 Neutralization of the DNA/RNA backbone is another method for stabilizing 
DNA or RNA duplexes. Charge repulsion occurs when more than one DNA single 
strand forms a high order structure since the negative charge density is too high to hold 
the structure. To overcome this barrier to form a double helical structure, metal ions 
such as sodium, potassium and magnesium and polycations like aminoglycosides can 
be used to neutralize the electronegative potentials in the backbone, thus minimizing 
the repulsion effect. 
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Figure 1.10. Three main conformations adopts by nucleic acid and two sugar puckering 
modes.  
 
 The various conformations that DNA can adopt exhibit different binding 
properties upon interacting with small ligands. As discussed previously, the small 
ligands bind to duplex DNA/RNA mainly via intercalation and groove binding. Since 
the major groove is larger than the minor groove, the majority of groove binders 
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selectively bind to the minor groove because their charges and shapes are 
complementary. In addition to the groove size, the binding of small ligands to the 
duplex is also sequence dependent.  For example, Hoechst 33258 prefers AT-rich 
duplexes (76), with imidazole-pyrrole-pyrrole (Im-Py-Py) (77) recognizes the GC base 
pair. For most drug-DNA interactions, these small molecules essentially act as a rigid 
body, with little conformational change upon binding. However, the DNA/RNA duplex 
conformation may be changed upon binding. 
 In describing the B-form DNA minor groove recognition, the lexitropson family 
of compounds, typically netropsin and distamycin, have been studied extensively due to 
their inherent high affinity for DNA duplex. Because of the changes in the minor 
groove width and the unusually flexible TpA base step, the particularly binding 
preference for these compounds is 5’-AATT and 5’-ATAT rather than 5’-TTAA and 
5’-TATA (78), (79). Structural analyses obtained through NMR and crystallographic 
studies have indicated that the recognition of a ligand by DNA arises from H-bonded 
contacts with A/T (N3 and O2), electrostatic interaction with the backbone of theDNA, 
and the van der Waals interaction with the floor and the walls of the groove. It has also 
been observed that the stacking interaction between the O4’ atom of sugar and the 
pyrrole ring of the ligand contributes to the stability of the complex formation (80).  In 
addition to the structural findings, binding of lexitropsin with the DAN minor groove is 
also accompanied by high binding affinity, favorable enthalpy change and binding 
entropy (81). The thermodynamics of drug-DNA interaction has been the focus of 
much past research; however, the recent introduction of the high sensitive 
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microcalorimetric technique has made this study in this yield more straightforward. 
Consistent with other minor groove binding ligands, the interaction between lexitropson 
and DNA are characterized by enthalpy-entropy compensation mechanisms. Studies 
have shown that netropsin has a binding affinity of 4.3×107 M-1 at 1:1 binding to the 
A3T2T3 oligomer, with the entropy change contributing more to the binding free energy 
than enthalpy (82). However, significant differential effects have been observed in the 
binding of netropsin to poly(dA)•poly(dT) and poly(dA-dT)2 duplex systems, 
suggesting that conformational change plays an important role in the binding 
(poly(dA).poly(dT) experiences a conformational change) (83). Additional classic B-
form DNA minor groove binders such as berenil, Hoechst 33258, and propamidine 
have also been studied, results indicating binding affinities in the range of 105 – 107M-1 
and the heat capacity changes (∆Cp) in the range of -150 ~ -400 cal/mol.K. The ∆Cp 
value for minor groove binders is typically higher than for intercalators, for which this 
value is usually less than -200 cal/mol.K (84).  
 Recently, the study developed in Arya’s laboratories has found B-form DNA 
recognized by aminoglycosides, which were previously thought to have no effect on B-
form DNA. This recognition, specifically dual recognition, was achieved by 
synthesizing the neomycin-Hoechst 33258 conjugate (15) or the neomycin-neomycin 
dimer (44) and then binding them to the B-form duplex, in particular the AT-rich 
sequences. It was found that this binding affinity is significantly higher (approximately 
2 orders) than the classic B-form DNA binders mentioned previously. These findings 
open the door for the development of compounds that target the B-form DNA duplex. 
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 Recognition of A-form nucleic acid, in particular the RNA duplex, by small 
ligands, however, exhibits a higher binding affinity than the B-form DNA systems. A 
good example is the 16S A site rRNA interaction with aminoglycosides (37). As 
discussed above, this system was found to achieve a high binding affinity in the 
nanomolar range, but different from the B-form DNA-minor groove binder system, this 
binding is predominately enthalpy driven and the binding site is within the major 
groove of the RNA.    
 Very few small molecules, however, have been found to be able to bind to the 
DNA•RNA hybrid duplex. Recent report has shown that ethidium bromide is the 
preferred catalyst for this hybrid recognition (85). The binding affinity is in low 
micromolar range. Aminoglycosides, were also found by Arya to bind to this hybrid in 
the 100 nM range. The methidium-Neomycin conjugate (NM) was subsequently 
synthesized to achieve a high binding affinity and specificity of drug binding to 
DNA•RNA hybrid.  Initial results have shown the powerfulness of this conjugate, 
which binds to the DNA•RNA hybrid specifically at an affinity of approximately 0.1 
nm (unpublished data).  
 In conclusion, the recognition of B-form DNA by small ligands usually exhibits 
a lower affinity than the A-form-small ligand recognition system. However, the dual 
recognition achieved by the ligand dimer of the ligand-ligand conjugate increases the 
binding affinity and specificity dramatically, potentially increasing the potency of 
chemotherapy associated with duplex nucleic acids.  
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Triple Stranded Nucleic Acids 
 Triple stranded nucleic acid (triplex), first proposed by Pauling and Corey in 
1953 on the basis of X-ray diffraction (86), was confirmed by Felsenfeld in 1957 
through UV technique (87). The homopyrimidine.homopurine tracts of duplex DNA 
are known to be the targets of triplex formation through the major groove association of 
a TFO via Hoogsteen hydrogen bonding. The requirement to form a triplex structure is 
quite stringent: in most cases the duplex must contain an all-purine strand paired with 
an all-pyrimidine strand in the major groove, with the formed Hoogsteen bonds not as 
stable as the Watson-Crick base pair. The two possible motifs for triplex structure, 
based on the orientation of the third strand as well as the purine strand of the duplex, 
are antiparallel and parallel. In the antiparallel motif, the third strand contains all purine 
A or G, thereby forming an A-A.T or G-G.C triplex with the third purine strand parallel 
to the purine strand on the duplex. In the parallel motif, the third strand contains only 
pyrimidine, thus forming a C-G.C and T-A.T triplex. However, cytosine needs to be 
protonated at N3 in the C+-G.C triplex in order to form two H-bonds (Figure 1.11), 
requiring the pH of the solution to be as low as 5, a level much lower than the 
physiological condition. As a result, the formation of this type of triplex is limited in 
biological systems. As its name suggests, in this motif the orientation of third 
pyrimidine strand is parallel with respect to the center purine strand. Not limited to the 
DNA triplex, molecular modeling studies have shown the possibility of having a variety 
of triplexes, with compositions varying from all-DAN to all RNA even though not all 
of them are stable (88, 89). The research reported here focuses on the T-A.T triplex for 
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two reasons: (1) the C+-G.C triplex is unlikely formed in the biological system, and (2) 
The antiparallel motif of the triplex structure is not as energetically favorable as the 
parallel motif of triplexes under near physiological conditions, exhibiting a high 
dependence on the high concentration of divalent ions such as Mg+ for its stability (90). 
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Figure 1.11. Hydrogen bonds depiction of parallel and antiparallel DAN base triplets.  
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 To date, the only full and detailed conformational information about the DNA 
triplex comes from NMR studies. The basic observations of these NMR-derived 
parallel triplex structure are consistent: (1) The minor groove of the duplex is 
compressed, and (2) The helical axis of the duplex is displaced approximately 2 Å (84). 
In addition to the conformational change, the stability of the triplex has found to be 
much lower than its corresponding duplex because of the charge neutralization resulting 
from the high electronegative potential formed when three backbones are associated 
with one another. Bringing in a positive charge on the third strand (91), replacing the 
phosphodiester with a peptide at the backbone (PNA) (92), introducing the ionic 
strength of the solution ( for example, Na, P, Mg) (90), and applying polycations 
(aminoglycosides) (46), all have been shown to increase the stability of the triplex 
effectively.  
 Even though the formation of triplex is slow and less stable than the formation 
of duplex, this structure has received much attention as an antigene strategy. Triplex 
forming oligonucleotide (TFO) has served as a potential genetic drug regulating the 
gene expression after binding. Triplex formation also performs numerous functions in 
biological systems. The replication of polynucleotide is inhibited by the third-strand 
binding. In addition, HIV DNA has been reported to be inhibited from integrating into 
host genomes (93). Cooney and his coworkers have demonstrated the specific 
inhibition of transcription by means of triplex formation at the 
poly(purine).poly(pyrimidine) sites in the promoter regions (94). Wang used TFOs to 
study the molecular mechanism of triplex-mediated TCR (transcription-coupled repair) 
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in HeLa nuclear extracts, finding that the formation of the triplex induced increased 
DNA repair activity in promoter-containing plasmids (95). Hélène reported the binding 
of a 17-mer homopyrimidine oligonucleotide to the major groove of SV40 DNA, 
thereby inhibiting enzymatic cleavage (96). Mayfield and his coworker observed the 
inhibition of the transcription of the Ha-ras gene through triplex formation (97). 
 Because of the numerous activities the triplex may exhibit in the biological 
systems, increasing its stability has been the focus of much research, with many 
endeavors being conducted using small ligands.  Intercalators such as acridines, 
ethidium, proflavine, and ruthenium complexes (98-101), as well as DNA minor 
groove-binding ligands such as berenil, netropsin, and Hoechst 33258 (102-104), have 
been shown to bind to DNA triplex. However, those ligands do not bind to the triplex 
selectively, and some of them even destabilize it. Benzo(e)pyridoindole (BePI), the first 
triplex-specific ligand described (105), binds to the triplex through an intercalation 
mechanism, increasing the melting temperature of triplex over the duplex significantly. 
Diethyloxadicarbocyanine (DODC) (106), first identified as tetraplex-specific ligand, 
has been shown by Chaires to bind to a DNA triplex with an affinity even higher than 
tetraplex but with no effect on the duplex. BQQ (one of the derivatives of BePI), 
naphthylquinolines and pyrene have also been identified as triplex-specific intercalators 
(Figure 1.12). Of the limited number of small ligands that have shown to bind 
specifically to the triplex, most of them have been found to be intercalators.  
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Figure 1.12.  Chemical structures of triplex-binding compounds. 
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Figure 1.13. (top): Computer generated model showing aerial view of neomycin (red) 
bound to three different grooves of the TAT DNA triplex. Neomycin is almost invisible 
when docked into the Watson-Hoogsteen groove. (Bottom): Stereo view of neomycin 
bound to the W-H groove of the DNA triplex.  Only the two pyrimidine strands are 
shown for clarity.   Neomycin occupies 6-7 base-pairs per triplex (47). 
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 Aminoglycosides have been shown in Arya’s laboratories to stabilize triplex 
nucleic acids both selectively and significantly. Among these aminoglycosides, 
neomycin exhibits the most potent effect, while, neomycin is the first groove-binding 
ligand to result in triplex stabilization effect. Molecular modeling has suggested that 
neomycin binds within the Watson-Hoogsteen groove (47) formed between the third 
strand and the pyrimidine strand. The drug recognition by that groove is a result of 
neomycin’s complementary charge and shape (Figure 1.13). Its ring I sits in the center 
of the groove, while the amines on ring II and IV help bridge the two pyrimidine 
strands together. Six new H-bonds are formed between neomycin amines, hydroxyl and 
thymidine O3, and phosphate oxygen, respectively (47). The absence of a fused, planar 
ring system eliminates the structural possibilities for intercalation. This finding is 
significant as it is the first example of DNA-based nucleic acid recognition by 
aminoglycosides. Not only is the DNA triplex stabilized dramatically by neomycin, but 
so too is the RNA triplex poly(rA)•2poly(rU) (46), and the hybrid triplex can be 
induced by neomycin as well (107). 
 
Quadruple Stranded Nucleic Acids (Tetraplexes) 
 The formation of a tetraplex or a quadruplex DNA structure has been suggested 
as a potential chemotherapeutic target of a new antitumor compound. This structure is 
formed from the tandemly repeating guanine clusters, present primarily in the single-
stranded segment at the 3’ ends of chromosomal DNA (also called telomere) and 
characterized by a stacked arrangement of several G4 planar tetrads in which each G 
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interacts with the adjacent one via forces of the Hoogsteen bonds. Eight H-bonds are 
formed in one G-tetrad (Figure 1.14), stacking on one another to form a G-tetraplex. 
This G-tetraplex can be formed between one, two or four G-rich strands via 
intramolecular or intermolecular interactions. However, the G-tetraplex formed from 
one or tow strands must contain some unpaired thymine bases to form a loop. G-
tetraplex also has two motifs: parallel and antiparallel. In the parallel motif, all four 
strands are associated with one another in the same orientation (5’->3’), while 
antiparallel describes all the other cases. The isomeric forms of G-tetraplexes can be 
distinguished based on the difference in strand orientation, loop geometry and strand 
stoicometry, several representative structures being shown in Figure 1.15.   
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Figure 1.14.  Structures of an individual guanine base G-tetrad and the eight H-bonds 
formed between guanines.  
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Structures of intramolecular G-tetraplexes 
 
Structures of intermolecular G-tetraplexes 
 
Figure 1.15.  Topologies of G-tetraplexes.  
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These G-rich sequences occur frequently in human genomes and in many other 
organisms (108, 109). The formation of G-tetraplex has been reported to exhibit many 
biological functions. For example, G-tetraplex has been found to exist at the promoter 
region of oncogenes such as c-myc (110), in the regulation region of the insulin gene 
(111) and in the regulatory regions of a number of genes including the switch 
recombination (112). Of the many G-rich sequences in the organisms, telomere has 
been the primary focus over the past few years due to its important biological role and 
its potential as an antitumor target. This G-rich tail at the end of chromosome is very 
important in maintaining chromosome integrity, avoiding end-to-end fusions and 
unwanted recombination events, and protecting the ends of chromosome from 
degradation. While the length of the telomere is important in maintaining the integrity 
of the chromosome, approximately 100 base pairs of this DNA is lost during every 
round of cell division since DNA polymerase cannot copy the G-rich tail completely. 
Thus, this shortening of the telomere length can induce the cellular senescence (113). 
However, telomerase has shown the ability to maintain the length of telomere. This 
enzyme has recently been found to be associated with the longevity of most cancer 
cells, and its function may be important in this disease’s immortalization and 
proliferation (114). The important feature of this enzyme is that its function depends on 
its binding to the telomere G-rich single stranded DNA tail. A large number of studies 
have confirmed that about 80-90% of human tumors show elevated levels of telomerase 
expression, with a corresponding absence being found in normal somatic cells (114), 
which suggests an interesting topic in treating the tumor since the telomere can 
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potentially be used as antitumor target. Thereby, G-tetraplex formation can inhibit the 
recognition of tumor cell telomere DNA by the telomerase, subsequently inhibiting the 
proliferation of tumor cells.  
molecular dynamic simulation has shown that either metal ions (such as 
potassium and sodium) or NH4+ ions are important for tetraplex formation (115). 
Specifically, X-ray studies of the G-tetraplex have revealed the location of the cation 
binding site (Figure 1.16), with the large cation K+ being found to locate between two 
G-tetrad planes, and the well-resolved small cation Na+ locating both within and 
between these two G-tetrad planes (116). More importantly, the K+ stabilized G-
tetraplex was reported to inhibit telomerase function in 1991 (117). The binding feature 
of these cations are determined by the electrostatic potential (the center of the tetrad is 
electronegative), the size of the cavity formed in the middle of tetraplex, the ion size, 
and the hydration energy. Furthermore, it has also been found that the metal ion-tetrad 
interaction is the most important contribution to the total free energy associated with 
tetraplex formation, even exceeding the Hoogsteen hydrogen energy involved in the 
base-base interaction (118). 
 
Figure 1.16. Side (left) and top (right) view of sandwich G-tetrad with K+ (116).   
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Targeting the G-tetraplex with small ligands to improve its stability has been the 
subject of much recent research. One of the first studies involved the binding of 
ethidium bromide to the G-tetraplex d(T4G4)4 (119). Due to its planar structure feature 
ethidium bromide has, this molecule was suggested to intercalate into the G-tetrads 
adjacent one another. Anthracene-9,10-diones, used as a triplex-specific ligand, also 
has been found to bind to G-tetraplex (120), with X-ray crystal structures revealing the 
planar portion of the structure intercalates into the G-tetrad via the pi overlap and the 
flexible pendant side chains sit in the wide grooves of the tetraplex (120).  
Subsequently, a 2,6-diamidoanthraquinone molecule was found to interact with a 5’-
(T2AG3T2)4 tetraplex, exhibiting the inhibition effect of telomerase (121). In addition to 
those compounds, other tetraplex binding ligands include porphyrins (122), 
dicarbocyanine (123), dicationic perylene derivative (PIPER) (124), among others 
(Figure 1.17). Basically, those compounds, are either planar or extended planar 
aromatic molecules with one or more positive charge centers, all having the potential to 
interact with the G-tetrad. Among those compounds, a cationic tetrapyridyleporphyrin 
compound (H2TMPyP) has attracted considerable interest recently due to two factors: 
(1) This porphyrin molecule has approximately the same molecular dimension as the G-
tetrad, and (2) Porphyrin has been shown recently to inhibit telomerase activity in intact 
MCF7 human breast carcinoma cells (125). However, differing results have been 
reported concerning the porphyrin binding mode, mechanism and binding 
stoichiometry, most probably due to the different pH, salt and buffer of the solutions 
used that tetraplex conformations are know to be sensitive to. For example, in 
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potassium salt and at a pH of 7.0, Haq hypothesized that porphyrin intercalates into 
similar GpG sites with a binding affinity of (0.3~2)×105 M-1 without inducing the 
neighboring exclusion of adjacent sites, rather than through the external electrostatic 
interaction or end-paste binding modes (126).   
 Arya’s laboratory has studied the binding of aminoglycosides, specifically 
neomycin, to the G-tetraplex d(T2G20T2)4  using sodium and a pH of 6.8. The 
preliminary results have revealed two types of binding sites, one at 3 tetrads/neomycin 
and a second at 7 tetrads/neomycin.  Binding affinity for first one is as high as 
(3.6±1.6)×108 M-1 and (1.8±0.1)×106 M-1 for second one. The values of these binding 
affinities at both sites are higher than any reported ligand-tetraplex binding data. Since 
neomycin lacks the feature of planar structure, the intercalation mode can be ruled out. 
However, neomycin, as a polycation compound, prefers binding to the terminal tetrad 
which has an electronegative center. The second binding site is proposed to be within 
the four broad and shallow grooves through various forces, for example, the van der 
Waals, electrostatic interaction or H-bonds. However, the binding is not tight due to the 
lack of complementary conformation between neomycin and grooves. This hypothesis 
requires additional structural study to confirm it. If supported, the significantly high 
binding affinity exhibited through the binding of neomycin to parallel d(T2G20T2)4 
tetraplex, then, will offer improvement in the antitumor therapy.   
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Figure 1.17. Chemical structures of some representative tetraplex binding ligands.  
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CHAPTER 2 
THERMODYNAMIC STUDY OF AT-RICH TRIPLEX-AMINOGLYCOSIDES 
RECOGNITION 
 
Introduction 
 Much attention has been given to the oligonucleotide-directed triple helix 
formation of nucleic acids (127-129)  due to its possible regulatory role in vivo (130) 
and its potential applications to medicine and biotechnology (131, 132).  In the 
intermolecular triplex system, the double helix associates with a single-strand triple 
helix-forming oligonucleotide (TFO) via Hoogsteen hydrogen bonds in the major 
groove. Because TFOs bind in the major groove of duplex DNA, they can be designed 
for use as transcription inhibition agents, resulting in targeted mutagenesis (133). Wang 
used TFOs to study the molecular mechanism of triplex-mediated TCR (transcription-
coupled repair) in HeLa nuclear extracts, finding that the formation of a triplex induced 
much stronger DNA repair activity in promoter-containing plasmids (95). In addition, 
Hélène also showed that a 17-mer homopyrimidine oligonucleotide could bind to the 
major groove of SV40 DNA, inhibiting enzymatic cleavage (96). Recently, TFO-
peptide conjugates have also been shown to act as sequence-specific transcription factor 
initiators. The triplex structure contains two motifs: purine and pyrimidine. In the 
purine motif, the homopurine third strand binds antiparallel to the purine strand of the 
duplex through reverse-Hoogsteen hydrogen bonds.  In the pyrimidine motif, the third 
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strand, composed of pyrimidine bases, binds parallel to the purine strand of the Watson-
Crick duplex by forming Hoogsteen hydrogen bonds.   
 For the intramolecular triplex, found to exist in biological systems in 1986 
(134), formation is different from that of intermolecular triplex. In this case, the 
homopurine-homopyrimidine mirror repeats within the DNA duplex denature to allow 
one strand to fold back, forming Hoogsteen hydrogen bonds with the adjacent DNA 
duplex sequence. This form of intramolecular triplex, known as H-DNA (135), is most 
favorable under conditions of negative DNA supercoiling (136), acidic solutions, or in 
the presence of divalent cations (137).  As with the intermolecular triplex, the 
intramolecular triplex was also reported to have an effect on the transcriptional 
regulation and replication in vivo (138-140).  H-DNA, proven to exist in E. Coli and 
eukaryotic cells (141-143), is also frequently found in promoter regions and around 
recombination hot spots (144), suggesting that it most probably plays a regulatory role 
in gene expression (145), recombination (146), and/or transcription of human viruses in 
the human chromosome in vivo (147).  H-DNA may also function in the suppression of 
the human γ-globin gene (148). 
 However, the triplex is not as stable as its corresponding duplex. The 
association of a third strand with a duplex (kon≈10-103 M-1s-1) is a much slower process 
than the association of two single strands in forming a duplex (kon≈106 M-1s-1) (149, 
150).   Many studies have been carried out, attempting to improve the thermal stability 
of DNA triple helices (107).  Mergny used BePI to stabilize H-DNA during in vivo 
elongation under physiological conditions and in the absence of superhelical stress 
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(105). Diethyloxadicarbocyanine (DODC) has also been shown to selectively stabilize 
the triple helix structure (106). Other intercalators such as acridines, ethidium, 
proflavine, and the ruthenium complexes (98-101), as well as DNA minor groove-
binding ligands, such as berenil, netropsin, and Hoechst 33258, have been shown to 
bind to DNA triple helices (102-104). However, the ligands do not selectively bind to 
the DNA triple helices, with some of them even destabilizing triple helices. The 
previous work has shown the remarkable ability of neomycin and other 
aminoglycosides (Figure 2.1) and aminoglycoside-based conjugates to stabilize DNA, 
RNA, and hybrid triple helices (45-48, 107, 151). In particular, neomycin was found to 
induce the stabilization of DNA•RNA hybrid duplexes as well as hybrid triple helices 
(107), significantly adding to the number of nucleic acids (other than RNA) that 
aminoglycosides have been shown to target.  Among the aminoglycosides studied, it 
was found that neomycin significantly stabilized DNA and RNA triple helices (46). In 
this chapter, we report our observations regarding the role of aminoglycosides in the 
thermal stabilization of AT-rich triplexes and their interactions with aminoglycosides 
from a thermodynamic perspective.  
O
O
O
HO
HO
NH2
NH2
O O OH
H2N
OHH2N
OH NH2
HO NH2
OH
O
 
Neomycin 
O
O
O
HO
HO
OH
NH2
O O OH
H2N
OHH2N
OH NH2
HO NH2
OH
O
 
Paromomycin 
O
O
O
HO
HO
NH2
NH2
OH OH
H2N
HO NH2
OH
O
 
 
Ribostamycin 
Figure 2.1. Chemical structures of aminoglycosides used in this study. 
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Investigation of AT-rich triplex thermal stability 
Salt dependence study 
 It has been previously demonstrated that at 260 nm both Hoogsteen (HS) and 
Watson-Crick (WC) transitions can be observed (152). It has been reported that at 280 
nm there is a clear hyperchromic absorbance change, corresponding to the triplex–
duplex transition (152).  In the absence of KCl, a monophasic transition is observed, 
due to duplex denaturation.  When the ionic strength increases from 50 mM to 250 mM, 
two transitions can be clearly observed at 260 nm. The transition at the lower 
temperature corresponds to the HS transition, which is consistent with the melting 
temperature at 280 nm. The transition at the higher temperature is due to the WC 
melting.  When the ionic strength increases to above 800 mM, the melting profiles 
become monophasic with only one transition observed at 260 nm. This transition 
presumably corresponds to the denaturation of the triplex directly to the coil state due 
to the high salt conditions. The increase of the ionic strength raises the ∆Tm of triplex 
more than that of the corresponding duplex. This phenomenon is seen for both the 5'-
dA12-x-dT12-x-dT12-3' and the poly(dA)•2poly(dT)  (see appendix).  
 Figure 2.2a shows the melting temperature increase (∆Tm) with respect to the 
KCl concentration. The increase of KCl concentration from 50 mM to 2 M results in a 
55 °C increase in the HS transition, with a corresponding increase in the WC transition 
of only 25 °C in the absence of neomycin.  However, in the presence of neomycin (rdb = 
0.67), KCl exhibits a smaller effect on the HS transition. As shown in Figure 2.2a, both 
the duplex (when the KCl concentration is below 50 mM) and the triplex (when the 
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ionic strength is below 150 mM) are destabilized in the presence of neomycin, with a  
20 °C decrease in the HS transition and only a 4 °C decrease in the WC transition. 
When the ionic strength increases above 50 mM for the duplex or 150 mM for the 
triplex, the stability of both also increases. The observation of destabilization of both 
triplex and duplex may be due to the competitive binding of neomycin and K+ ions to 
DNA, with this effect being much more significant in the triplex. The phase diagram 
(Figure 2.2b) also reveals three different phases in the triplex melting process. In 
Region I, the solution contains only single strands of dA12 and dT12; in Region III, the 
triplex is formed completely; while Region II represents the coexistence of duplex 
dA12•dT12 and single strand dT12. The transition lines meet when the concentration of 
KCl is above 1200 mM (triple point), and together, they form the boundary between 
Region I and Region III.  
 Similar results can be seen for the polynucleotide triplex poly(dA)•2poly(dT). 
Increased ionic strength also increases the thermal stability of triplex, but with less 
effect on the duplex as shown in Figure 2.2c. Triplex thermal stability at the saturated 
amount of neomycin was investigated, the results being shown in Figure 2.2d. In this 
study, the rbd ratio (base triplet to drug) used were 6.2, 6.8, 5.9 and 5.8 under 100, 150, 
200, and 250 mM KCl, respectively. The comparison of the stabilization effect of 
neomycin on intramolecular and polynucleotide triplex leads to the following 
conclusions: (1) At low ionic strengths (up to 150 mM KCl), the intramolecular triplex 
is more stable than the polynucleotide triplex in the absence of neomycin, most 
probably because of the vicinity of three strands held by a linker. When increasing the 
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KCl above 150 mM, the stabilization effect of the salt on the polynucleotide becomes 
potent. (2) Under the same ionic strength, neomycin stabilizes the poly(dA)•2poly(dT) 
triplex much more significantly than the 5'-dA12-x-dT12-x-dT12-3' triplex, with a 30oC 
increase for poly(dA)•2poly(dT) but only a 6.5 oC increase for 5'-dA12-x-dT12-x-dT12-3' 
triplex. (3) For both poly(dA)•2poly(dT) and  5'-dA12-x-dT12-x-dT12-3' triplex, the 
stability of duplex is relatively unchanged in the either absence or presence of 
neomycin, with neomycin having no significant effect on the stability of triplex at ionic 
strengths above 150 mM.  
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Figure 2.2: (a) Plots of ∆Tm3→2 and ∆Tm2→1 of 5'-dA12-x-dT12-x-dT12-3' as a function 
of KCl with or without 8 µM neomycin. (b) Phase diagram of Tm as a function of 
log [K+] for 5'-dA12-x-dT12-x-dT12-3' with or without 8 µM neomycin. The data 
points represent the Tm. Each phase labeled as I, II, and III refers to the single 
strand, duplex and triplex states that DNA adopts, respectively. (c) UV melting 
profile of poly(dA)•2poly(dT) at various KCl. (d) A bar graph of triplex Tm increase 
(∆Tm) of  poly(dA)•2poly(dT)  at saturated amount of neomycin.  Buffer: 10 mM 
sodium cacodylate, 0.5 mM EDTA, and pH 6.8. DNA triplex concentration was 1 
µM in strand for oligomer and 15 µM in base triplet for polymer. 
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Drug Dependence Study 
 To investigate the stabilization effect of different aminoglycosides on the 
intramolecular triplex, the UV melting studies were conducted in the presence of three 
aminoglycosides (neomycin, paromomycin, and ribostamycin).  As shown in Figure 
2.3a, the representative UV melting profiles (rdb=0.67) reveal the different abilities of 
these aminoglycosides in stabilizing the intramolecular triplex. The melting 
temperatures for the 5'-dA12-x-dT12-x-dT12-3' triplex increase in the presence of 8 µM 
of the drug at 100 mM KCl (Figure 2.3a). However, there is no effect observed on the 
thermal stability of the corresponding duplex (the melting temperature remains around 
57 °C), suggesting that these aminoglycosides selectively stabilize the intramolecular 
triplex.  
 As shown in Figure 2.3a, among the three aminoglycosides studied here, 
neomycin is found to be the most effective in enhancing the thermal stability of the 
intramolecular triplex, with nearly an 11 °C increase in the melting temperature at the 
highest rdb studied; paromomycin exhibits a 6 °C lower in triplex melting temperature 
than neomycin; no significant change in the melting temperature is observed for the 
triplex in the presence of ribostamycin, as shown in Figure 2.3b.  This observation is 
consistent with the previous studies showing that neomycin stabilizes the 
poly(dA)•2poly(dT) triplex most effectively and selectively among the 
aminoglycosides (45, 46).  
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pH Dependence Study 
 UV melting analysis was also used to investigate the effect of pH on the 
stabilization of 5’-dA12-x-dT12-x-dT12-3' triplex. These UV experiments were 
conducted at increments of 0.2 pH units, ranging from pH 5.5 to 8.0 for 5’-dA12-x-dT12-
x-dT12-3' (Figure 2.4a).  In the absence of neomycin, the melting temperature of the 
triplex (29 ºC) and duplex (58 ºC) remain unchanged over the pH range studied (see 
appendix), suggesting that the intramolecular triplex 5'-dA12-x-dT12-x-dT12-3' does not 
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Figure 2.3: (a) UV of 5'-dA12-x-dT12-x-dT12-3' triplex at 260 nm in the presence of 
aminoglycosides. From left to right, the UV melting profiles correspond to 0 µM 
drug, 8 µM ribostamycin, paromomycin and neomycin respectively. (b) A plot of 
∆Tm3→2 of 5'-dA12-x-dT12-x-dT12-3' triplex as a function of increasing rdb values [rdb = 
drug/base triplet ratio].  Buffer conditions: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 100 mM KCl, and pH 7.2.  DNA triplex concentration was 1 µM in strand.  
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uptake any protons upon its formation. However, in the presence of 8 µM neomycin, 
the melting temperature of the triplex was found to be dependent on pH. With 
increasing pH values, the melting temperature decreases gradually (Figure 2.4b).  At a 
low pH (5.5-5.9), the triplex exhibits nearly monophasic transitions at 260 nm, 
suggesting a 3->1 transition. Biphasic transitions are observed at pH above 5.9 (Figure 
2.4a).  These results indicate that neomycin is more effective in stabilizing the 
intramolecular triplex at a lower pH value than at higher one.  Thus, the more amino 
groups of neomycin protonated, the more effective neomycin is in stabilizing the 
intramolecular triplex. However, an opposite trend was observed when studying 
poly(dA)•2poly(dT) triplex stability at pH 5.5 and 6.8 under the same salt conditions. 
The potency of neomycin in stabilizing the polynucleotide triplex at pH 5.5 is not as 
strong as at pH 6.8 (see appendix). The thermal stability of poly(dA)•2poly(dT) is 
raised by neomycin (rbd 6.2) approximately 31.5 oC at pH 6.8, but only 8.5 oC at pH 5.5. 
The reason for this difference observed between the intramolecular triplex 5'-dA12-x-
dT12-x-dT12-3' and intermolecular triplex poly(dA)•2poly(dT) may be due to the 
following reasons: (1) At pH 5.5, the electronegative potential of the DNA backbone is 
partially neutralized by the free protons in the solution. This factor is not favorable for 
the binding of neomycin to those triplex structures, reducing the electrostatic 
interaction. As a result, neomycin exhibits a lower potency in stabilizing 
poly(dA)•2poly(dT)  triplex at low pH.  (2) The intramolecular triplex 5'-dA12-x-dT12-
x-dT12-3' structure may be slightly different from the intermolecular triplex. It has been 
reported that the duplex conformation in the intramolecular triplex structure is 
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somewhat different from the free duplex conformation (153), suggesting that the linker 
between the two strands could affect the conformation of triplex. CD scans of 
neomycin titration with 5'-dA12-x-dT12-x-dT12-3' are slightly different from the scans of 
poly(dA)•2poly(dT) (see appendix),  revealing a small difference between both 
triplexes structures. This difference may be due to end effects resulting from the 
hexaethylene glycol chains. The significant stabilization effect of neomycin toward 
intramolecular triplex at pH 5.5 may be due to its possible interaction with 
hexaethylene glycol linker, which contains six oxygen atoms.    
 
0
0.2
0.4
0.6
0.8
1
24 32 40 48 56 64 72 80
No
rm
a
liz
e
d 
ab
s
T(oC)
260 nm
(a)
 
-5
0
5
10
15
20
25
5.5 6 6.5 7 7.5 8 8.5
∆∆ ∆∆T
m
pH
∆T
m
2->1
∆T
m
3->2
(b)
 
Figure 2.4. (a) UV melting profiles at 260 nm of the 5'-dA12-x-dT12-x-dT12-3' triplex 
in the presence of 8 µM neomycin. From left to right, the pH values of solutions 
were 7.4, 6.9, 6.7, 6.3, 5.9 and 5.5, respectively. (b)  Plots of the ∆Tm3→2 and ∆Tm2→1 
of the 5'-dA12-x-dT12-x-dT12-3' triplex as a function of increasing pH value. The Tm 
for the triplex was determined from the profiles at 280 nm. ∆Tm=Tm(any pH)-
Tm(8.0). All the buffer solutions contained 10 mM sodium cacodylate, 0.5 mM 
EDTA and 100 mM KCl. DNA triplex concentration was 1 µM in strand. 
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Thermodynamic Study of Aminoglycosides Binding to AT-rich Triplex 
Intramolecular triplex 5'-dA12-x-dT12-x-dT12-3' 
At pH 5.5: As discussed previously, the stabilization effect of aminoglycosides 
toward intramolecular triplex is more potent at a low pH than a high one. It is important 
to study the interaction at a pH value where the aminoglycosides are fully protonated, 
thereby to eliminate that effect from drug protonation. Inspection of the pKa values of 
six amino groups on neomycin indicates that neomycin is fully protonated at pH 5.5 
(35). The merit of study at this pH is that all the observed binding enthalpy, binding 
entropy, binding constant, and binding site size reflect the intrinsic interaction between 
the drug and the DNA triplex. However, study at such a low pH leads to practical 
problems since the neomycin-triplex interaction becomes entropy-driven, and thereby 
the ITC signal intensity and derived binding enthalpy decreases dramatically as shown 
in Figure 2.5c. In order to obtain enough signals, a substantial amount of sample is 
required. Furthermore, triplex stability at low pH may become another concern due to 
the potential charge repulsion between three strands. However, the destabilization of 
both 5'-dA12-x-dT12-x-dT12-3' and poly(dA)•2poly(dT) triplex not observed by a low 
pH of 5.5.   
 Model fitting with two binding sites yields a binding affinity of (9.1 ± 4.5) × 106 
M-1, a binding enthalpy of -0.15±0.01 kcal/mol, and a binding entropy of 9.7 kcal/mol 
for the  first binding event.  Approximately 98% of the binding force results from 
entropy, with only 2% from enthalpy. (154). In the aminoglycoside-DNA triplex 
complex, it has been shown that hydrogen bonds can be formed between drug 
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molecules and DNA triplex (47), providing a favorable enthalpy contribution to the free 
energy.  However, the extremely small binding enthalpy observed here suggests that the 
hydrogen bond is not a dominating force in binding. Pilch has shown that in the 
absence of the effect of drug protonation, paromomycin binding to the A-site of 16S 
rRNA is entropy-driven, providing 72% of the driving force for binding, with only 28% 
coming from the enthalpic contribution at pH 5.5 (35). The factors causing this 
favorable entropic contribution include the conformational change upon drug-DNA 
triplex complexation, the counterion release caused by the electrostatic interactions 
between drug and DNA triplex, and the desolvation of both the drug and the DNA 
triplex upon binding (35) 
 Since the ITC signal to noise ratio becomes larger when the binding signal 
intensity decreases to less than 0.1, it is important to desirable to apply more than one 
technique to confirm and validate the ITC derived binding constant for a system. 
Fluorescence intercalator displacement (FID) assay, a technique ruling out the 
limitation of ITC in calculating the intrinsic binding constants, was introduced by 
Boger (155, 156). This assay, nondemanding and nondestructive, is applicable to a 
high-throughput screening. In this assay, an intercalator such as ethidium bromide or 
thiazole orange preintercalates into the triplex base triplets at the saturated amount. The 
ligand added later, if binding to the sites neighboring to or same as intercalator, will 
exclude the intercalator from the binding sites. The amount of excluded intercalator, 
measured with fluorescence technique, is directly proportional to the amount of bound 
ligand.  
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 There are two widely used and well characterized intercalators in this assay, 
ethidium bromide and thiazole orange. Ethidium bromide, which intercalates into 
nucleic acid with relatively small affinities (157), can be easily displaced by a ligand 
added later. However, due to its low fluorescence enhancement property, ethidium 
bromide was not preferred here.  
 Thiazole orange was introduced because of its high fluorescence enhancement 
upon intercalation, which is approximately a 3000-fold increase (only a 20-fold 
increase for ethidium bromide) (157). Boger has reported that the binding affinity 
obtained from FID experiment is lower than the one obtained from direct titration (156, 
157). Among ethidium bromide and thiazole orange, thiazole orange-displacement 
study even gives lower binding affinity than ethidium bromide-displacement study 
because the former binds to DNA tighter than latter. The extent of underestimation of 
binding affinity by FID experiment varies with DNA sequences and ligands (156, 157). 
 As shown in Figure 2.5a, the decrease in fluorescence intensity upon 
quantitative titration of neomycin into DNA triplex is directly related to the extent of its 
binding to the triplex. The application of the two binding sites model provides a relative 
binding affinity of (1.2 ± 0.1) × 106 M-1 for first binding event and (6.8 ± 1.3) × 105 M-1 
for the second binding event at pH 5.5 and 150 mM KCl (Figure 2.5ab). The binding 
constant for the first binding event calculated from FID assay is ~7 times lower than the 
one provided by direct ITC titration (Figure 2.5cd); however, it is the same for both 
techniques for the second binding event. This difference of the binding constants 
observed for the first binding site may result from the binding environmental change 
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produced by the occupation of first binding site by thiozole orange, thereby decreasing 
the binding affinity of neomycin to the triplex. Even though FID experiment 
underestimates the binding affinity slightly, it can be concluded that the binding affinity 
of neomycin to intramolecular triplex is in the scale of 1-9 ×105 M-1 at pH 5.5 and 150 
mM KCl. Furthermore, an additional advantage of the FID assay is that allows for the 
interaction to be observed directly without taking into account the protonation reaction 
involved in the system; thus reflecting the intrinsic interaction between aminoglycoside 
and DNA triplex. 
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Figure 2.5. (a) FID of neomycin into 5'-dA12-x-dT12-x-dT12-3'. (b) A plot of 
fluorescence difference upon each neomycin addition vs. the corresponding 
neomycin concentration. Red line reflects the data fits with two binding sites model. 
(c) ITC of neomycin binding with 5'-dA12-x-dT12-x-dT12-3' triplex. (d) Corrected 
injection heat as a function of [drug]/[triplex] ratio. The solid line is the data fitting 
with two sets of binding sites model (Origin 5.0). Buffer: 10 mM sodium cacodylate, 
0.5 mM EDTA, 150 mM KCl, pH 5.5. T=10oC. 
 
 At pH 6.8: As indicated previously, the complexation of aminoglycosides with 
DNA triplex involves the protonation of aminoglycosides. To investigate the number of 
protonation upon binding, ITC was used to study the binding of neomycin and 
paromomycin to the 5'-dA12-x-dT12- x-dT12-3' triplex in two different buffers, sodium 
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cacodylate and MOPS. Both contained either 10 mM sodium cacodylate or MOPS, 0.5 
mM EDTA, and 150 mM KCl at pH 6.8. The ITC profiles and corresponding data fits 
are shown in Figures 2.6 for the two aminoglycosides in the sodium cacodylate buffer 
(see appendix for the ITC profiles in the MOPS buffer). Panels (a) and (b) in Figures 
2.6 correspond to injections of neomycin and paromomycin into the 5'-dA12-x-dT12-x-
dT12-3' triplex solution.  Each of the heat burst curves results from 5 µL aliquots of the 
drug injection. The area under each of these heat burst curves is integrated to yield the 
associated injection heat. The injection heat is corrected by subtracting the 
corresponding dilution heat, determined by titrating the same amount of drug solution 
into the buffer under the same conditions. The corrected injection heat as a function of 
the [drug]/[triplex] ratio are listed in the panels (c) and (d) in Figure 2.6, the data points 
reflecting the experimental injection heats and the solid line reflecting the model fitting 
using Origin 5.0. The model yielding a reasonable fit of experimental data is the one 
having two binding sites. The size of the binding site is also confirmed through CD 
titration (see appendix). Using the resulting values of Ka, the binding free energy (∆G) 
can be obtained using the following standard relationship: 
 
∆G = - R T ln (Ka)                        (1) 
 
The calculated binding free energy can then be used to determine the corresponding 
entropy contribution (T∆S) in the drug-triplex interaction using the following standard 
equation: 
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 T∆S = ∆H - ∆G                           (2) 
where ∆H is the observed binding enthalpy derived directly from the fits of ITC data. 
The thermodynamic parameters (∆H, ∆G, T∆S, and Ka) are summarized in Table 2.1.  
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Figure 2.6. ITC studies of intramolecular triplex 5'-dA12-x-dT12-x-dT12-3' with 
neomycin (a) and paromomycin (b) in 10 mM cacodylate, 0.5 mM EDTA, 150 mM 
KCl, pH 6.8; T=10ºC. [DNA] = 4µM/strand, [Drug]=600 µM. (c-d) Corrected 
injection heat as a function of [drug]/[triplex] ratio. The data points represent the 
experimental injection heat and the solid lines correspond to the calculated fits of the 
data by using a model with two binding sites (Origin 5.0). 
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 From Table 2.1, the following conclusions can be drawn: First, in both buffers, 
the observed binding enthalpy (∆Hobs) of neomycin with triplex is primarily 
exothermic. Specifically, the binding enthalpies for neomycin and paromomycin are -
5.9 and -4.8 kcal/mol in cacodylate buffer and -4.4 and -2.7 kcal/mol in MOPS buffer, 
respectively. At pH 6.8, the observed enthalpy includes contributions from the intrinsic 
binding enthalpy, drug protonation enthalpy, and buffer ionization heat.  
 Second, at pH 6.8 in both buffers, the neomycin-intramolecular triplex 
intraction is enthalpy-driven.  Approximately 80% of the driving force for binding is a 
result from enthalpy, with only 20% due to entropy. For paromomycin, the enthalpic 
contribution, smaller than for neomycin, is approximately 75% in cacodylate buffer and 
44% in MOPS buffer. Given the fact that the intrinsic binding is entropy-driven at pH 
5.5, the enthalpically favorable binding at pH 6.8 suggests that a non-negligible drug 
protonation effect is involved during binding. In addition to drug protonation, hydrogen 
bonding and van der Waals interactions are the other two factors that may account for 
the favorable enthalpy increase (154, 158-160).  Hydrogen bonds can be formed 
through drug-water, DNA-water, drug-DNA triplex interactions and even by water-
water interactions (154). When a drug molecule transfers from a water solution to the 
binding site on the DNA triplex, it can result in a net surplus of hydrogen bonds instead 
of simply a replacement of DNA-water and drug-water hydrogen bonds because only a 
fraction of the possible hydrogen bonds are formed in the water solution (154). The van 
der waals interaction is often considered so weak that it contributes only a small net 
favorable enthalpy.  
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Third, the Wiseman parameter “c”, which denotes the product of 
macromolecular concentration with the binding site size and the association constant, is 
used for evaluating the appropriate application of ITC in bimolecular interaction. This 
parameter also determines the shape of ITC titration curve. For example, the lack of a 
lower baseline is due to the low c value (161). Previously the recommended 
Table 2.1.  Thermodynamic profiles of aminoglycosides binding to the 5'-dA12-x-
dT12-x-dT12-3' triplex in 10 mM sodium cacodylate or MOPS, 0.5 mM EDTA and 
150 mM KCl with pH 6.8.   T=10 ºC. 
 
Cacodylate buffer MOPS buffer 
Parameter neomycin paromomycin neomycin paromomycin 
Kobs(M-1) (3.8±0.4)×105 (8.7±0.2)×104 (1.6±0.3)×105 (6.7±3.7)×104 
∆Hobs (kcal/mol) -5.9 ±0.2 -4.8±0.2 -4.4±0.3 -2.7±0.8 
T∆S(kcal/mol) 1.1 1.6 2.3 3.5 
∆G (kcal/mol) - 7.0±0.2 -6.4±0.2 -6.7±0.3 -6.2±0.8 
n(drug/triplex) 1.1±0.0 1.2±0.2 1.1±0.1 1.2±0.3 
C value 2.1 0.8 1.3 0.7 
All the data are derived from ITC experiments. The values of Ka, ∆H and T∆S are 
determined from fits of ITC profile by the model with two sets of binding sites. 
The results shown here correspond to the first specific binding event. Binding to 
second site is nonspecific, not shown here.  ∆G is determined by the equation ∆G 
=∆H -T∆S.  
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experimental window of c values was 5~1000, with optimal values ranging from 
10~500.  For those systems with c < 5 and c > 1000, the data fits are believed to contain 
considerable uncertainties even when the appropriate models are applied. However, this 
conclusion may not always be the case based on a study conducted by Turnbull and 
Daranas who discussed in detail the application of ITC with low c values (0.01< c <10), 
especially for low affinity systems (161).  In their study, they proposed four 
requirements in the design of ITC experiments involving low c value: the binding 
stoichiometry; a sufficient binding isotherm used for curve fitting; a concentration of 
both macromolecule and ligand known to be accurate; an adequate level of signal-to-
noise in the binding data. Meeting these four requirements supports the validity of ITC 
model fitting for determining the association constant Ka and the resulting ∆G value. 
However, these researchers advocate great caution in interpreting the ∆H value. The c 
values shown in Table 2.1 fall in the low range (all smaller than 5), with highest value 
of 2.1 for neomycin. However, it is not feasible to bring the c value to the so-called 
experimental window 10 < c < 500 because then the ligand concentrations becomes too 
high to operate with. Therefore, after obtaining the binding stoichiometry from CD 
titration and fulfilling all the other requirements listed above, a reliable Ka can be 
determined. An ITC excess site titration is also conducted to obtain few uniform heat 
bursts to calculate a reliable binding enthalpy (see appendix).  These results indicate 
that the discrepancies in binding enthalpies obtained from ITC model fitting and ITC 
excess site titration are ~7% for neomycin and ~20% for paromomycin. Thus, the lower 
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the binding affinity of the system is, the more significant the model fitted binding 
enthalpy deviates from real value.  
 Fourth, it can be observed that all the binding enthalpies in the cacodylate buffer 
are greater than those in the MOPS buffer. This difference is due to the different 
ionization heat of the two buffers (-0.19 kcal/mol for cacodylate buffer and +5.07 
kcal/mol for MOPS buffer at 10 ºC) (162).  
 As indicated previously, at pH 6.8, the drug-triplex interaction involves a 
contribution from drug protonation.  The number of protons linked to the drug-triplex 
complexation can be determined by solving the following two equations simultaneously 
(37):  
 
nHHH ionobs ∆∆+∆=∆ 1int1                         (3) 
nHHH ionobs ∆∆+∆=∆ 2int2                         (4) 
 
Where ∆Hint represents the intrinsic binding enthalpy (a value that excludes the 
enthalpic contribution from the buffer ionization), ∆Hion the heat of buffer ionization, 
the numerical subscripts the different buffers, and ∆Hobs the observed binding 
enthalpies obtained from the data fitting of ITC profiles. A positive value of ∆n 
indicates a net uptake of protons while a negative value indicates the net release of 
protons. Using the data listed in Table 2.1, ∆Hint and ∆n for drug binding with an 
intramolecular triplex are calculated (Table 2.2).  
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 Table 2.2 shows positive values for ∆n, suggesting that aminoglycoside 
complexation with the intramolecular triplex is coupled to the uptake of protons. The 
∆n values are 0.29 and 0.40 for intramolecular triplex binding to neomycin and 
paromomycin at 10 oC, respectively. The fractional protonation number implies the 
shift of pKa of amine group upon binding. Notice that the pKa of 3-amine group on the 
ring I is 5.74, while the remaining amine groups on both neomycin and paromomycin 
have the pKa values all above 7.55 (36). Thus, it can be determined that the 3-amine 
group on the ring I is induced a pKa shift upon drug-DNA complexation at pH 6.8. 
With the ∆n values of 0.29 and 0.40 observed for neomycin and paromomycin, the pKa 
value of 3-amine group is calculated to be 6.56 for neomycin and 6.77 with the 
relationship pKa = pH-log[(A-)/HA], implying a pKa shift of 0.82 for neomycin and 
1.02 for paromomycin, respectively. To observe the effect of temperature on 
protonation, similar experiments were also conducted at 20 oC (data not shown), 
yielding a ∆n value of 0.38 and 0.29 for neomycin and paromomycin, respectively. 
Comparison of the ∆n value at 10 oC and 20 oC reveals that the binding-linked 
protonation is not affected significantly by temperature, suggesting that at physiological 
temperature, the intramolecular triplex-aminoglycoside interaction may have the same 
extent of protonation as reported here. It has been shown that a large number of binding 
linked protons are involved in aminoglycosides binding to A-site RNA duplex 
interaction at pH 7.0 (∆n values are 1.42, 1.55, 1.11 for neomycin, paromomycin, and 
ribostamycin, respectively) (37). The difference in ∆n at similar pH values may be due 
to the different binding orientation of the aminoglycosides with the A-site RNA duplex 
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and DNA triplex.  NMR studies have shown that aminoglycosides bind to the major 
groove of A-site RNA duplex. Rings I and II of the aminoglycosides are essential for 
the specific binding with RNA while the contribution from rings III and IV are minor 
(20). It was revealed previously that the aminoglycoside (in particular neomycin) most 
probably binds to the W-H DNA triplex groove, with rings I, II and IV as the key 
components involved in this process (47). The 3′-amino group on ring II has the lowest 
pKa value for both neomycin and paromomycin (35). If ring II is essential for binding, 
the amino group on this ring is most probably linked to protonation upon binding at a 
pH close to 7.0. This situation (coupled with the fact that the 3′-amine on ring II may 
not be involved in neomycin-DNA triplex interaction) may explain why the A-site 
RNA-aminoglycoside interaction gives a bigger ∆n value than the triplex-
aminoglycoside interaction. 
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Table 2.2.  Buffer dependence of the observed binding enthalpies, intrinsic binding 
enthalpies and the number of linked protons for the neomycin and paromomycin 
binding with 5'-dA12-x-dT12-x-dT12-3' in 10 mM buffer, 0.5 mM EDTA and 150 mM 
KCl; pH 6.8, T=10 oC. 
Drug buffer ∆Hion (kcal/mol) 
∆Hobs 
(kcal/mol) 
∆Hint    
(kcal/mol) 
∆n 
(per drug) 
Neomycin cacodylate -0.19 -5.9±0.2 -5.8±0.2 0.29±0.10 
Neomycin MOPS +5.07 -4.4±0.3 -5.8±0.2 0.29±0.10 
Paromomycin cacodylate -0.19 -4.8±0.2 -4.7±0.2 0.40±0.19 
Paromomycin MOPS +5.07 -2.7±0.8 -4.7±0.2 0.40±0.19 
∆Hion (ionization heat) of both buffer are obtained from reference (162). ∆Hobs are 
derived from the ITC experiments. ∆Hint (intrinsic binding enthalpy) and ∆n (the 
number of binding linked protons) are calculated from the equations (3) and (4).  
 
Polynucleotides triplex poly(dA)•2poly(dT) 
 For the study reported here, polynucleotide DNA triplex poly(dA)•2poly(dT) 
was studied for comparison with intramolecular triplex. A ∆Tm-based approach, derived 
by McGhee (163), was used to obtain binding affinities.  The following equation was 
used to calculate the association constants at the corresponding melting temperatures 
where the triplex complexed with drug:  
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Where Tmo is the melting temperature of the drug-free DNA triplex; Tm the melting 
temperature of drug-bound DNA triplex; ∆HHS the enthalpy change corresponding to 
melting enthalpy of Hoogsteen bonds in the absence of drug, determined from the DSC 
measurement; L is the free drug concentration at Tm (estimated by one-half of the total 
drug concentration), and n the binding site size determined through CD experiments. 
After obtaining the association constants at Tm, the following integrated van’t Hoff 
equation (6) was used to calculate the association constants at 10 ºC (164): 
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where ∆Hobs is the observed binding enthalpy of the drug to the triplex as derived from 
ITC excess site binding experiments conducted at 10 ºC; R the gas constant, and ∆Cp 
the heat capacity change, determined from equation (7) by using binding enthalpies at 
various temperatures. The calculated binding constants are shown in Table 2.4.  
 This approach is often useful and preferred, especially when the equilibrium 
constant for a given process is outside the optimal operating window or when ∆Cp 
measurements can be determined. This method uses a high concentration of DNA 
triplex to obtain several uniform binding heat bursts. Integration of each peak yields a 
comparable value for heat per injection. Correction of the heat per injection signal with 
respect to the total number of moles of ligand added per injection gives an independent 
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estimate of binding enthalpy without resorting to binding models or biased fitting 
procedures (165, 166). The values of ∆H measured from a number of titrations using 
this way represent a substantial sample size for averaging, giving statistically reliable 
error estimates.   
 At pH 5.5: The protonation reaction of aminoglycosides apparently contributes 
to the observed binding enthalpy, the heat capacity and the binding constants calculated 
at pH 6.8. However, the appropriate application of Equation (6) requires the 
thermodynamic parameters of binding enthalpy and heat capacity change from the 
intrinsic binding, both of which can be obtained from the interaction at pH 5.5 where 
protonation no longer exists. Observation of the thermal stability of 
poly(dA)•2poly(dT) at both pH 5.5 and 6.8 indicates that the formation of DNA triplex 
is not affected by pH. However, the heat capacity change (-98 cal/mol.K) (Figure 2.7b) 
at pH 5.5 decreases two fold of magnitude, compared to the one (-218 cal/mol.K) at pH 
6.8. Most importantly, the thermal stability of triplex is increased only 6 degrees by 
neomycin at pH 5.5 at an rbd of 8.8 (Figure 2.7a). In addition to the triplex transition, 
another two transitions are observed, one at 67 oC corresponding to duplex denaturation 
and a secong one at 80 oC due to the 3->1 transition. This phenomenon is also observed 
in the poly(dA)•poly(dT) duplex melting profile, in which the two strands of duplex 
disproportionate after denaturation to form a triplex in the presence of neomycin, 
directly melting to a single strand at 80 oC (see appendix). Hud has reported previously 
the 3->1 transition of poly(dA)•2poly(dT) at 82 oC in the presence of coralyne (167). In 
this case, two triplex transitions have been observed, one at 29 oC (3->2) and another at 
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80 oC (3->1), the former identified as expected one since it reflects the neomycin 
binding to preexisted triplex, while the second (3->1) reflects the neomycin-induced 
structures. Thus, this result suggests that the neomycin binding to polynucleotide triplex 
is rather unfavorable at low pH. As mentioned previously, even though neomycin is 
fully protonated at pH 5.5, the electronegative potential of the backbones decreases. 
This is unfavorable for neomycin binding, especially for the electrostatic interaction. 
Furthermore, it was observed that the binding enthalpy of neomycin with DNA triplex 
at pH 5.5 is approximately -1.0 kcal/mol at 10 oC. Entropy then is calculated to be -6.50 
kcal/mol using Equations (1) and (2), contributing 86% of driving force to the binding 
of neomycin with poly(dA)•2poly(dT) triplex. This significant entropic contribution to 
the binding force is consistent with that observed for the 5'-dA12-x-dT12-x-dT12-3' at 
low pH. The small value of binding enthalpy in magnitude observed at low pH 
indicates that the interacting force like hydrogen binding and Van der Waals are not as 
strong as those at high pH. 
 At pH 6.8: However, the binding affinities of DNA triplex with 
aminoglycosides cannot be obtained at pH 6.8. As indicated previously, the binding 
enthalpy observed at pH 6.8 includes the drug protonation heat. As a consequence, the 
heat capacity change calculated from binding enthalpies is not intrinsic as well. Thus, 
the binding affinities calculated using equations (5) and (6) at pH 6.8 will be 
overestimated due to the overestimation of both binding enthalpies and heat capacity 
changes.   
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 However, the binding enthalpy at pH 6.8 still can be used to calculate the 
protonation number of neomycin upon complexation with poly(dA)•2poly(dT) triplex.  
The binding enthalpies of neomycin-poly(dA)•2poly(dT) interaction were obtained 
under both cacodylate and MOPS buffer. A positive value of ∆n 0.23 (Table 2.3) was 
calculated using Equations (3) and (4). This number is quite consistent with the 
protonation number calculated for neomycin interacting with 5'-dA12-x-dT12-x-dT12-3’ 
(0.29), suggesting that the binding-linked drug protonation is not affected by the length 
of the nucleic acid. 
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Figure 2.7. (a) UV melting profiles of poly(dA)•2poly(dT) triplex at absence and 
saturated amount of neomycin. (b) A plot of ITC derived binding enthalpies vs 
corresponding temperatures. The slope reflects the heat capacity change ∆Cp. Buffer 
condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 5.5.   
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Study of the Heat Capacity Change 
 To determine the heat capacity of drug binding with the DNA triplex, parallel 
ITC experiments at various temperature were conducted to obtain the observed binding 
enthalpies (∆Ηobs) (see appendix). Theoretically, one can obtain the binding enthalpies 
by fitting the ITC profiles as described above. However, it has been found that when 
the binding signal is not significant, the data fitting becomes model-dependent and is 
sensitive to any small change in data processing, a conclusion especially true for 
paromomycin binding with the triplex. As shown in Table 2.1, the uncertainty of the 
binding constant for paromomycin is much larger than for neomycin. As a result, ∆Hobs 
could reflect significant errors. The model-independent protocol, the ITC excess site 
binding experiments as discussed above, is then used to obtain reliable binding 
enthalpies (see sample ITC excess titrations in appendix). The ∆Hobs obtained from 
several different temperatures facilitates determination of the heat capacity change 
Table 2.3.  Buffer dependence of the observed binding enthalpies, intrinsic 
binding enthalpies and the number of linked protons for the neomycin binding 
with poly(dA)•2poly(dT) triplex in 10 mM buffer, 0.5 mM EDTA and 100 mM 
KCl; pH 6.8, T=10 oC. 
Drug buffer ∆Hobs                                                            (kcal/mol) 
∆Hion    
(kcal/mol) 
∆Hint     
(kcal/mol) 
∆n               
(per drug) 
Neomycin cacodylate -7.4±0.1 -0.19 -7.3±0.1 0.23±0.06 
Neomycin MOPS -6.2±0.1 +5.07 -7.3±0.1 0.23±0.06 
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related to the drug interaction with the intramolecular triplex by applying the following 
equation: 
 
T
HC p ∂
∂
=∆                      (7) 
 
5'-dA12-x-dT12-x-dT12-3' triplex 
 Our calculations reveal that the magnitude of ∆Cp value decreases with 
increasing salt concentration at pH 6.8 for 5'-dA12-x-dT12-x-dT12-3' (Table 2.4).  The 
∆Cp value for the neomycin interaction with the triplex decreases in magnitude from -
310 cal/(mol·K) to -47 cal/(mol·K) and for paromomycin from –229 cal/(mol·K) to -13 
cal/(mol·K) as the salt concentration increases from 100 mM to 250 mM KCl. Even 
though all those observed heat capacity changes are overestimated to some extent due 
to the drug protonation, the intrinsic heat capacity changes are expected to be still 
negative. Recall that ∆Cp values for other minor groove binding drugs, such as 
netropsin, propamidine, berenil, Hoechst 33258, and distamycin, have been found to 
fall in the range of -150 to -350 cal/(mol·K) when binding to A3T3 duplex (37, 168), 
while furan derivatives, such as DB244, DB75 and DB226, have ∆Cp values between -
95 and -180 cal/(mol·K) (169). Intercalators including ethidium, propidium, 
daunomycin, and adriamycin have been observed to exhibit ∆Cp values of -140 to -160 
cal/(mol·K)  with calf thymus DNA, a smaller range than that of the groove binders 
(170). A positive ∆Cp value of +10 cal/(mol·K) for ethidium binding to calf thymus is 
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also observed using van’t Hoff analysis (171). However, to date, all groove binder-
DNA interactions have been found to have a negative ∆Cp.  
 Negative ∆Cp was observed for neomycin-nucleic acid interactions at both pH 
5.5 and 6.8 (Table 2.5). The negative ∆Cp is thought to be a distinctive feature of site-
specific binding in protein-DNA interactions, and the negative sign partially results 
from the removal of large amounts of nonpolar surface from the water on complex 
formation (172, 173). Solvent-accessible surface area change (∆SASA) has an impact 
on the value of ∆Cp  as well (37, 168).   Spolar has defined the following relationship 
between ∆Cp and  ∆SASA, ∆Cp= 0.32(±0.04)∆Anp - 0.14(±0.04)∆Ap, where ∆Anp 
represents the binding-induced changes in the nonpolar surface area and ∆Ap represents 
the binding-induced changes in the polar surface  area (174). This relationship implies 
that the removal of nonpolar surface causes the ∆Cp value to be more negative while the 
removal of polar surface leads to a more positive ∆Cp value. In addition to the removal 
of nonpolar solvent accessible surface area, generally, changes of vibrational modes of 
macromolecules and water molecules (175), and involvement of conformational 
equilibrium of macromolecules or some other coupled binding reaction (176, 177) are 
the other two main factors contributing to the ∆Cp value. However, in our system, the 
conformational equilibrium of nucleic acid does not exist at the temperature range 
studied here since those temperatures were carefully determined based on the thermal 
denaturation profiles from either UV or DSC. Binding coupled protonation of drug 
molecule was believed to contribute to the observed ∆Cp value at pH 6.8 since it has  
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Table 2.4. Heat capacity changes of neomycin and paromomycin binding with 5'-
dA12-x-dT12-x-dT12-3' triplex at four salt concentrations in 10 mM sodium 
cacodylate, 0.5 mM EDTA, and pH 6.8.  
[KCl]        
(mM) 
Drug 
∆Hb(5 °C) 
(kcal/mol) 
∆Hb(10 °C) 
(kcal/mol) 
∆Hb(15 °C)  
(kcal/mol) 
∆Cp   
(cal/mol·K) 
100 Neomycin -6.9±0.1 -8.4±0.1 -10.0±0.3 -310±43 
150 Neomycin -4.8±0.1 -5.5±0.1 -6.3±0.2 -158±30 
200 Neomycin -3.6±0.0 -4.1±0.1 -4.5±0.0 -84±12 
250 Neomycin - -2.7±0.0 -2.8±0.1 -17±22 
100 Paromomycin -3.8±0.1 -5.0±0.10 -6.1±0.1 -229±36 
150 Paromomycin -3.2±0.0 -3.7±0.1 -4.1±0.1 -96±24 
200 Paromomycin - -2.2±0.0 -2.3±0.1 -26±18 
250 Paromomycin - -1.2±0.0 -1.2±0.0 -13±6 
100 Ribostamycin - -3.0±0.1 -3.4±0.1 -76±30 
∆Hb were obtained from the ITC excess sites binding experiments.  
 
been found that drug protonation is associated with a non-zero ∆Cp (178). While at pH 
5.5, the contribution of drug protonation to ∆Cp does not exist any more. Recently, 
Lohman also reported the effect of anion to the ∆Cp value in the protein-nucleic acid 
interaction, with the magnitude of ∆Cp being larger when salt type switches from NaF, 
NaCl to NaBr (179). The effect of anions such as Cl- and SO42- to the ∆Cp may also 
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exist in the small molecule-nucleic acid interaction system by interacting weakly with 
the positively charged neomycin, but not significant given the reason that such type of 
interactions are likely to be weak in solution. The heat capacity change, thus, not only 
is linked to the changes between nonpolar and polar surface area change upon 
complexation, but also is dependent on the solution conditions.  
 We observe a decrease of ∆Cp in magnitude as the slat concentration increases. 
The salt effect of observed ∆Cp here, similar to those reported for protein-DNA 
interaction, could be explained by the disruption of salt bridges formed between 
positive can negative residues. Based on this model, the salt bridges formed at low salt 
condition are intact but disrupted upon another molecule binding. This disruption of salt 
bridge contributes to the large and negative ∆Cp. When salt concentration increases, the 
salt bridge is not easy to be disrupted by another interacting molecule, thereby inducing 
the smaller ∆Cp value in magnitude.    
 Among the three aminoglycosides studied here, a much less negative ∆Cp was 
observed for the binding of ribostamycin than for neomycin and paromomycin. This 
comparatively less negative ∆Cp value for the binding of ribostamycin than neomycin 
and paromomycin is most probably due to the absence of ring IV in ribostamycin, 
which, in turn, reduces the amount of nonpolar surface that can be buried upon DNA 
triplex binding (37). 
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Salt Dependence of Binding Affinities of Aminoglycosides with AT-rich Triplex 
poly(dA)•2poly(dT) triplex 
 The observed binding constants for neomycin with poly(dA)•2poly(dT) triplex 
calculated using ∆Tm method at 10 ºC over a range of KCl concentrations pH 5.5 are 
summarized in Table 2.5. As this table shows, the Kobs value decreases as KCl 
concentration increases, indicating that electrostatic interactions play an important role 
in the drug-triplex interaction. The apparent number of drug NH3+ groups participating 
in electrostatic interactions with the triplex can be estimated from plots of log (Kobs) vs. 
log([KCl]). The observed linear dependencies have been described by the following 
relationship (180, 181): 
 
])Klog([m)Klog()Klog( oobs +Ψ−=              (8) 
 
Where Kobs is the observed binding constant, m the number of ion pairs formed 
between the drug and the DNA triplex, Ψ the thermodynamic counterion binding 
parameter for the DNA triplex, and Kº the equilibrium constant for the drug- DNA 
interaction.   
 A plot of log (Kobs) vs. log ([KCl]) yields a slope of - mΨ, giving the least 
number of ion pairs formed between the drug and DNA triplex. As seen in Figure 2.8, 
the linear dependence of log (Kobs) vs. log [KCl] yields a slope of 2.8 for the neomycin-
DNA triplex complexation, suggesting that there are about 3 ion pairs formed upon 
binding. Recall it was revealed (181) that tobramycin has been found to bind to 
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poly(rI)•polu(rC) as a trication (3 out of 5 NH3+ participating in electrostatic 
interaction).  Neomycin and paromomycin contribute at least 3 and 3.6 amino groups, 
respectively, when forming an electrostatic interaction with A-site 16S rRNA (37). 
Berenil has been shown to bind to poly(dA)•poly(dT), poly(dA-dT)2, poly(dI-dC)2 and 
poly(rA)•poly(rU) with apparent valence values of 2.3, 1.4, 1.9 and 2.3 (182). The 
result reported here suggests a strong electrostatic contribution to the drug-triplex 
complexation, which is comparable to the aminoglycosides-16S A-site rRNA 
interaction.  
 At pH 6.8, however, the salt dependence study of the binding affinities of 
neomycin to poly(dA)•2poly(dT) or 5'-dA12-x-dT12-x-dT12-3' cannot be achieved 
because the observed binding affinities calculated with ∆Tm method at this pH is 
overestimated due to the overestimation of binding enthalpy and heat capacity changes 
in the presence of drug protonation, thereby not reflecting the intrinsic binding.   
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Figure 2.8. Salt dependence of the neomycin binding with poly(dA)•2poly(dT) 
triplex in 10 mM sodium cacodylate, 0.5 mM EDTA and 5.5. T= 10 °C.  
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Table 2.5. Thermodynamic profiles of poly(dA)•2poly(dT) and 5'-dA12-x-dT12-x-
dT12-3' interaction with aminoglycosides in 10 mM sodium cacodylate, 0.5 mM 
EDTA,  pH 6.8 or 5.5 and various KCl concentrations. T = 10 oC. 
poly(dA)•2poly(dT) 
Drug 
[KCl] 
(mM)/ 
pH 
 
∆HHS 
(kcal/mol 
base triplet) 
Tm0 
(ºC) 
Tm 
(ºC) 
∆Cp 
(cal/ mol.K) 
Kobs(10oC) 
(M-1) 
Neomycin 100/6.8 1.20 22.7 54.2 -218±15 - 
Neomycin 150/6.8 1.59 33.9 46.5 -116±34 - 
Neomycin 200/6.8 2.00 41.0 43.9 -76±13 - 
Neomycin 100/5.5 1.16 22.4 28.6 -98±13 (6.2±0.5)×105 
Neomycin 120/5.5 1.50 27.5 32.4 -90±18 (4.0±0.1)×105 
Neomycin 140/5.5 1.70 31.4 34.4 -87±4 (2.4±0.1)×105 
Paromomycin 100/6.8 1.20 22.7 32.2 -83±15 - 
Paromomycin 150/6.8 1.59 33.9 36.3 -29±9 - 
Paromomycin 200/6.8 2.00 41.0 42.5 -23±11 - 
Ribostamycin 100/6.8 1.20 22.7 26.2 -30±8 - 
5'-dA12-x-dT12-x-dT12-3' 
Neomycin 100/6.8 1.33 30.00 36.50 -310±43 - 
Neomycin 150/6.8 1.59 34.87 37.04 -158±30 - 
Neomycin 200/6.8 1.78 37.26 38.72 -84±12 - 
Neomycin 250/6.8 1.81 42.41 43.75 -17±22 - 
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Models of Neomycin vs. Paromomycin Docked in the W-H groove: The Difference A 
Charge Makes 
 We have previously proposed a model for neomycin binding to the W-H groove 
of the DNA triplex (47).  The modeling studies suggest that the most likely mode of 
neomycin binding involves the primary amine in neomycin ring I that occupies the 
center of the groove, while the amines on ring II and IV help bridge the two pyrimidine 
strands together.  A stereo view of this model is shown in Figure 2.9.  The salt 
dependent ITC studies further substantiate this model, with 3 ion pairs being formed 
between the neomycin amines and the TAT triplex groove, as shown in Figure 2.9. In 
addition to the charge complementarity, the shape complementarity of neomycin and 
the W-H groove has also been suggested as a key factor in the recognition of the DNA 
triplex by neomycin. A molecular dynamics simulation (up to 1 ps) shows this model of 
neomycin to the DNA triplex to be relatively stable.  On the other hand, a different 
picture emerges if paromomycin is docked into the W-H groove in a similar orientation 
(Figure 2.10). The replacement of 6'-amine group on neomycin ring I with an 6'-OH in 
paromomycin destabilizes the complex such that in about 500 ps, paromomycin is 
released from the groove, and as a result, the 6'-OH group cannot realize efficient 
electrostatic interaction or H-bonding within W-H groove.  Only the 2'-amino group 
can form this interaction, but it may be relatively weak due to its inflexibility and its 
long distance from the DNA backbone. Paromomycin perhaps binds to the W-H groove 
in a different orientation from neomycin (for example, ring II or ring IV being docked 
into the W-H groove). This difference in stability is also borne out by the lower binding 
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affinity of paromomycin vs. neomycin (Table 2.1), as well as the difference in DNA 
triplex stability induced by the two drugs (Figure 2.3), showing how a single charge 
can have a dramatic effect on the recognition of biomolecules. 
 Our previous work (48) has also suggested that aminoglycoside specificity 
(neomycin in high nM- low µM range) may be for nucleic acid forms that show some 
features characteristic of an A-type conformation {RNA triplex (46), DNA-RNA 
hybrid duplex (107), RNA duplex (42),  DNA triplex (45, 46, 183), A-form DNA 
duplex (43) and DNA tetraplex (184)}  rather than for naturally occurring RNA. 
Conflicting results, however, have been reported regarding the conformation of the 
triplex and of the Watson-Crick duplex within the triplexes. Both A-like (185-188) and 
B-like (189-191) geometry have been described in the literature. Arnott and Selsing 
first reported A-like geometry and 3'-endo (N-type) sugar pucker of 
poly(dT)•poly(dA)•poly(dT) using fiber diffraction studies (187). More recently, 
studies using FT-IR (192, 193), fiber diffraction, and solution NMR (153, 190, 191, 
194)  on different DNA triple helices (inter-, intra) have suggested that the structure of 
the DNA triple helix is more characteristic of B-form than of the A-form. In contrast to 
the results reported by Arnott and his coworkers, B-like geometry and 2'-endo (S type) 
sugar pucker were observed. Thus far, most pyrimidine-purine-pyrimidine triplexes 
studied have an axial rise similar to B-DNA, an X-displacement intermediate between 
the A- and B-DNA, a low helical twist which is similar to that in A-DNA, and a 
predominance of S-type sugar puckers which are generally found in B-DNA. Because 
DNA triplexes have both A-like and B-like characteristics, others have used terms such 
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as Ψ-DNA, P-DNA, among others to describe the DNA triplex conformation (195, 
196). Given the data available, it can be safely said that DNA triplexes have some A-
form characteristics. The lower association constant observed in 2-deoxystreptamine 
containing aminoglycoside-triplex interactions than in RNA triplex, RNA duplex and 
RNA•DNA hybrids (48) can then be explained by the fact that the DNA triplex lacks 
all the A-form characteristics that are present in RNA containing duplexes and 
triplexes.  Based on this hypothesis, as the A-form features increase in a set of nucleic 
acid structures, the association constant of aminoglycoside-nucleic acid should 
increase. According to the available set of aminoglycoside-nucleic acid interactions, 
this seems to be the case (48). 
Conclusion 
 The following conclusions can be drawn from these results above:  Among the 
aminoglycosides studied here, neomycin is the most effective agent in the stabilization 
of the 5'-dA12-x-dT12-x-dT12-3' and polynucleotide poly(dA)•2poly(dT) triplex. The 
∆Tm method can be applied to calculate the observed binding affinities for 
poly(dA)•2poly(dT) triplex at pH 5.5, a value excluding the drug protonation. The salt 
dependent studies at pH 5.5 reveals that there are about 3 ion pairs formed upon 
neomycin binding with poly(dA)•2poly(dT). Both FID and ITC techniques confirm that 
the binding affinity for neomycin binding with TAT triplex is in the range of 1-9 ×105   
M-1. This work reported here gives an increasing understanding of drug-triplex 
interactions from a thermodynamic standpoint, potentially forming the basis for 
investigations of ligand-induced in vivo H-DNA formation.       
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Figure 2.9.  Stereo view of neomycin bound to the W-H groove of the DNA 
triplex.  Only the two pyrimidine strands are shown for clarity.   Neomycin 
occupies 6-7 base-pairs per triplex. 
 
 
102 ps 252 ps 462 ps 
Figure 2.10. A 500 ps MD simulation of paromomycin bound to the W-H groove, 
with ring I inside the groove.  Three snapshots show the dissociation of 
paromomycin with time.  Dissociation of ring I drives the molecule outside the 
groove. 
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CHAPTER 3 
KINETICS AND THERMODYNAMICS OF AMINOGLYCOSIDE BINDING TO A 
DNA DUPLEX AND TRIPLEX: AN SPR STUDY 
 
Introduction 
 Since oligonucleotide-directed triple helixes have been shown to have potential 
applications in biology and therapy (127-129, 197), it has induced a great deal of 
interest in many labs. Triplex-forming oligonucleotides (TFOs) can be designed to be 
used as transcription inhibition agents and the formed triplex has been shown to lead to 
targeted mutagenesis (133). Wang has used the TFOs to study the molecular 
mechanism of triplex-mediated TCR (transcription-coupled repair) in HeLa nuclear 
extracts and found that the formation of triplex induced a much stronger DNA repair 
activity in promoter-containing plasmids (95). Hélène also has shown that a 17-mer 
homopyrimidine oligonucleotide was designed to bind to the major grooves of SV40 
DNA and found that it inhibited the enzymatic cleavage under conditions that allowed 
for triple helix formation (96). The homopurine-homopyrimidine sequences are found 
frequently in the promoter regions and around recombination hot spots (144), which 
suggests that triple helix formation in these regions is most probably playing a 
regulatory role in gene expression (145), recombination (146), and transcription of 
human viruses into the human chromosome in vivo (147). With its importance in the 
biological and therapeutic systems, improvement of the stability of triple helices has 
become a prime concern in its application. It is well known that DNA triplexes are not 
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as stable in biological solutions as the duplexes, so over the past 15 years, many ligands 
have been tested for their ability in stabilizing the triple helix. Groove binders (such as 
berenil, netropsin and Hoechst 33258) (102-104), intercalator (acridine (99), 
ethidium(101), quinacrine (98) and ruthenium complexes (100)) were all shown to bind 
to the triple helices. Groove binders do not show selectivity in binding to the DNA 
triple helices, and some of them even destabilize triple helices. Our previous work has 
shown the remarkable ability of neomycin and other aminoglycosides (see Scheme 1) 
and neomycin conjugates to stabilize DNA, RNA, and hybrid triple helices (45-47, 107, 
151, 198, 199). Neomycin was shown by us to induce the stabilization of DNA•RNA 
hybrid duplexes as well as hybrid triple helixes (107). This significantly added to the 
number of nucleic acids (other than RNA) that aminoglycosides have been shown to 
target.  Among the aminoglycosides studied, we found that neomycin significantly 
stabilizes DNA and RNA triple helixes (46).  
 In order to fully understand the DNA-drug interaction, a wide range of 
established techniques have been used to study the details of binding. X-ray 
crystallography and NMR spectroscopy can reveal the drug-DNA complex structure. 
UV absorbance monitors the hypochromicity upon DNA denaturation. Circular 
dichroism detects the conformation change upon drug binding to DNA. Isothermal 
titration calorimetry (ITC) and differential scanning calorimetry (DSC) give the 
detailed thermodynamic information about drug-DNA interactions. However, none of 
those techniques can directly provide the kinetic data in real time. SPR, a label-free 
technique, has been widely used in the past several years for characterizing the 
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properties of macromolecule-small ligand or macromolecule-macromolecule 
interactions in real time. These studies involve measuring binding affinity of ethidium 
bromide, dimethyl sulfoxide (DMSO), 4΄, 6-diamidino-2-phenylindole (DAPI), 
spermine and DB244 with DNA double helix (200, 201), binding of TFOs to murine c-
myc promoter (202), interaction of aminoglycosides with RNA (203), recognition of G-
quadruplex Telomeric DNA by BOQ1 (204), and protein-protein interactions (205). In 
these SPR studies, one interacting species can be immobilized on the surface of the 
biosensor chip, and the other interacting species then flows over the surface. The 
interaction is detected by measuring the refractive index change on the surface, which 
is in turn proportional to mass concentration change on the surface (201, 203). In 
addition to the advantage that the analysis is operated in real time, SPR also provides 
other numerous advantages such as minimal requirement for samples (generally in 
picomole or nanomole scale), label free for any interacting species and rapid screening 
of small molecule libraries (201). In this report, we reveal the interaction between 
aminoglycosides and a DNA triple helix and a DNA double helix. As described in our 
previous studies, the aminoglycosides were found to have a significant effect on 
stabilization of DNA triple helix (45-47, 107). Neomycin has exhibited the highest 
stabilization among all aminoglycosides, however, it is not known yet if the 
aminoglycoside-DNA triplex/duplex interaction is governed by kinetic or equilibrium 
properties or both. Using SPR, we report the kinetic/thermodynamic basis of the 
aminoglycoside-triplex/duplex interaction.  
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Melting temperature determination by UV thermal analysis 
 In order to determine the running temperature of SPR experiments, UV analysis 
is necessary to be performed under the same buffer condition applied for the SPR 
experiments. The UV melting profile of dT30-dA30•dT30 intermolecular triplex in the 
TAM buffer at 260 nm and 280 nm are shown in Figure 3.1. Two transitions are 
observed, and the melting temperature around 34 ○C corresponds to triplex and the 
other one at 61 ○C corresponds to duplex. The triplex melting transition is not clear at 
260 nm, indicating a weak interaction between third strand and duplex. However, to 
determine the formation of triplex, 280 nm is the best wavelength for most triplexes to 
observe. Thus, 20 ○C, about 14 ○C lower than our triplex melting temperature, was 
selected as our SPR running temperature.  
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Figure 3.1. UV melting profile of dT30-dA30•dT30 triplex in the absence of 
aminoglycosides at 260 nm (a) and 280 nm (b).  Buffer: 40mM Tris, 5mM MgCl2, 
pH 7.0. [DNA] = 2 µM in strand. 
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BIAcore surface plasmon resonance experiment 
 The kinetic and thermodynamic study of aminoglycosides-DNA triplex 
interaction was performed on a BIAcoreX instrument at 20 ○C. After the 5'-biotin-dT30 
was immobilized on the surface, triplex was formed by injecting the duplex-forming 
and triplex-forming strands, correspondingly, as described above. A range of drug 
concentrations was then injected onto the triplex until the saturation of drug-triplex 
binding was observed. The apparent binding response was the sum of the these 
components listed below (206): 
 
R = R0 + Rbinding + R buffer 
 
where R0 is the starting baseline level, Rbinding is the SPR response due to the drug 
binding to DNA, Rbuffer refers to the bulk shift. Corrected sensorgrams were obtained by 
subtracting the control flow cell sensorgram from the reaction flow cell sensorgram by 
overlaying two sensorgrams together.  The bulk response contribution then was 
removed. R0 can be removed by normalizing the Y axis.  The "double referencing" 
(201, 207)has been previously used to process data. In this method, a buffer injection 
with same volumes used for sample injection is required. The control cell corrected 
buffer sensorgrams were obtained in the same way as described above, and then 
subtracted from all the control cell corrected sample sensorgrams to remove the 
systematic or baseline drifts. In our case, the observed baseline drift is ~1 RU/min, in 
the range of instrumental noise, so it was not necessary to take this influence into 
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account in our data processing. 
 
 
 The SPR sensorgrams were analyzed using BIAevaluation 3.1 software. The 
corrected sensorgrams were obtained by subtracting the control signal (flow channel 1) 
from sample signal (flow channel 2). To obtain the binding affinity, steady state 
analysis was used by making a binding isotherm of steady state response vs. 
corresponding drug concentration. The resulting binding isotherms then were fitted 
with Origin 7.0 for nonlinear least squares optimization using a single binding site 
(208): 
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Figure 3.2. (a-c) SPR sensorgrams of interaction for neomycin (a), paromomycin (b) 
and ribostamycin (c) with 5′-dT30-dA30•dT30 triplex. (d-f) Binding isotherms: The 
steady state response of panel a-c, plotted as a function of concentration for neomycin 
(d), paromomycin (e), and ribostamycin (f), respectively. Buffer: 40 mM Tris-acetate, 
5 mM MgCl2, and pH 7.0. T=20 ○C. 
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where K1 is dissociation equilibrium constants, C is the free drug concentration which 
is fixed by the drug concentration in the flow solution, RUss is the steady state response 
in RU corresponding to every drug concentration, RUmax is the maximum binding 
response in RU for binding one ligand per binding site (201).  
 
 
 Kinetic parameters were obtained by fitting the dissociation and association 
phases of SPR sensorgram separately or globally using BIA evaluation 3.1. Generally, 
global fitting was used if the goodness of fits was satisfactory by visual inspection. 
However, when global analysis did not yield good fits, separate fitting of kinetic data 
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Figure 3.3. Scatchard plot of 5′-biotin-dT30-dA30•dT30 triplex binding with 
neomycin (a), paromomycin (b), and ribostamycin (c) at 20 oC. The drug bound 
response is calculated from steady state region and C is the drug concentration in the 
flow solution. The data were processed according to the reference (201). 
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was carried out. For ligand dissociation from DNA triplex on the surface, the 
dissociation kinetics can be described by a single-exponential decay for single site 
binding (209, 210), defined as 
 
offR
)0tt(*1dk
e*)0t(1R)t(R +
−−
=        (2) 
 
where kd1 is dissociation rate constant, R1 is the amplitude of the dissociation with a 
rate constant kd1, t0 is the starting time of the fitted data, R(t) is the response at time t, 
and Roff is the residual response at infinite time.  With the aid of dissociation rate 
constants derived from equation (2), the association rate constants for one binding site 
is shown in equation (3) (209, 210), 
 
)0t(R
1dk1ak*C
))0tt(*)1dk1ak*C(e1(*1maxR*1ak*C
)t(R +
+
−+−
−
= 







   (3) 
 
where ka1 and kd1 are the rate constants describing one interaction with maximal 
response of Rmax1, Rt0 is the fitting parameter equivalent to the signal at the injection 
time (t=0), t0 is the starting time of injection, and the R(t) is the binding response at time 
t. 
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Figure 3.4. (a) CD scan of neomycin titration into dT30-dA30•dT30 triplex at 20 oC. 
Black line represents the CD scan of DNA alone. (b) A plot of CD intensity at 258 nm 
vs. respective rbd values. Linear fit of two apparent linear data portions yields a cross 
intercepts at 5 and 1.8. Buffer: 40 mM tris-acetate, 5 mM MgCl2, and pH 7.0.  
 
 Figure 3.2 show the overlaid corrected real-time sensorgrams of 
aminoglycosides binding to a DNA triplex on an SA chip surface (upper panel). The 
response (in resonance unit, RU) resulting from the refractive index change of the 
surface is proportional to the mass of bound drug molecules, which is in turn related to 
the drug concentrations (201, 206). The lower panel shows the binding isotherms of 
every aminoglycoside-DNA triplex/duplex interaction, which were made by plotting 
the steady state response of each sensorgram as a function of corresponding drug 
concentrations. The experimental binding data then were transformed to a Scatchard 
plot to observe the binding cooperativity, as shown in Figure 3.3.  Linear Scatchard 
plots were observed for paromomycin and ribostamycin interacting with DNA triplex 
(Figure 3.3) and all the aminoglycosides interacting with DNA duplex (Figure 3.5), 
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indicating a single class of binding sites exists in every case. Fits of either binding 
isotherms using one-site model (201) or Scatchard plots with linear regression (211) 
give same binding affinities for each experiment, and the resulting data are listed on 
column 5 in Table 3.1. However, a concave downward curve is observed for the 
neomycin binding with DNA triplex, suggesting a system with cooperativity. However, 
it cannot be determined by SPR technique for the types of binding site size, thus further 
work like CD titration should be applied to obtain the binding site size for neomycin 
binding to dT30-dA30•dT30 triplex. As shown in Figure 3.4a, CD titration of neomycin 
into this triplex induces a strong negative band at 290 nm, and a positive feature at 260 
nm. The negative band at 247 nm, which is characteristic of B-form structure, gradually 
disappears upon neomycin addition as well. All those features indicate a new structure 
formation, Z-form DNA, unexpectedly. It has been reported previously that poly(dG-
dC)•poly(dG-dC) undergoes a B- to Z- form transition due to the salt effect (212, 213). 
The observed opposite sign patterns in CD appear to be a consequence of the different 
handedness of their respective polymeric backbones. We observed for first time that 
neomycin induces an AT-rich DNA triplex transformation from B to Z form. While we 
did not observe the AT-rich triplex transformation by neomycin under other salt 
conditions (sodium cacodylate, 100 mM KCl or NaCl), thus apparently this 
conformational transformation is due to the buffer effect.  
 Figure 3.4b reveals two types of binding site sizes of neomycin binding to 
dT30-dA30•dT30 triplex, one around 5 base triplets/drug (~ 6 drugs/DNA duplex) and 
another around 1.8 base triplets/drug (~ 10 drugs/DNA duplex). Due to the large 
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number of binding site sizes for the second binding event, we propose that the second 
binding event is most probably due to the neomycin binding to Z-form triplex since Z-
form structure contains larger and shallower grooves which can accommodate more 
binding sites for neomycin. However, for such a complicated system, there is no model 
available to fit the binding sensergrams to obtain the binding affinities. ITC study 
conducted below is then applied for observing the binding affinity of neomycin to dT30-
dA30•dT30 triplex.  
 Inspection of binding affinities obtained from the data fits (Table 3.1) indicates 
that paromomycin binds to the DNA triplex (3.20 × 104 M-1) about 20 fold greater in 
binding affinities than that for for ribostamycin (1.7 × 103 M-1). A similar trend was also 
observed for aminoglycosides interacting with DNA duplex, with neomycin binding 
affinity (1.19 × 105 M-1) about 10 folders higher than paromomycin (1.32 × 104 M-1) 
and 100 times higher than ribostamycin (1.15 × 103 M-1). In comparison of 
aminoglycosides binding affinities with duplex and triplex, it was found that all the 
aminoglycosides bind to triplex stronger than to the corresponding duplex. 
Paromomycin interacts with triplex ~3 times stronger than with duplex. No big 
difference in binding affinities was observed between ribostamycin-duplex and 
ribostamycin-triplex interaction. The reason may be due to the weak binding affinity 
that has been out of the SPR detection limit (~ 104-1012 M-1) (214). The results above 
clearly allow us to conclude that aminoglycosides prefer to DNA triplex rather than 
DNA duplex. This observation is satisfactory consistent with our previous reports (45-
47, 107).  
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 One of the advantages of SPR is that both equilibrium and kinetic data can be 
extracted from the SPR data simultaneously.  In order to get the precise kinetic 
parameters, the association phase and dissociation phase should be selected carefully 
when operating the separate kinetic data fitting. The split view of sensorgrams is an 
additional aid in selecting the fitting range. For a simple 1:1 langmuir binding model, 
the functions ln[abs(dR/dt)] and ln(R0/R) were linear during the association part and 
dissociation part, respectively. However in a global analysis, the fitting data was 
selected as much as possible in order to reflect the real binding event accurately.  The 
selected data then were fitted by the equation (2) for dissociation phase and the 
equation (3) for association phase, and the yielded data are listed in column 2 and 3 in 
Table 3.1.  
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Figure 3.5. Scatchard plot of 5′-bt-dT30-dA30 duplex binding with neomycin (a), 
paromomycin (b), and ribostamycin (c) at 20 oC. The drug bound response is 
calculated from steady state region and C is the drug concentration in the flow 
solution. The data were processed according to the reference (201). 
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Table 3.1.  Kinetic and equilibrium data for triplex/duplex - drug complexation by 
SPR 
 ka 
(M-1s-1) 
kd 
(s-1) 
KAa 
(M-1) 
KAb 
(M-1) 
 
Triplex 
Neomycin  
First site: NA NA NA (2.5±1.3)×10
7
 
Neomycin 
Second site: NA NA NA (2.7±0.5)×10
6
 
Paromomycin (5.03±0.15)×103 (1.43±0.01)×10-1 (3.52±0.13)×104 (3.20±0.12)×104 
Ribostamycin (3.30±0.16)×102 (1.56±0.02)×10-1 (2.12±0.13) ×103 (1.70±0.11)×103 
 
Duplex 
Neomycin (1.18±0.06)×104     (1.05±0.00)×10-1     (1.13±0.06)×105       (1.19±0.12)×105 
Paromomycin (1.79±0.06)×103     (1.51±0.02)×10-1      (1.18±0.06)×104      (1.32±0.06)×104 
Ribostamycin (1.52±0.03)×102     (1.42±0.01)×10-1      (1.07±0.03)×103      (1.15±0.06)×103 
The ka and kd data were obtained from data fits of binding sensorgrams separately or 
globally. a The data were obtained from kinetic studies, which equal to ka/kd. b The 
data were obtained by fitting binding isotherm using one-site model or two-site 
model. 
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Figure 3.6. Representative kinetic fits of ribostamycin binding with dT30-dA30•dT30 
triplex at dissociation portion (a) and association portion (b), and neomycin binding 
with dT30-dA30 at dissociation portion (c) and association portion (d). The black lines 
in each graph represent the fitting data. In each graph, from bottom to top, the 
concentration of neomycin increases gradually.  
(a) (b) 
(c) (d) 
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 The examples of kinetic fits are shown in Figure 3.6. Due to unavailability of 
appropriate kinetic model for more than two binding sites, neomycin-triplex kinetic 
study cannot be achieved. As shown in Table 3.1, the association rate constants for 
paromomycin and ribostamycin binding to triplex are significantly different, with 
paromomycin  (5.03 × 103 M-1s-1) about 15 times faster than ribostamycin (3.30 × 102 
M-1s-1). However, both paromomycin and ribostamycin have a similar dissociation rate 
of~1.50 × 10-1 s-1. The difference of binding affinities between paromomycin and 
ribostamycin, therefore, is only determined by their very different association rate 
constants. Inspection of the kinetic parameters of aminoglycosides interacting with 
DNA duplex reveals surprisingly that all the aminoglycosides have a similar 
dissociation rate constant (~1-1.5 × 10-1 s-1), indicating that the binding affinities for 
duplex are only determined by the association rate constants, which are 1.18 × 104 M-1s-
1
 for neomycin, 1.79 × 103 M-1s-1 for paromomycin, and 1.42 × 102 M-1s-1 for 
ribostamycin. Even more interesting is that the dissociation rates of aminoglycosides 
from duplex are similar to the dissociation rates of paromomycin and ribostamycin with 
triplex, implying again that association rate is the key factor in the affinity differences 
of the aminoglycoside-triplex interaction (particularly, paromomycin and ribostamycin) 
vs. the aminoglycoside-duplex interaction. We also calculated the binding constants 
from the ratio of ka/kd, and they are listed on column 3 in Table 1 and Table 2. The 
binding constants (ka/kd) are in excellent agreement with those determined by the 
steady-state analysis, confirming the reliability of the kinetic data. 
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 Recall that other minor groove binding drug, such as bis-benzimidazoles (215), 
were found to have the ka values in the range of ~104-105 M-1s-1 and kd values in the 
range of ~10-2-10-3 s-1 using SPR when binding to the different sequences of DNA. 
Intercalators such as ditercalinium (216), ethidium (217, 218), anthracene-9,10-dione 
(219), carboxy dimidium (218), desphenyl dimidium (218), and ethyl phenidium (218) 
were observed to have the ka values of ~106-107 M-1s-1 and kd values of ~1-103 s-1  
when binding to the polynucleotide duplex, a faster association and dissociation rate 
than minor groove binders. Ligands with dual modes of binding, such as DAPI (220), 
show a smaller ka (~ 104 M-1s-1) and kd (~10-3 s-1) when binding to oligonucleotide 
duplex. Quadruplex binder (216), such as DAPI, was found to have the similar range of 
kinetic constants as it bind to oligonucleotide duplex. However up to date, there are few 
articles reporting the kinetic properties of ligand-DNA/RNA triplex interaction. 
Aminoglycoside, particularly neomycin, has been shown to be the most effective agent 
in stabilizing a DNA or RNA triplex as well as an intramolecular triplex. It has a much 
higher binding affinity than the other neomycin-class aminoglycosides (46, 47). The 
higher binding affinity of neomycin for DNA over paromomycin and ribostamycin 
results from, at least partially, the effect of a faster association rate. This study is the 
first detailed report on elucidating the aminoglycosides-DNA triplex/duplex interaction 
in real time scale from a kinetic standpoint. 
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Isothermal Titration Calorimetry (ITC) experiment 
  Due to the difficulties to describe the binding properties between neomycin and 
dT30-dA30•dT30 triplex, we also conducted ITC study under same condition used in the 
SPR experiment (40 mM tris acetate, 5 mM MgCl2, pH 7.0, and T=20 ○C). The ITC 
profile and corresponding data fits are shown in Figure 5.  Each of the heat burst curves 
resulted from 5 µL aliquots of drug injection. The area under each of the heat burst 
curves was integrated to yield the associated injection heat. The injection heat was 
corrected by the subtraction of the corresponding dilution heat, which was determined 
by titrating the same amount of drug solution into the sample buffer alone under the 
same conditions. The corrected injection heat as a function of the [drug]/[triplex] ratio 
are listed in Figure 3.7b.  In the Figure 3.7a, the data points reflect the experimental 
injection heats, while the solid line reflects the successfully fitting using Origin 5.0.  
 The experiment data was fitted very well using the model with two sets of 
binding sites, and the yielded thermodynamic parameters are listed in Table 3. As seen 
from Table 3.2, association constants are (3.1 ± 1.5)×107 M-1 for the first binding site 
and (2.7 ± 0.5) ×106 M-1 for the second binding site.  The interactions for both sites are 
entropy-driven, with 77% driving force contributed from entropy for first binding 
event, and 81% entropy contribution for second binding event. The binding site sizes (6 
bound neomycin for first site and 12 bound neomycin for second site) from ITC data 
fits are very close to the values determined from CD titration above (6 and 10 neomycin 
for first and second binding sites, respectively), indicating the correct application of an 
ITC model.  
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Table 3.2. ITC derived thermodynamic profiles for neomycin binding to dT30-
dA30•dT30 triplex in 40 mM tris-acetate, 5 mM MgCl2, pH 7.0. T=20 ○C 
n 
(drug/triplex) 
 
KA 
(M-1) 
∆H 
(kcal mol-1) 
T∆S 
(kcal mol-1) 
∆G 
(kcal mol-1) 
6.0 (2.5 ± 1.3)×107 -2.34±0.22 7.71 -10.05±0.22 
12.0 (2.7 ± 0.5) 
×106 -1.65± 0.08 6.98 -8.63±0.08 
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Figure 3.7. (a) ITC titration of neomycin with DNA dT30-dA30•dT30 triplex. (b) 
Corrected injection heat as a function of [Neomycin]/[Triplex] ratio. The data points 
represent the experimental injection heat and the solid lines were corresponding to 
the calculated fits of the data using a model with two sets of binding sites (Origin 
5.0). Buffer condition: 40 mM Tris-acetate, 5 mM MgCl2, pH 7.0. T=20 ○C. 
[Triplex]=2 µM in strand; [neomycin]=1 mM. 
(b) (a) 
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 We have found previously neomycin binds to an intramolecular triplex 5'-dA12-
x-dT12-x-dT12-3' (see Figure 3.8) with a binding constant at (1.4±0.2)×106 M-1, and a 
poly(dA)•2poly(dT) triplex at a constant of (3.5±0.7)×107 M-1 under 100 mM KCl ionic 
strength. This obtained binding constant for first binding site by SPR is close to the one 
for polynucleotide triplex, however about 20 times greater than the intramolecular 
triplex. One reason for such discrepancy may be attributed to the structure difference 
between intermolecular and intramolecular triplex. Intramolecular triplex usually is 
more rigid due to the linker configuration, thus there is less conformational change 
upon neomycin binding to it. However, intermolecular triplex has much more 
flexibility, which has be found to favor the drug - triplex interaction in our previously 
study. The structure flexibility is also supported by the evidence of conformational 
transformation of intermolecular dT30-dA30•dT30 triplex from B to Z form.  
Furthermore, when comparing the binding affinities of intermolecular triplexes between 
poly(dA)•2poly(dT) and dT30-dA30•dT30, it is also noticed that binding affinity of dT30-
dA30•dT30 obtained under 5 mM MgCl2 solution (2.5 ± 1.3)×107 is slightly small than 
the one of poly(dA)•2poly(dT) conducted under 100 mM KCl solution (3.5±0.7)×107 
M-1.  In general, Mg2+ is more potent in stabilizing DNA triplex than K+, thus 
exhibiting stronger effect in precluding other cations such as neomycin from binding to 
DNA. As a result, the binding affinity of drug molecule binding to triplex is usually 
smaller in Mg2+ system than in monocationic K+ or Na+ systems.  
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Figure 3.8. Structure of intramolecular triplex 5'-dA12-x-dT12-x-dT12-3'. X denotes 
hexaethylene glycol. 
 
Conclusion 
 Surface plasmon resonance (SPR) has been applied to detect the interaction 
between DNA double helix 5′-biotinylated (5′-bt) dT30-dA30, triple helix 5′-bt dT30-
dA30•dT30 and the aminoglycosides: neomycin, paromomycin and ribostamycin. The 
ligand-triplex interaction then was observed by introducing the drug onto the triplex-
formed surface. The best fits from the obtained binding isotherms of triplex-drug 
interaction yielded the association equilibrium constants (Keq), which were (3.20±0.12) 
× 104 M-1 for paromomycin, and (1.70±0.11) × 103 M-1 for ribostamycin. In addition, 
the binding equilibrium constants for the drug-duplex interaction using the same 
method were (1.41±0.20) × 105 M-1, (1.32±0.20) × 104 M-1, and (1.15±0.20) × 103 M-1 
for neomycin, paromomycin and ribostamycin, respectively. The kinetic study showed 
that the association rate constant for paromomycin binding with bt-dT30-dA30•dT30 
triplex (5.03 × 103 M-1s-1) is about 15 times faster than ribostamycin (3.30 × 102 M-1s-1). 
However, both paromomycin and ribostamycin exhibit the similar dissociation rate 
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(~1.5 × 10-1 s-1). All the aminoglycosides dissociate from bt-dT30-dA30 duplex at a 
similar rate (kd ≈1-1.5 × 10-1 s-1), but the association rate constants differ by an order in 
magnitude, with neomycin (~104 M-1s-1) > paromomycin (~103 M-1s-1) > ribostamycin 
(~102 M-1s-1).  These kinetic results indicate that the different binding constants 
observed for aminoglycosides interacting with DNA duplex or triplex are most 
probably governed by the association rather than the dissociation process. ITC studys 
show the much higher binding affinity of neomycin interacting with dT30-dA30•dT30 
triplex, with a value of (2.5 ± 1.3)×107 M-1, which is about two orders higher than 
paromomycin. This result is consistent with our previous observation that neomycin is 
the most potent triplex binder among the aminoglycosides studied.  
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CHAPTER 4 
RECOGNITION OF NUCLEIC ACIDS BY NEOMYCIN— 
A NUCLEIC ACID SURVEY  
 
Introduction 
As the intracellular targets of small drug molecules with a variety of chemical 
structures, nucleic acids have attracted attention in the application of chemotherapy.  As 
one of three important biological macromolecules, the most important biological 
function of nucleic acid is to code for the synthesis of a specific protein, with different 
triplet combinations of bases responsible for one amino acid. The phosphate backbone 
of nucleic acids carries a permanent negative charge and exhibits a relatively large 
degree of freedom. When two or more single strands associate to form such higher 
order nucleic acid structures as a triplex or a tetraplex (hydrogen bonds formation 
shown in Figure 4.1), charge repulsion occurs due to high electronegative potentials on 
the backbones, neutralized by the introduction of sodium, potassium, magnesium and 
polycations.  
 The binding of small drug molecules to nucleic acids can inhibit the functions 
exhibited by nucleic acids in biological systems. For example, targeting DNA duplex 
can inhibit DNA replication itself and transcription (synthesis of RNA) (81, 221); 
targeting the triplex can achieve an antigene strategy (130, 133); interacting with the 
tetraplex can potentially treat tumors (121, 222, 223); interacting with a DNA•RNA 
hybrid may inhibit transcription processes (224); and targeting a single strand RNA 
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may inhibit the translation process (synthesis of protein). Thus, the targeting of a 
nucleic acid by a small drug molecule can achieve therapeutic purposes in treating 
tumors, cancers, and viral and bacterial diseases. Specifically, these approaches have 
shown initial success in treating the diseases such as cancers and tumors.  
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Figure 4.1. Representative chemical structures of hydrogen bonds formed between 
DNA duplex, triplex and G-tetraplex studied here. 
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 Aminoglycosides, initially identified as antibacterial drugs important in the 
treatment the infections caused by gram-negative bacteria, were bound in Arya’s 
laboratories to significantly stabilize DNA and RNA triplexes (46), the first example of 
DNA-based nucleic acid recognition by aminoglycosides. Among them, neomycin 
(Figure 4.2a) is the most potent one. More recently, Pilch reported that 
aminoglycosides also show high binding affinities to DNA/RNA hybrids (224). In 
addition, NMR studies conducted by Puglisi showed that paramomycin binds to the 
asymmetric internal loop of A-site 16S rRNA duplex within the major groove (20). 
Computer modeling conducted previously revealed that neomycin binds to the major 
groove, specifically, the Watson-Hoogsteen groove of the T-A•T triplex (47). 
Tobramycin has been demonstrated to interact within the major groove of 
poly(rI)•poly(rC) duplex (181). Aminoglycosides, due to their large size and shape, are 
believed to bind to nucleic acids within the major grooves. Competition dialysis has 
revealed that the common thread of the conformation feature of nucleic acids that 
aminoglycosides,  at least neomycin, prefer to bind to the A-form structure that nucleic 
acid adopts (48). However, recent studies conducted in Arya’s laboratories have found 
that the neomycin-neomycin dimer (44) and the neomycin-Hoechst 33258 conjugate 
(225) bind to a canonical B-form structure, poly(dA)•poly(dT), via a minor and major 
groove dual recognition mode, exhibiting high affinities in the nanomolar range, 
comparable to the value of neomycin binding to the poly(rA)•poly(rU) duplex structure 
alone. This study is the first example indicating that aminoglycoside is recognized by 
B-form DNA. Not limited to the structures mentioned above, neomycin was also found 
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to exhibit tight binding to the G-tetraplex (unpublished data), a DNA structure formed 
from telomere which is a single G-rich DNA strand tailed at the end of chromosome. 
Formation and stabilization of the G-tetraplex has potential application in antitumor 
therapy.  
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Figure 4.2. Chemical structures of neomycin (a) and fluorescein-neomycin conjugate 
(b). 
 
 Aminoglycosides, specifically neomycin, has shown the ability to bind to a 
variety of nucleic acid structures, perhaps explained as one of the reasons for the 
adverse side effects such as renal toxicity and ototoxicity induced by their use in the 
treatment of medical conditions. Increasing drug selectivity, an important focus in the 
treatment of various malignant diseases, has been a long focus in the chemotherapy 
approach. The modification of aminoglycosides has been explored for this purpose in 
many laboratories (226, 227), with their conjugating with intercalators or minor groove 
binders being accomplished to achieve binding specificity and selectivity for targeted 
nucleic acids (151, 225). However, those modified drugs have to be compared with 
their parent molecules when binding to different nucleic acid structures. To achieve this 
(a) (b) 
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comparison, nucleic acid biophysics has been used as the fundamental basis in relating 
the structural information to the thermodynamic stability and functional properties of 
those complexes formed between the drug and nucleic acid.   
 The study of the thermodynamics of small molecule-nucleic acid interactions 
provides important insight into the forces that drive bimolecular interaction. In this 
study, we have examined the binding properties exhibited by neomycin interacting with 
different nucleic acid structures ranging from B-form to A-form, including single, 
double, triple, and quadruple strands. However, it has been known for long that 
neomycin is protonated when interacting with DNAs or RNAs, leading to a problem in 
obtaining the intrinsic binding enthalpy and heat capacity change at physiological pH. 
Thus, the binding affinity calculated with ∆Tm method (37) using these thermodynamic 
parameters is usually overestimated. Inspection of the pKa values of the six amino 
groups on neomycin allows for the determination of pH 5.5 at which neomycin is fully 
protonated (35). Thereby, study at this pH reflects the intrinsic binding properties of 
neomycin, however, probably inducing some other problems like stability of nucleic 
acids, enthalpy unfavorableness, etc. Therefore, we conducted complete 
thermodynamic studies at both pH 6.8 and 5.5, aiming to find out whether the binding 
preference of neomycin at physiological pH is same as its fully protonated status. In a 
word, this nucleic acid screen by neomycin can provide a fundamental basis for 
understanding neomycin’s interaction and selectivity over a variety of nucleic acids and 
serve as a database when comparing the binding effect of neomycin with modified 
neomycin or neomycin-small molecule conjugates.  
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Competition Dialysis 
 
 Previous data has shown that neomycin not only prefers the natural 16S A-site 
rRNA but also exhibits a significant stabilizing effect on DNA or RNA triplexes. These 
results imply that neomycin may have more than one target in organisms and that its 
binding to those targets may be considered. To explore this issue, competition dialysis 
was used here as a nucleic acid screen technique to illustrate the binding of neomycin to 
different structures of nucleic acids both quantitatively and simultaneously. A 
fluorescein-neomycin conjugate (Figure 4.2b) was used in the competition dialysis 
study instead of neomycin to address the non-fluorescent property of neomycin. In 
addition, the binding of fluorescein to nucleic acids was investigated individually to 
observe its effect on neomycin binding.  
 As shown in Figure 4.3 (a,c,e), this method monitors the comparative neomycin 
binding to 14 different nucleic acid structures, including single strand  nucleic acids 
[poly(dT), poly(A), poly(U)], duplex [poly(dA)•poly(dT), poly(rA)•poly(dT), 
poly(rA)•poly(rU), poly(dA)•poly(rU), poly(dG)•poly(dC), calf thymus], triplex 
[poly(dA)•2poly(dT), poly(rA)•2poly(rU)], tetraplex (T2G20T2), i-motif (polydC), and 
neomycin natural target (16S A-site rRNA). The amount of neomycin binding to each 
nucleic acid was shown as a bar graph. Since all nucleic acids are dialyzed 
simultaneously in the same drug solution, the amount of the bound neomycin is directly 
proportional to the binding affinity for each nucleic acid. 
  Figure 4.3 suggests the following conclusions. First, The results indicate that 
neomycin prefer to bind to 16S A-site rRNA as expected, yielding a bound drug of 85 
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nM in 100 mM Na+, 50 nM  in 150 mM Na+, and 15 nM in 200 mM Na+. Binding to 
the RNA triplex poly(rA)•2poly(rU) is comparable to the natural target at low salt 
condition, with 60 nM, 20 nM, and 5 nM bound neomycin in 100, 150 and 200 mM 
Na+, respectively.  Neomycin also shows signficant binding to RNA duplex 
poly(rA)•poly(rU), DNA triplex poly(dA)•2poly(dT), T2G20T2 tetraplex, and hybrid 
duplex poly(dA)•poly(rU), with approximately 10~20 nM bound drug on those 
structures. However, neomycin exhibits little binding effect to the DNA duplex 
poly(dA)•poly(dT), hybrid duplex poly(rA)•poly(dT), calf thymus DNA, i-motif DNA 
and all single strand nucleic acids studied here. Second, the binding of neomycin to 
nucleic acids is affected by the salt concentration. As Na+ concentration increases from 
100 to 200 mM, the amount of bound neomycin decreases approximately 4~5 times for 
every nucleic acid structure except for the T2G20T2 tetraplex. These results are 
consistent with the thermodynamic study on neomycin-nucleic acids interaction which 
will be shown later. Third, this salt-independent binding of neomycin to the T2G20T2 
tetraplex most probably indicates that electrostatic interaction does not play an 
important role in the neomycin-tetraplex complexation. The binding constants of 
neomycin to this tetraplex may exhibits similar in the salt range studied here.  Fourth, 
fluoresecin itself shows little binding affinity to all nucleic acids under all three salt 
conditions as show in Figure 4.3 (b,d,f). The fluoresecin bound is smaller than 4 nM 
under all three salt conditions. This observation suggests that the binding of 
fluorescein-neomycin accurately represents the binding of neomycin, implying that 
fluorescin makes no contribution of any measured value on the bound neomycin. Fifth, 
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the absence of the poly(dA)•2poly(dT) data under 100 mM Na+ is due to the instability 
of the triplex under ambient temperature (~22oC). The melting temperature of this 
triplex is as low as 21 oC.  
 Competition dialysis data reveals that neomycin not only selectively binds to the 
natural target 16S A-site rRNA but also shows comparable binding to other nucleic acid 
structures, including DNA and RNA triplex, hybrid duplex, highly ordered TGT 
tetraplex, and GC rich DNA sequence. Analysis of the nucleic acid structures that 
neomycin favors suggests that they all display features characteristic of A-type 
conformation, the one is known to be adopted by RNA. The hybrid duplex, especially 
poly(dA)•poly(rU), exhibits intermediate conformation between the A and B forms, but 
more typically an A-form (228). The low bound drug observed for poly(rA)•poly(dT) 
can be attributed to the fact that this hybrid can exist in the B-form (228). In addition, 
dG•dC-rich sequences is also known to an adopt A-conformation in the presence of a 
cation (229). A red shift of the CD signal was observed after the addition of neomycin, 
indicating a B to A transformation, observed by Wang as well as  Kypr in the similar 
CD experiments (43). Highly ordered nucleic acids such as G-tetraplex and triplex also 
adopt a  conformation exhibiting some A-like features (230), with a strong band in the 
vicinity of either 260 nm or 205 nm. 
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Figure 4.3. (a,c,e) Competition dialysis results of fluoresein-neomycin with various 
nucleic acids at 100 mM Na+ (a), 150 mM Na+ (c), and 200 mM Na+ (e). (b,d,f) 
Competition dialysis results of fluoresein with various nucleic acids at 100 mM Na+ 
(b), 150 mM Na+ (d), and 200 mM Na+ (f). Experimental condition: 200 µL of 
different nucleic acids (7.5 µM per monomeric unit of each polymer) was dialyzed 
for 72 hrs with 400 mL 100 nM ligand in 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM 
Na2EDTA, pH 7.0  and various Na+ concentrations as indicated in graphs. 
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Thermodynamic Study of Nucleic Acids-Neomycin Interactions 
Polyadenylic acid (polyrA) 
 Although poly(rA) was initially believed to exist as a flexible, contracted and 
irregularly coiled single chain in a neutral saline solution, Fresco and Klemperer 
predicted that some type of intrachain contact must be involved with a substantial 
proportion of the nucleotide in a single chain (57). Warner reported that poly(rA) is 
hypochromic to the extent of approximately 35% with respect to the mononucleotide, 
suggesting that a contact force such as hydrogen bonding may exist between the 
adenine bases (231). The slight increase of the UV absorbance at 260 nm, observed in 
the study reported here, suggests that intrachain contact between the poly(rA) bases is 
involved here, but not significant. However, the structure of poly(rA) is significantly 
affected by the acidity of the solution. The melting temperature of poly(rA) becomes 
higher with a decrease of pH, suggesting an extensive hydrogen-bonded structure is 
probably formed (supporting information). X-ray crystallographic studies reported by 
Watson (60) and Rich (59) and the solution properties investigations  of poly(rA)  
conducted by Fresco and Klemperer (57) concluded that the form of poly(rA) under 
acid condition is a two-chain helix model. These chains are held together by hydrogen 
bonds between the adenine residues, the base pairs are in the interior and the phosphate 
groups lie on the periphery of the helix. This double stranded conformation of poly(rA) 
has been established to be quite different from the standard double stranded RNA 
(232), the hypothesis being that the poly(rA) double helix may be much like the 
interrupted helical model (57). The increase of thermal stability of poly(rA)•poly(rA) at 
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low pH was attributed to the protonation of adenine groups which favors the hydrogen 
bonds formation (57). In addition to the pH, helix length was also found to affect its 
thermal stability (57). Increasing the length of helix was found to promote this duplex 
melting temperature as well, but with a less magnitude than pH (57). The 
poly(rA)•poly(rA) duplex formed at low pH  was believed to fall into A conformation 
(228). However, this duplex structure can easily aggregate under the conditions of high 
molecular weight single-chains, high ionic strength or high polymer concentration (57).  
 pH 5.5: A duplex poly(rA)•poly(rA) is formed at pH 5.5. As shown in Figure 
4.4a, a strong positive band ~260 nm and a small negative band ~ 240 nm are observed, 
characteristic of the  poly(rA)•poly(rA) duplex. This duplex structure only contains on 
type of groove (228) because of the rotational symmetry of the A-A base pair. 
Neomycin stabilizes this RNA duplex significantly, raising the melting temperature 
from 44 oC to 61 oC (Figure 4.4c). Titration of neomycin into this duplex does not 
change its overall conformation and yields a binding site size of 6.5 base pair per drug 
(Figure 4.4b), approximately one helical turn (eight base pair) binds one drug. 
Neomycin binds to this A-form RNA structure with a high binding affinity of 
(1.7±0.2)×107 M-1. Up to date, very few ligands are studied for their interaction with 
poly(rA)•poly(rA) duplex, most likely due to the non-existence of this structure under 
physiological conditions.  
 pH 6.8: Poly(rA) exists as a single strand at pH 6.8. The single stranded 
poly(rA) also undergoes a broad denaturation with increasing temperature, indicating a 
structural transition from a stacked helix to a random coil as shown in Figure 4.5a. In  
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Figure 4.4. (a) CD scans of neomycin titration with poly(rA)•poly(rA) duplex. The 
scan with solid circle is the one of RNA alone. The insert CD spectra is RNA alone 
(continuous line) and drug-saturated complex (dashed line). (b) A plot of CD signals 
at 263 nm vs. corresponding rbd values. (c) UV melting profiles of RNA duplex in the 
absence (1) and presence (2) of neomycin at rbd of 6.5. Buffer: 10 mM sodium 
cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 4.5. (a) UV melting profiles of poly(rA). (b) CD melting profile of poly(rA) 
in the presence of neomycin at rbd of 4. (c) CD spectra of poly(rA) in the absence and 
presence of neomycin. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM 
NaCl, and pH 6.8. 
 
the presence of neomycin, the thermal denaturation results reveal that the transition 
becomes sharper, as shown in CD melting profile (Figure 4.5b), a positive transition 
for the poly(rA)-neomycin complex with increasing temperature being observed. These 
observations indicate a conformational change of poly(rA) upon neomycin binding. In 
order to investigate the neomycin induced poly(rA) conformation, a CD study was 
conducted. The CD spectrum of poly(rA) in the absence of neomycin at pH 6.8 shows a 
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positive band around 265 and 220 nm and a strong negative band at 250 nm, 
characteristic of single-stranded poly(rA) (65). When neomycin is added to the 
poly(rA) solution, the intensities of these above bands shift toward zero, but the 
positions of the peaks remain the same (Figure 4.5c). The CD spectra after addition of 
neomycin is completely different from the one obtained at pH 5.5, indicating that 
poly(rA) structure induced by neomycin at pH 6.8 does not adopt the duplex structure.  
 Small molecules, such as protoberberine alkaloids [berberine (65), palmatine 
(233), coralyne (66)], have been shown to bind strongly to single stranded poly(rA). 
The binding mode for these ligands is hypothesized to be a partial intercalation in 
which the drug molecule is inserted between neighboring adenine bases through the 
stacking of the drug between the bases on the chain (65).  The binding of neomycin to 
poly(rA), found here, generates a CD spectrum similar to those of berberine and 
palmatine, suggesting the involvement of similar binding mode and secondary 
structure. However, additional structural studies are needed to explain more fully the 
poly(rA) structure induced by neomycin. 
 The binding affinity of neomycin binding with single strand poly(rA), however, 
cannot be calculated with the method applied here because of the difficulties in 
determining the accurate melting temperature of poly(rA) and generating the ∆Cp value 
using ITC. 
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Polyuracylic acid (polyrU) 
 RNA homopolymer U does not show a clear melting transition in the 
temperature range studied (10-75oC) at either high or low pH. It has been reported that 
poly(rU) does not possess any specific structure at ambient temperatures, indicating a 
lack of stacking interaction between the uridine bases, thereby leading to a random-
coiled conformation (69). However, poly(rU) has been found to exhibit a secondary 
structure, an antiparallel double helix, at low temperatures (58). This structure is 
formed by folding poly(rU) molecule back on itself, adopting an A conformation(234). 
The stability of this duplex is quite low, exhibiting a melting temperature ~5 oC. 
Counterion and polyamine such as spermine have been shown to stabilized this 
poly(rU)•poly(rU) duplex significantly (235). Modification of the Uracil was also 
found to raise the thermal stability of this duplex dramatically. Substitution of 2-keto by 
sulfur (S2) raises the melting temperature of this duplex from 5.8 oC to 68.5 oC (236). 
This increased stabilization effect by this modification is attributed to S2 stacking over 
N1 of the adjacent nucleotide and the large polarizability and hydrophobic character of 
sulfur.  
 A CD scan was conducted at high temperature for random structured poly(rU) 
(Figure 4.6a), a strong positive band at 270 nm, a negative band at 243 nm and a very 
strong positive band at 203 nm observed. These peaks can be considered as 
characteristic CD peaks for single stranded poly(rU). The CD scan at 20 oC shows a 
blue shift of the 270 nm band to 265 nm and the development of a new negative peak 
around 210 nm (Figure 4.6b), indicating the formation of a secondary structure. This 
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secondary structure, the antiparallel double-stranded poly(rU), shows an unexpected 
significant binding enthalpy in magnitude when interacting with neomycin (Figure 
4.6cd). In contrast to other nucleic acids investigated, this observed binding enthalpy 
dramatically increases in magnitude as the temperature decreases (Figure 4.6d). One 
possible reason for this phenomenon is that neomycin favors the double stranded 
poly(rU), having no effect on the single-stranded poly(rU). The significantly lower 
binding enthalpy at 20 oC is due to the decreased number of poly(rU) duplex species in 
solution.  Furthermore, addition of neomycin to poly(rU) at 20 oC increases the CD 
signal toward the more positive values (Figure 4.6b), slightly inducing a blue shift of 
bands at 270 and 210 nm. The blue shift observed here is same as that observed as the 
temperature decreases (see supporting information), suggesting that neomycin may 
induce the formation of a poly(rU) structure similar as that formed at low temperatures, 
an antiparallel double helix.  
 Same as the problems encountered in the poly(rA) system, ∆Tm method is not 
valid here to calculate the binding constant of neomycin binding with poly(rU) at both 
pH 5.5 and 6.8 due to the difficult to experimentally determine the melting temperature 
increase of poly(rU) single strand by neomycin. 
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Figure 4.6: CD titration of neomycin into poly(rU) at 59 oC (a) and 20 oC (b). The CD 
spectrum with solid circle represents the RNA alone. The insert is the CD spectra of 
RNA alone (continuous line) and drug-saturated complex (dashed line). (c) ITC 
titration of neomycin with poly(rU) 20 oC and 10 oC.   Buffer: 10 mM sodium 
cacodylate, 0.5 mM EDTA, 100 mM NaCl and pH 6.8.  
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AT-rich duplexes: poly(dA)•poly(dT) & poly(dA-dT)•poly(dA-dT) 
 The conformation of polynucleotide AT-rich duplexes poly(dA-dT)•poly(dA-
dT) and poly(dA)•poly(dT) belongs to the B family containing a narrow and shallow 
minor groove and a deep and wide major groove, but the physical properties of both 
differ. For example, the melting temperature of poly(dA)•poly(dT) (AT duplex, 69.3 
oC) is about seven degree higher than poly(dA-dT)•poly(dA-dT) (alternating AT 
duplex, 61.7 oC) (see supporting information). Furthermore, AT duplex does not 
convert into A form structure at high salt concentration or low relative humidity (237), 
whereas alternating AT duplex, like most DNAs, can convert from a B-type to A-type 
pattern under those dehydrated conditions. In addition, a disproportionation of a AT 
duplex to a T•A-T triplex and a single-stranded poly(dT) is observed, similar to that of 
poly(rA)•poly(rU) (228), but not observed for alternating AT duplex.  In general, the 
structure of AT duplex is more rigid than the alternating AT duplex, the latter being 
able to assemble into a nucleosomes (238).  
 The stability of those AT-rich duplexes can be affected by metal ions (for 
example, Na+, Mg2+, Ni2+, and Cs2+) (239), chemical compounds (5, 6, 76) and pH 
(240). Alternating AT duplex was recently reported to denature into single strand by 
titration of acid (240). Metal ions are known to primarily interact with phosphate 
backbone as counterions, thereby increasing the thermal stability of nucleic acids (239). 
Most chemical compounds that show preference for AT-rich duplexes are groove 
binder. A limited number of groove binders are known to bind within the major groove 
of B-DNA. Thus, the study of small molecules binding to B-form DNA, such as 
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Hoechest 33258, berenil and netropsin, is largely focused on the minor groove. 
However, since a number of biologically important interactions happen in the major 
groove, it is of considerable interest to discover the factors governing major groove 
recognition.  
 pH 5.5: Disproportionation of poly(dA)•poly(dT) in the presence of neomycin 
was observed at pH 5.5, as shown in Figure 4.7a. The absorbance of the solution 
gradually decrease from 30 oC, indicating the rearrangement of poly(dA) and poly(dT). 
This rearrangement completes at 80 oC and the poly(dA)•2poly(dT) formed after 
disproportionation denatures directly from 3->1 at 91 oC. Due to the formation of 
poly(dA)•2poly(dT) under this condition, the stabilization effect of neomycin on the 
poly(dA)•poly(dT) cannot be evaluated, thus preventing the application of ∆Tm method 
in calculating the binding constant. 
 However, alternating AT duplex poly(dA-dT)•poly(dA-dT) does not 
disproportionate into a triplex, providing a good system to investigate the binding 
property of neomycin to B-form DNA sequence. The stabilization effect of neomycin 
on poly(dA-dT)•poly(dA-dT) is small, with  melting temperature being raised only ~ 1 
oC (Figure 4.7b ). The heat capacity change derived from ITC titration yields a number 
of -16±10 cal/mol.K, indicating almost no solvent accessible surface area change upon 
binding. The binding constant of neomycin interacting with poly(dA-dT)•poly(dA-dT) 
was calculated to be (1.2±0.1)×105 M-1.  About 74 % of the driving force is contributed 
from entropy, whereas only 26 % obtained from binding enthalpy. The entropy-driven 
binding feature is common for the studies of neomycin interacting with nucleic acids at 
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low pH, where the protonation heat of neomycin is not included in the observed binding 
enthalpy (35).   
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Figure 4.7. (a) UV melting profiles of poly(dA)•poly(dT) in the absence (1) and 
presence (2) of neomycin at rbd of 5. (b) UV melting profiles of poly(dA-
dT)•poly(dA-dT) in the absence (1) and presence (2) of neomycin at rbd of 5. Buffer: 
10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
 
 pH 6.8: Both poly(dA-dT)•poly(dA-dT) and poly(dA)•poly(dT) exhibit higher 
binding enthalpies at pH 6.8, as expected. The values are -7.7±0.3 kcal/mol for 
poly(dA)•poly(dT), but only -3.7±0.2 kcal/mol for poly(dA-dT)•poly(dA-dT) at 20 oC 
(Figure 4.8). The larger magnitude of binding enthalpy obtained for poly(dA)•poly(dT) 
implies that more hydrogen bonds are probably formed in its complexation with 
neomycin. In addition, both duplexes show small heat capacity changes when 
interacting with neomycin, specifically,-26±24 cal/mol.K for poly(dA-dT)•poly(dA-dT) 
and 58±25 cal/mol.K for poly(dA)•poly(dT) (supporting information). Thermal stability 
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analysis reveals that neomycin does not increase the melting temperatures of both 
duplexes, with only 0.5 oC increase observed, a number within the instrumental 
uncertainty (supporting information). The binding constants determined using ∆Tm-
method are (1.9±0.4)×105 M-1 for poly(dA-dT)•poly(dA-dT) and (2.7±0.7)×105 M-1 for 
poly(dA)•poly(dT), almost same for both within the experimental uncertainty. All those 
results confirm the low binding affinity of neomycin to AT-rich B-type duplexes.  
 However, the recognition of neomycin by B DNA was improved by conjugating 
with another aminoglycoside or intercalator. The primary study conducted by Arya has 
shown that neomycin-neomycin dimer and neomycin-tobramycin conjugate exhibit an 
unexpected high selectivity to the AT-rich duplex, even destabilizing the T•A-T triplex 
at high concentrations (44) and showing a binding affinity as high as ~108 M-1.  This 
study also shows specific recognition of AT-rich B-form DNA by neomycin-Hoechst 
33258 conjugates (NH) (15). In addition to the enhanced thermal stability of AT-rich 
duplexes, it reveals that NH with a longer linker is not as potent as the shorter linker 
upon interacting with AT-rich duplexes, the latter yielding a binding constant of 
(1.6±1.0)×108 M-1, slightly higher than Hoechst 33258 alone (1.1×108 M-1). Hoechst is 
regarded as a specific B-form minor groove binder.  The neomycin in the conjugate, 
then, is believed to interact within the major groove. To date, there are few 
carbohydrates known to recognize the major groove. Within this small group, some 
representative ligands include altromycin B (alkylating agent), nogalamycin, 
respinomycin, and NB-506 (tandem intercalative-groove binding ligands). Of the dual 
groove binding ligands synthesized by Arya group, the neomycin-Hoechst 33258 
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conjugates and neomycin-neomycin dimer (unpublished data), expand the list of 
nucleic acids that aminoglycosides bind to and the list of small molecules that target the 
major groove of B-type DNAs. 
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Figure 4.8. (a,b) ITC titration of neomycin into poly(dA)•poly(dT) (a) and poly(dA-
dT)•poly(dA-dT) (b) at 20 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 
mM EDTA, pH 6.8. 
 
GC-rich duplexes: poly(dG)•poly(dC), poly(dG-dC)•poly(dG-dC), d(A2G15C15T2)2,  
and calf thymus DNA  
 GC-tract DNA can adopt either A-type or B-type conformation, depending on 
the guanine-guanine base stacking. Poly(dG)•poly(dC) fiber is known to exhibit A-type 
conformation (241, 242), but in the aqueous solution and low salt concentration (30 
mM NaCl),  poly(dG)•poly(dC) was found to adopt a B conformation (243). This B 
conformation of  poly(dG)•poly(dC) can be converted to A form by changing salt 
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concentrations (243) and this A form can be stabilized significantly by the cytosine-5-
methylation (243). However, the study of the long runs of the Gn•.Cn sequence is 
problematic due to the tendency for aggregation and the susceptibility of base pair 
slippage (244, 245), both observed at the low melting enthalpy of GC base pairs. Even 
more of an issue, more than one structure may exist in the 1 poly(dG) : 1 poly(dC) 
aqueous solution (246). For example, at pH 8.0, poly2(dG)•poly(dC) triplex was found 
in solution in addition to the poly(dG)•poly(dC) duplex (246). As shown in Figure 4.9a, 
the DSC melting profile of poly(dG)•poly(dC) exhibits two peaks, one around 93.2 oC 
and another around 102.7 oC at pH 6.8. The much smaller binding enthalpy (~2 
kcal/mol) observed for both peaks compared to AT base pair (~5 kcal/mol) indicates 
the possible aggregation or slippage of base pairs. This structure of poly(dG)•poly(dC) 
is affected by ionic strength, only one transition peak at 96.2 oC being under 150 mM 
KCl (data not shown).  More strikingly, the structure of the original poly(dG)•poly(dC) 
is not re-formed after renaturation, the newly formed structure melts at approximately 
60 oC (data not shown). The addition of neomycin to this GC-tract duplex red shifts the 
positive peak at 257 nm and induces a strong negative peak around 210 nm as well 
(Figure 4.9b), suggesting a more A-like conformation. However, the spectrum also 
displays two shoulders at 257 and 290 nm, precluding the existence of a complete A-
form conformation in the solution. This heterogeneous composition of the 
poly(dG)•poly(dC) aqueous solution prevents obtaining reasonable thermodynamic 
data upon neomycin interaction. Subsequently, a GC-tract oligomer, d(A2G15C15T2)2 
has been used as a model for poly(dG)•poly(dC).  
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Figure 4.9. (a) DSC melting profile of poly(dG)•poly(dC) at pH 6.8. (b) CD scans of 
neomycin titration with poly(dG)•poly(dC) at pH 6.8. (c) CD scans of neomycin 
titration with d(A2G15C15T2)2 at pH 5.5. The scan with solid circle is DNA alone. The 
insert CD spectra are DNA alone (continuous line) and drug-saturated complex 
(dashed line). (d) DSC melting data of d(A2G15C15T2)2 in the absence (1) and 
presence (2) of neo at rdb of 10 at pH 5.5.  Buffer: 10 mM sodium cacodylate, 100 
mM NaCl, 0.5 mM EDTA. 
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d(A2G15C15T2)2 
 pH 5.5: Even though the GC-tract sequences are known to have the propensity 
to form A-DNA, the intrinsic aqueous structures do not show an absolute A-form under 
the conditions studied for d(A2G15C15T2)2 (Figure 4.9c). However, a small amount of 
neomycin converts the self-complementary d(A2G15C15T2)2 duplex toward the A-form, 
observed as a CD band at 270 nm, a finding consistent with published data (43). In 
addition to neomycin, spermine and hexaamminecobalt (III) were also shown to 
transform the Gn•Cn-tract sequence from B to A, identical to the change caused by 
neomycin (43). The structural basis of the B to A transition can be explained as the 
closeness of two negatively charged sugar-phosphate backbones along the major 
groove of A conformation, which can be neutralized effectively by the positively 
changed amine groups on those ligands (43).  
 Neomycin has a greater stabilizing effect on the d(A2G15C15T2)2 duplex at pH 
5.5 than pH 6.8, with 7 oC increase at rbd  of 10 at pH 5.5 (Figure 4.9d) but less than 
two degree increase at pH 6.8 (Figure 4.10a). However, the ITC-derived heat capacity 
change (-173±23 cal/mol.K, supporting information) is significant at such a low pH 
value, implying large removal of nonpolar surface area in the solution which suggests a 
better binding. The binding constant of neomycin with d(A2G15C15T2)2 duplex was 
calculated using ∆Tm method to be (1.8±0.6)×107 M-1  at pH 5.5, with ~92% of driving 
force contributing from entropy.  
 pH 6.8: Conformation of d(A2G15C15T2)2 duplex at pH 6.8 was shown to be 
same as the one observed at pH 5.5 using the CD technique (supporting information). 
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However, the heat capacity change observed at pH 6.8 is 235±10 cal/mol.K (Figure 
4.10b), about two times higher than one obtained at pH 5.5. This phenomenon implies 
that the protonation heat of neomycin may be temperature-dependent as well, 
contributing to the total observed heat capacity change. The binding constant at pH 6.8 
was calculated to be  (9.1±0.1)×107 M-1, which is overestimated due to the 
overestimated heat capacity change and binding enthalpy at this pH, but less than five 
folds when compared to the value obtained at pH 5.5.  
 
Poly(dG-dC)•poly(dG-dC)  
 Alternating GC sequence poly(dG-dC)•poly(dG-dC) was also studied, however, 
showing very different conformational features from Gn•Cn-tract sequence. As seen in 
Figure 4.10c, poly(dG-dC)•poly(dG-dC) displays a negative band around 247 nm and 
two positive overlapping bands in the vicinity of 265 and 285 nm. Those peaks at 247 
and 285 nm are determined to be B-type base stacking  by comparison with its related 
canonical B-form structure d(GCGCGCGC),  and the one at 265 nm corresponding to 
A-type base stacking (229). Although poly(dG-dC)•poly(dG-dC) exhibits some features 
of the A-form structure, overall it is still regarded as a B-type DNA. It has been 
previously reported that poly(dG-dC)•poly(dG-dC) undergoes a B- to Z- form transition 
due to the salt effects (212, 213). This Z conformation of poly(dG-dC)•poly(dG-dC) is 
only stable at high salt condition (4 M NaCl) (247). However, bromination at C8 
position of the guanine imidazole ring can stabilize the Z-form at low salt conditions 
(150 mM NaCl) (248). As shown in Figure 4.10d, titration of neomycin into this 
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duplex does not result in the conformational change until an rbd above 6 is reached. 
Conformational change was observed with the gradual disappearance of the negative 
band at 247 nm, the formation of a new strong negative band around 295 nm and the 
positive band around 270 nm blue shifting toward 260 nm (Figure 4.10c). All of those 
features indicate the unexpected formation of a new structure, Z-form DNA.  The 
opposite sign patterns observed in the CD spectra appear to be a consequence of the 
different handedness of the respective polymeric backbones. This result is striking since 
it is the first time that neomycin has been found to induce a Z-form DNA.  
 The thermodynamic study of poly(dG-dC)•poly(dG-dC) reveals little thermal 
stability increase caused by neomycin (0.5 oC) and a small heat capacity change (-
27.7±22 cal/mol.K) (see supporting information). The binding affinity calculated using 
the ∆Tm-method yields a value of (5.0±2.5)×105 M-1, quite consistent with the one 
obtained for neomycin-AT-rich B-form DNA interaction within experimental 
uncertainty. 
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Figure 4.10. (a) DSC melting profile of d(A2G15C15T2)2 in the absence (1) and 
presence (2) of neomycin at rbd of 10. (b) Observed binding enthalpy change of 
neomycin binding to d(A2G15C15T2)2 at various temperature. (c) CD titration of 
neomycin into poly(dG-dC)•poly(dG-dC). The CD spectrum with solid circle 
represents the DNA alone. The insert is the CD spectra of DNA alone (continuous 
line) and drug-saturated complex (dashed line). (d) A plot of CD intensity at 251 nm 
vs. respective rbd values. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM 
NaCl and pH 6.8. 
 
 
 
 140 
Calf thymus DNA  
 Calf thymus DNA has been found to undergo a transition from B to Z by the 
polyamines such as spermine, spermidine, and putrescine (249). A recent study has 
shown that the conformation of calf thymus DNA can be partially converted from B to 
A by the intercalation of ethidium bromide, acridine orange, and methylene blue (250). 
Calf thymus DNA, which contains 42 % GC, was studied here aiming to investigate the 
GC-content dependence of binding affinity of neomycin with GC-rich sequences. CD 
spectra of calf thymus DNA shows a strong positive band around 270 nm, a strong 
negative band around 247 nm and a relatively weak band around 210 nm, indicating a 
standard B-form DNA (supporting information). Titration of neomycin into DNA 
solution slightly red shifts the band at 270 nm, indicating that the base-stacking may 
change toward A type. However, the overall the structure of neomycin-bound calf 
thymus still exhibits the B-type characteristics. The B to Z transformation is not 
observed by neomycin under this condition. The binding constant of neomycin binding 
with calf thymus DNA was calculated to be (4.8±3.3)×105 M-1, falling into the same 
range for typical B DNA-neomycin interaction.  The results reveal that the binding 
affinity of neomycin to GC-rich sequences is not GC-content dependent, but 
conformation- dependent. d(A2G15C15T2)2, inclined to have a A-type conformation, has 
a much higher binding affinity than poly(dG-dC)•poly(dG-dC) and calf thymus, which 
are known to exhibit a B-type  conformation.  
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Hybrid duplexes: poly(dA)•poly(rU) and poly(rA)•(dT) 
 DNA•RNA hybridization was first demonstrated by Rich based on the 
measurement of hypochromism observed in UV in 1960 (251), but the structural 
analysis was not solved until 1982 (252). Hybrid duplex is believed to adopt an 
intermediate conformation, one between the A form of RNA and the B form of DNA. 
Its global structure tends to be closer to the A-form, with the RNA strand containing A 
features and the DNA strand showing more B-from structure moiety. It has been 
reported, however, that the hybrid duplex containing a DNA purine strand and a RNA 
pyrimidine strand (dR•rY) shows much less stability than the corresponding one 
consisting of a RNA purine and a DNA pyrimidine (rY•dY) (253, 254). As shown in 
Figure 4.11a, poly(dA)•poly(rU) (dA•rU) denatures at 43.6 oC, while 
poly(rA)•poly(dT) (rA•dT) melts at 64.7 oC.  This variation is attributed to the chemical 
difference arising from the 5-Me of thymindine in the DNA and the 2’-OH of the ribose 
in the RNA (255). These two effects vary depending on the secondary structures, either 
reinforcing or opposing their effect on thermal stability. It was found that the C-5 
methyl group of the thymine exhibits a stabilization effect in all complexes, while the 
2’-OH group can be either stabilizing or destabilizing depending on the type of 
complex. When investigating the ligand-induced stabilization of dA•rU, ethidium 
bromide has been shown to increase the thermal stability of this DNA•RNA hybrid 
selectively and significantly (256). While at molar salt concentration, rA•dT hybrid is 
destabilized by forming a poly(rA)•2poly(dT) triplex (257). However, under the 
condition of 100 mM NaCl, only rA•dT is observed. Previous studies of 
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oligonucleotide hybrid duplexes have shown that rR•dY duplex exhibits more A-like 
conformation than the dR•rY (258). However, there is an only exception for 
polynucleotide hybrid rA•dT which can adopt B type conformation under certain 
solution conditions (259).  
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Figure 4.11. (a) DSC melting profiles of poly(dA)•poly(rU) and poly(rA)•poly(dT). 
(b) CD scans of poly(dA)•poly(rU) and poly(rA)•poly(dT) at 20oC. Buffer: 10 mM 
sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl, pH 6.8. 
 
 pH 5.5: As observed  in Figure 4.11b, CD spectrum of dA•rU exhibits a strong 
positive band at 260 nm and strong negative band at 210 nm, indicating an A type 
conformation. However, a strong negative band at 247 nm and a broad positive band 
shoulder from 270 to 285 nm were observed from CD spectrum from rA•dT, 
characteristic of B type conformation. These two different conformations of hybrids 
display quite different binding properties when interacting with neomycin. Greater 
magnitude of heat capacity change is observed for dA•rU (-160±18 cal/mol.K) than for 
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the rA•dT hybrid (-30±20 cal/mol.K) (see supporting information). The more negative 
∆Cp observed for the dA•rU than for the rA•dT indicates that the neomycin-dA•rU 
complexation buries more nonpolar surface, implying that neomycin binding to dA•rU 
may be more charge or shape complementary, thereby inducing a conformational 
change more favorable for binding. A positive binding enthalpy of (2.8 kcal/mol) was 
observed for neomycin binding to dA•rU (see supporting information). In general, 
ligand-nucleic acid interaction is characteristic of an exothermic one. However, at low 
pH, the binding becomes entropically favorable. The factors that contribute the 
favorable entropy include desolvation of interacting species, conformational change 
upon binding, dehydration and hydrophobic effect (35). Therefore, the endothermic 
feature of binding enthalpy observed here can be explained by one or more factors 
mentioned above.   
 The binding constant for neomycin-dA•rU interaction was calculated to be 
(9.4±0.1)×106 M-1, approximately three times higher than that of (3.4±0.4)×106 M-1 for 
rA•dT.  
 pH 6.8:  Both rA•dT and dA•rU adopt same conformations as the ones at pH 5.5 
(supporting information), confirming pH has no effect on hybrid structures. Neomycin 
stabilizes dA•rU significantly at both low and high pH, raising the melting temperature 
approximatly 20 oC at the saturated amount (supporting information). This significant 
effect induced by neomycin is much higher than ethidium bromide which is believed to 
interact with hybrid duplex specifically and selectively (unpublished data). We also 
calculated the binding constants of neomycin binding to these two hybrids, yielding a 
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value of (2.3±0.4)×108 M-1 for dA•rU and (8.5±0.1)×106 M-1 for rA•dT. The binding 
constant, especially for neomycin-dA•rU interaction, is overestimated more than one 
order of magnitude by comparing to the value at pH 5.5, implying drug protonation 
contributing significantly to this system.  
 
RNA duplexes: 16S A-site rRNA and poly(rA) •poly(rU) 
16S A-site rRNA  
 The natural target of aminoglycosides, 16S A-site rRNA, has been studied for 
its interaction with aminoglycosides in depth in the past 20 years. The bactericidal 
activity of the aminoglycosides is believed to be achieved by disrupting the rRNA 
conformation in such a way that accurate recognition between the codon of the mRNA 
and the anticodon of tRNA is lost, thereby inhibiting the translocation. It has been 
shown previously that the neomycin-class aminoglycosides target the specific 
conserved sequence in the 16S rRNA A-site of the 30S ribosomal subunit (260). The 
first molecular insights into the aminoglycoside-A site binding mode were obtained for 
paromomycin and gentamicin C1a using NMR (40, 261) in the late 1990s. Later X-ray 
crystal structures were resolved for paromomycin (262), tobramycin (263) and 
geneticin (264) bound to RNA sequences containing the A-site. The common feature of 
all these structures is that the neamine moiety binds similarly, with specific contacts 
with A site rRNA at the major groove within a pocket created by an A1408-A1493 
base-pair and A1492 in bulge region.  The resulting conformational change of the A 
site of 16S rRNA favors the binding of the tRNA to ribosome, thus inducing a 
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mistranslation. The contacts between the aminoglycosides and the A site of rRNA 
produced by other rings in addition to the neamine moiety are believed to involve non-
specific electrostatic interactions, which contributes in a minor way to the specificity of 
the binding. In addition to the structural study of aminolgycoside-A site interaction, 
Pilch has conducted a complete thermodynamic characterization for the paromomycin-
A site interaction, finding a binding affinity of paromomycin to 16S A site rRNA in a 
low nanomolar range at neutral pH (37).  Here, we present a thermodynamic study 
between A site 16S rRNA and neomycin which possesses one more amino group than 
paromomycin. 
 pH 5.5: Figure 4.12a shows the CD spectra of 16S rRNA from 200 to 300 nm 
obtained by titration of neomycin. These spectra exhibit a strong negative band at 210 
nm and a strong positive band around 260 nm, both characteristic of a canonical A 
conformation. The titration of neomycin gradually increases the intensity in magnitude 
at 210 and 265 nm, with nearly no change at other wavelengths. The CD spectra change 
at these wavelengths implies that the base pair stacking upon neomycin binding 
converts toward more A form. The extracted CD signal at 265 or 210 nm can be plotted 
with the respective rsd ratios, yielding the binding site size of one drug per RNA 
(Figure 4.12b). However, it has been shown that neomycin binding to 16S rRNA 
exhibits two binding site sizes previously, one at one drug per duplex and the other at 
two drugs per duplex (37). This unobserved second binding site on CD titration is most 
likely due to the non-specificity of binding, which does not induce a conformational 
change clearly observed from CD spectra. The binding enthalpy of neomycin 
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interacting with 16S rRNA A site is -2.4 kcal/mol at 20 oC, contributing 23% driving 
force to the binding free energy. Its binding constants was calculated to be 
(8.7±0.9)×107 M-1, the highest one among all the sequences studied here.  
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Figure 4.12. (a) CD scans of neomycin titration with 16S rRNA A site. The scan with 
solid circle is the one of RNA alone. The insert is the CD spectra of RNA alone 
(continuous line) and drug-saturated complex (dashed line). (b) A plot of CD signals 
at 265 nm vs. corresponding rbd values. The cross of two apparent linear portions 
reveals binding site sites. (c) UV melting profiles of RNA in the absence (1) and 
presence (2) of neomycin at rsd of 1. Buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 100 mM NaCl, pH 5.5. 
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 pH 6.8: Study of neomycin interacting with 16S A site rRNA at pH 6.8 yields 
same conformational change and same binding sites as those at pH 5.5. But the thermal 
stability increase induced by neomycin is smaller, with four degree increase at pH 6.8 
but seven at pH 5.5 (Figure 4.12c), indicating the stabilization effect of neomycin over 
this RNA is more potent at protonated status. The binding constant obtained with ∆Tm 
method is (1.2±0.3)×109 M-1, about 10 times overestimated by comparing to the value 
at pH 5.5. Furthermore, the heat capacity change derived from ITC titration, -350 
cal/mol.K, is more than two times higher than the one, -150 cal/mol.K obtained at pH 
5.5. Such a big discrepancy is due to the high extent of drug protonation. Thus, it is 
likely that the system with high binding affinity involves high contribution from drug 
protonation, therefore the overestimation for binding constant obtained at high pH is 
greater, as observed in the dA•rU and d(A2G15C15T2)2 systems. 
 
Poly(rA)•poly(rU) 
 Poly(rA)•poly(rU) was first discovered in solution by Warner(265). The 
conformation of poly(rA)•poly(rU) is the familiar A-form. An equimolar mixture of 
poly(rA) and poly(rU) does not necessary form a duplex. Poly(rA)•2poly(rU) triplex 
can be induced at a higher temperature (266), at a high sodium/potassium  
concentration or in the presence of magnesium ions (69). The question of what type of 
species exists at the 1 poly(rA): 1 poly(rU) ratio triggered much debate in the 1960-70s. 
Warner concluded a duplex formation since he was unable to detect free poly(rA) in the 
equimolar mixtures (267). Fresco, on the other hand, concluded a three-stranded 
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complex poly(rA)•2poly(rU) formation at equilibrium regardless of the relative 
proportion of poly(rA) and poly(rU) in the mixture (268). More recently, Miles and 
Frazier demonstrated directly the existence of duplex poly(rA)•poly(rU) using infrared 
spectroscopy under most ionic conditions (269). This result was confirmed by Stevens 
and Felsenfeld, who used ultraviolet to observe the hypochromism at 280 nm at lower 
ranges of polymer concentration in the presence of 1 mM magnesium ions (266). It has 
been suggested that the hypochromism observed at 280 nm as the temperature increase 
corresponds to the denaturation of duplex poly(rA)•poly(rU) and the rearrangement of 
poly(rA) and poly(rU) to form the three-stranded poly(rA)•2poly(rU) and the free 
poly(rA). Upon further heating, the three-strand complex then denatures to a single-
stranded coil form.  The formation of poly(rA)•2poly(rU) at equimolar mixture of 
poly(rA) and poly(rU), however, has been demonstrated by Blake and Fresco (270) to 
be the transient by–product in the poly(rA)•poly(rU)  formation, which disappears very 
slowly (~72 hours) in 200 mM Na+. Thus, the discrepancies observed by different 
groups were most likely due to the incompletion of equilibrium for duplex formation.   
 In addition to the triplex formation in solution, polynucleotide RNA molecules 
are capable of forming different secondary or tertiary structures. These structures can 
serve as specific drug recognition species, thereby modulating the biological activities 
of the host RNA.  RNA-targeting drugs include aminoglycosides (271), heterocyclic 
intercalating ligands (272), cyclic peptides (273) and aromatic diamidines (182). 
Aminoglycosides have been primarily used as antibacterial drugs as mentioned 
previously. However, it has been found that aminoglycosides also show favorable 
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binding to the other RNA molecules such as various group I introns, the RRE of the 
HIV and the TAR of the HIV. Thus, aminoglycosides can also potentially be used as 
antiviral agents. 
 pH 5.5: As shown in Figure 4.13a, in the presence of neomycin, 
poly(rA)•poly(rU) disproportionates into a three stranded sequence poly(rA)•2poly(rU) 
and a single strand poly(rA), as is observed in the big drop of absorbance at 280 nm. 
The triplex then denatures directly from 3->1 at 81.6 oC.  The mid point of the 
denaturation portion of poly(rA)•poly(rU) was realized as the melting temperature of 
this duplex (266). However, in the absence of neomycin, disproportionation of 
poly(rA)•poly(rU) was not observed under the conditions used here (Figure 4.13a).  
 Poly(rA)•poly(rU) adopts an canonical A conformation, observed as a strong 
positive band around 260 nm and negative band at 210 nm from CD spectra (Figure 
4.13b). Binding of neomycin favors the RNA conformation moving toward more A 
type, indicated as the increased intensity at these two characteristic peaks. Binding 
enthalpy of neomycin with this RNA duplex is entropy-driven, even exhibiting a 
positive value at low temperatures (see appendix). But when increasing temperature, 
the contribution from entropy to the binding gradually decreases, but overall it is still 
the dominating factor. Poly(rA)•poly(rU) exhibits a high binding constant with 
neomycin, (1.9±0.1)×107 M-1, a value only smaller than 16S rRNA A site but higher 
than all other sequences studied here. 
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Figure 4.13. (a) UV melting profiles of poly(rA)•poly(rU) in the absence (1) and 
presence (2) of neomycin at rsd of 8. (b) CD scans of neomycin titration with 
poly(rA)•poly(rU). The scan with solid circle is the one of RNA alone. The insert is 
the CD spectra of RNA alone (continuous line) and drug-saturated complex (dashed 
line). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
 
 pH 6.8: Thermal continuous variation study was conducted to further confirm 
the non-existence of poly(rA)•2poly(rU) at physiological pH 6.8. The result shows a 
sharp end-point at 67% poly(rU) at 260 nm, indicating the possible formation of a 
complex at a molar ratio of 2poly(rU):1poly(rA), but no break is observed at 50% 
poly(rA): 50%poly(rU) at 260 nm (Figure 4.14a).  However, the existence of duplex 
poly(rA)•poly(rU) can not be ruled out since the optical density of poly(rA)•poly(rU) is 
exactly the same as the corresponding mixture poly(rA)•2poly(rU) and poly(rA), which 
is confirmed by the observation at wavelength 284 nm where a break at 50% poly(rA): 
50% poly(rU) is exhibited (Figure 4.14b). Another evidence to rule out the formation 
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of poly(rA)•2poly(rU) is the non-observation of  hypochromism at 280 nm where a 
triplex formation is usually confirmed clearly. 
 It has been reported that magnesium can induce the poly(rA)•2poly(rU) triplex 
in equimolar solutions of  poly(rA) and poly(rU) (69). Neomycin, a polycation with at 
least five positive charges, most likely induces the triplex RNA as well. However, CD 
spectra show that titration of neomycin into poly(rA)•poly(rU) duplex does not convert 
the spectra toward the one for neomycin- poly(rA)•2poly(rU) complex (see supporting 
information), indicating no RNA triplex induced under conditions studied here. The 
RNA duplex poly(rA)•poly(rU) exhibits a high binding affinity with neomycin at pH 
6.8, ~1.0×109 M-1, about 30 times overestimated by comparing to the values at pH 5.5. 
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Figure 4.14. Thermal continuous variation experiment of poly(rA) and poly(rU) 
mixtures observed at 260 nm (a) and 284 nm (b). Buffer: 10 mM sodium cacodylate, 
0.5 mM EDTA, 100 mM NaCl, pH 6.8. 
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Triplexes: poly(dA)•2poly(dT) and poly(rA)•2poly(rU) 
Poly(dA)•2poly(dT) 
 Triplex DNA or RNA can be formed by associating the triplex-forming single 
strand with a duplex via Hoogsteen hydrogen bonds in the major groove. The 
conformation of DNA triplex poly(dA)•2poly(dT) is a controversial issue. The 
molecular modeling and fiber diffraction data showed that this DNA contains a C3’-
endo sugar pucker, characteristic of A form (274). However an NMR study revealed 
that this triplex adopts a  C2’-endo sugar pucker, indicating a B form (275). A recent 
study has showed that some of the sugars do adopt both conformations part of time, and 
the stability of A-form triplex increases when the counterions are site-bound rather than 
area-bound (274). These observations indicate that poly(dA)•2poly(dT) structure may 
contain some A form features in the solution. Since the binding of third strand occurs 
within the major groove of the DNA duplex, many biological processes such as 
transcription, enzyme cleavage, replication, and gene expression are affected by this 
triplex formation. However, triplex stability is usually much lower than duplex stability 
because the Hoogsteen hydrogen bonds are much weaker than the Watson-Crick bonds 
under physiological conditions. Many studies have been conducted in an attempt to 
improve the stability of the triplex, thereby regulating the biological processes 
efficiently. Among those studies, triplex stabilization using chemical ligands has been 
investigated most widely. Intercalators such as the acridines, ethidium, proflavine, and 
the ruthenium complexes (98-101) and DNA minor groove-binding ligands such as 
berenil, netropsin, and Hoechst 33258 (102-104) have been found to bind to DNA 
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triplex, however, with little selectivity. The triplex selective binding ligands are few, 
including BePI (105) and Diethyloxadicarbocyanine (DODC) (106).  
 Aminoglycosides, recently found to be a new group of triplex-binding ligands 
by Arya, have been shown to exhibit a significant stabilizing effect on the triplex. 
Neomycin is the most potent one among the other neomycin class aminoglycosides 
such as paromomycin and ribostamycin. Neomycin’s stabilization effect is attributed to 
the fact that it contains the most amino groups (six). Computer modeling has shown 
that neomycin binds to the Watson-Hoogsteen groove of the DNA triplex, with ring I 
occuping the center of the groove with the amines on ring II and IV helping to bridge 
the two pyrimidine strands together. Six hydrogen bonds are formed between neomycin 
and the Watson-Hoogsteen groove (W-H). In addition to the charge complementarity, 
the shape complementarity of the neomycin and the W-H groove has also been 
suggested as a key factor in the recognition of the DNA triplex by neomycin.  
 pH 5.5: As shown in Figure 4.15a, the DSC melting profile confirms the 
formation of the poly(dA)•2poly(dT) triplex, with the melting enthalpy of triplex (1.26 
kcal/mol) being about four times smaller than the corresponding duplex (4.87 
kcal/mol), indicating that the interacting force between the third strand and the duplex 
is weaker than the one between the two duplex strands. The melting temperature of 
poly(dA)•2poly(dT) triplex is slightly concentration dependent, with the one observed 
in DSC profile (26.0 oC, 100 µM in base triplet) being two degree higher than the one 
obtained in UV melting profile (23.8 oC, 15 µM in base triplet) (Figure 4.15b).  The 
addition of neomycin (rbd of 6) into the DNA triplex solution does not affect the duplex 
 154 
stability (it remains at 69.7 oC), but it raises the triplex stability from 23.8 oC to 31.0 oC, 
as shown in Figure 4.15b. These results suggest that neomycin selectively stabilizes 
the triplex, with no effect on the AT rich duplex under physiological conditions.  ITC 
excess site titrations at various temperatures yield a large heat capacity change, -
264±24 cal/mol.K, indicating a large conformational change upon neomycin binding. 
The binding constant of neomycin interacting with the DNA triplex is at (1.2±0.1) ×106 
M-1, a value only higher than poly(dA)•poly(dT) duplex among the DNA sequences 
studied, most likely due to its more B like conformation. 
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Figure 4.15. (a) DSC melting profile of poly(dA)•2poly(dT). (b) UV melting profiles 
of triplex in the absence (1) and presence of (2) neomycin at rbd of 6. Buffer: 10 mM 
sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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 pH 6.8: The binding enthalpy of neomycin interacting with  poly(dA)•2poly(dT) 
is smaller at pH 6.8 than the value at pH 5.5 (supporting information). This is surprising 
since it is clear that, at pH 5.5, the drug protonation does not exist any more, thus the 
observed binding enthalpy is expected to be smaller than the one at high pH. In 
addition, due to the charge repulsion effect involved in nucleic acids at low pH, the 
melting enthalpy of nucleic acid sequence generally decreases. The completely opposite 
results obtained in this system, then, lead us to consider the stabilization effect of Na+ 
and neomycin on poly(dA)•2poly(dT) triplex. Compared to neomycin which contains 
more positively charged amine groups, the effect of Na+ to stabilize triplex is much less 
potent, thereby the thermal stability of DNA triplex was increased significantly (23.4-
50.0 oC at pH 6.8) upon addition of neomycin at rbd of 7 (Figure 4.16). However, at pH 
5.5, the electronegative potential of DNA backbone is decreased, thus the interacting 
forces with positively charged neomycin is reduced correspondingly, which is 
confirmed by the small thermal stability increase of triplex by neomycin (Figure 
4.15b). Considering the less stabilization effect of neomycin on DNA triplex at pH 5.5, 
the larger observed binding enthalpy at pH 5.5 than pH 6.8 seems inappropriate. We 
hypothesize the complex of neomycin-triplex formed at pH 5.5 is quite different from 
the one formed at pH 6.8, with the former structure being more enthalpically favorable.  
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Figure 4.16. UV melting profiles of poly(dA)•2poly(dT) triplex in the absence (1) 
and presence of (2) neomycin at rbd of 7. Buffer: 10 mM sodium cacodylate, 100 
mM NaCl, 0.5 mM EDTA, pH 6.8. 
 
Poly(rA)•2poly(rU) 
 The RNA triplex attracts less attention than the other RNA structures and DNA 
triplex even though it was the first three-stranded nucleic acid reported. Possible 
reasons for this include (1) RNA triplex formation is limited to homopyrimidine or 
homopurine tracts which, in turn, limits its wide therapeutic application, and (2) other 
RNA structures like the duplex itself are easily recognized by RNA binding ligands, 
implying the therapeutic purpose can be achieved solely by working with the duplex. 
However, the RNA triplex can be formed within transfer RNA (276), the Tetrahymena 
group I intron (277) and possibly the human immunodeficiency virus TAR RNA (278), 
implying that it may play important biological functions in organisms.  
 The RNA triplex adopts C3’-endo sugar pucker, thus characteristic of A 
conformation. Ligands like sanguinarine, berberine (279) and berenil (280) have been 
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shown to bind selectively to RNA triplex rather than duplex. The primary study on 
RNA triplex aminoglycoside interaction has shown that neomycin stabilizes the RNA 
triplex more significantly than the DNA triplex (46). The DSC melting profile reveals 
that RNA triplex poly(rA)•2poly(rU) exhibits the same thermal stability as its 
corresponding duplex at pH 6.8, ~59 oC (supporting information). The denaturation of 
the triplex dissociates three strands directly to the single coil strand, with the melting 
enthalpy of 5.46 kcal/mol associated with the Hoogsteen hydrogen bond, much stronger 
than the value of 1.0 kcal/mol observed in the DNA triplex and comparable to the value 
of 6.75 kcal/mol obtained from its corresponding RNA Watson-Crick hydrogen bond. 
The strong interacting force between the third strand and the duplex allows the RNA 
triplex to form easily even at the equimolar ratio mixture of poly(rA) and poly(rU) 
under the specific conditions mentioned previously. In the presence of neomycin, 
however, two melting transitions in DSC melting profile are observed for 
poly(rA)•2poly(rU) (Figure 4.17a).  Because of the difficulty in differentiating the 
thermal stability increase of triplex among these two transitions, the ∆Tm method is not 
valid to calculate the binding affinity of its binding to the poly(rA)•2poly(rU) triplex. 
At pH 5.5, two melting transition was observed in UV experiment, the one at 45.5 oC 
identified as triplex melting to duplex and single strand, the other at 56.2 oC identified 
as the duplex melting to single strands (Figure 4.17b). However, these two melting 
transitions are too close to be differentiated in DSC melting profile, providing the 
difficulty to calculate the accurate melting enthalpy of RNA triplex, thus precluding the 
calculating of binding constant using ∆Tm method in this study. 
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Figure 4.17. (a) DSC melting profile of poly(rA)•2poly(rU) in the presence of 
neomycin at rbd of 8.5 at pH 6.8. (b) UV melting profile of poly(rA)•2poly(rU) alone 
at pH 5.5. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA. 
  
Tetraplex: d(T2G20T2)4 and G10T4G10 
 Guanine-rich DNA strand tends to associate four strands to form Guanine-
Guanine tetraplex or quadruplex structures under physiological conditions of Na+ and 
K+ in vitro. However, this association has not yet been established in vivo.  The 
formation of the tetraplex is better facilitated under high ionic strength, K+ rather than 
Na+. A recent study shows that ethanol induces a tetraplex even better than potassium 
(281).  The interacting force between bases is believed to be Hoogsteen hydrogen 
bonds, formed between four guanines lying in a plane in either parallel or antiparallel 
orientation. The G-rich tetraplex structure can adopt a diverse pattern of folding, 
resulting from variations in loop size, sequence, and the possible combinations of 
strand orientation.  One interesting feature of the tetraplex structure is that a central 
channel is formed through guanine tetrad stacking. The cavity between the two tetrads 
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is associated with eight oxygens at position 6 of the guanines, providing a good binding 
site for cations. The binding of small molecules such as porphyrin (55), DODC (106), 
ditercalinium (216), and daunomycin (282) to the tetraplex structure have recently been 
studied. Molecules like porphyrin, the planar structures of which mimic the G-tetrad, 
appear to intercalate into the layers of the G-tetrad, end-paste or form a sandwich-type 
interaction between two tetraplex molecules via the pi-stacking, with weak binding 
constants of approximately 0.3~2 × 105 M-1 (55). Even though the interest on the study 
of small molecule-tetraplex interaction arises quickly, the achievement in determining 
the exact mode, the mechanism, the binding affinities, the binding stoichiometry, the 
binding sites and the thermodynamic profile remain unsatisfactory.  
 
d(T2G20T2)4 
 The tetraplex formed by four d(T2G20T2)4 exhibits a high thermal stability, with 
a melting temperature of 82 oC at pH 6.8. The addition of neomycin induces a slight 
melting temperature increase of tetraplex about three degrees (see appendix). The CD 
scan displays a strong positive band at 260 nm and a negative band at 240 nm (Figure 
4.18a), suggesting the formation of a parallel structure (283). To date, most molecules 
found to bind to the tetraplex are intercalators with a planar structural feature. The 
highest binding affinity was observed for TMPyP4 binding with an intramolecular 
tetraplex c-MYC 27 mer under 100 mM KCl condition at 25 oC, with a binding affinity 
of 1.6 × 107 M-1 for the first binding site and 4.2 × 105 M-1 for the second binding site 
(283).  Two types of binding sites were hypothesized for TMPyP4 binding with 
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tetraplex, one binding to the two end-cap region, and the other one binding to two 
intercalation cavities. The salt dependence study has shown that small electrostatic 
interaction involves in the TMPyP4-tetraplex complexation (283).  
 It is reported here for the first time that groove binder, neomycin, exhibits the 
propensity to bind to a parallel d(T2G20T2)4 tetraplex. As shown in Figure 4.18b, there 
are two types of binding sites, one around three neomycin / tetraplex and the other 
around seven neomycin / tetraplex. The ITC titration of neomycin with tetraplex reveals 
two binding site sizes as well, one around three and one around seven, findings 
consistent with the results from CD titration (Figure 4.18b). The ITC titration curve is 
fitted with a model having two sets of binding sites, yielding a binding affinity of 
(3.6±1.6)×108 M-1 for first site and (1.8±0.1)×106 M-1 for second at pH 6.8 (Table 4.3). 
 The binding affinity of neomycin with d(T2G20T2)4 is not affected by pH so 
significantly. The binding study conducted at pH 5.5 yields a high constant as well, 
with a value of (1.1±0.5)×108 M-1 for first binding site and (1.5±0.2)×106 M-1 for 
second one.  This result is exciting since the binding affinity observed is higher than 
any values reported for small ligand-tetraplex interaction, raising questions about the 
binding mode of neomycin to the tetraplex. The ITC titration curve shows that first 
binding site becomes saturated quickly (see appendix), implying that this binding site 
may be easily approachable. Notice that neomycin is a non-planar molecule, lacking the 
structural requirement for intercalation. It can be hypothesized that the quickly 
saturated first binding site may lie at the termini of the tetraplex. The oxygen rich G-
tetrad can easily form hydrogen bonds with neomycin, a polycationic compound. 
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However, due to the lack of the planar feature, not every ring of neomycin is involved 
into the interaction with the terminal tetrad, with one or more of them floating in the 
solution or forming nonspecific weak interactions with thymine at the termini. The 
second binding event involves seven binding sites, exhibiting a much lower binding 
affinity than the first one (Table 4.1).  This nonspecific interaction my occur within the 
four broad, shallow grooves of the tetraplex via hydrogen bonds, electrostatic 
interactions or van der Waals. However, the binding is not tight due to the lack of 
complementary conformation between neomycin and grooves of tetraplex. This 
hypothesis needs to be confirmed by a structural study in the future. This significantly 
high binding affinity exhibited by neomycin binding to the parallel d(T2G20T2)4 
tetraplex, then, have the potential to improve antitumor therapy.   
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Figure 4.18. (a) CD titration of neomycin into d(T2G20T2)4 tetraplex. The spectrum 
with solid circle represents the one of DNA alone. The insert is the CD spectra of 
DNA alone (continuous line) and drug-saturated complex (dashed line). (b) A plot of 
CD intensity at 261 nm vs. respective rbd values. Linear fit of two apparent linear data 
portions yields the binding site size. Buffer condition: 10 mM sodium cacodylate, 0.5 
mM EDTA, 100 mM NaCl, pH 6.8. T=20 oC. 
 
Table 4.1. Thermodynamic profile of d(T2G20T2)4 tetraplex interaction with neomycin 
in 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl, pH 6.8, T=20 oC. 
pH Binding 
site n 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
First 2 -1.2±0.1 9.6±0.1 -10.8 ±0.1 (1.1±0.5)×108 
5.5 
Second 10 -2.7±0.1 5.6±0.1 -8.3±0.1 (1.5±0.2)×106 
First 3 -7.3±0.1 4.2±0.1 -11.5 ±0.1 (3.6±1.6)×108 
6.8 
Second 7 -10.0±0.1 -1.6±0.1 -8.4±0.1 (1.8±0.1)×106 
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 Salt dependence study:  Since the amount of bound drug is proportional to the 
binding affinity, the observed similar amount of neomycin for tetraplex under three salt 
conditions indicates that the binding affinities under three salt conditions should be 
same. Thus, we conducted the parallel ITC studies in order to confirm the conclusion 
(see appendix). The resulted neomycin binding affinities derived from two binding site 
model were listed in Table 4.2.  Results show that  when Na+ increases from 100 to 200 
mM,  the binding affinity of neomycin for first binding site slightly decreases, with the 
number changing from 1.3 to 0.75 × 108 M-1, while from 2.5 to 0.36 ×106 M-1 for 
second binding site. Thus, even though it is not so significant, the effect of salt on the 
drug binding was observed in ITC studies. We hypothesized in the later section that in 
competition dialysis, fluorescein-neomycin does not exhibit high binding with the first 
binding site. Thereby, the amount of bound drug in the dialysis experiments is 
corresponding to the drug interaction with second site. However, the binding affinity 
for the second site is so low that the interaction is not even saturated under the drug 
concentration applied (100 nM) under all three salt conditions. Thereby based on our 
observation, it can be concluded that competition dialysis is not capable to distinguish 
the binding difference for the systems within low and similar binding affinities.  
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Table 4.2. ITC derived binding affinities of neomycin binding to d(T2G20T2)4 
tetraplex under 100, 150, and 200 mM Na+.  Buffer condition: 6 mM Na2HPO4, 2 
mM NaH2PO4, 1 mM Na2EDTA, pH 7.0. T=20oC. 
[Na+] mM 100 150 200 
Ka1 (first binding site) (1.3±0.3)×108 (8.4±4.6)×107 (7.5±4.0)×107 
Ka2 (second binding site) (2.5±0.2)×106 (6.0±0.6)×105 (3.6±0.3)×105 
 
G10T4G10  
 G10T4G10 was found to forms an infinite “G-wire” tetraplex (284). The 
denaturation of this structure was not observed from DSC melting experiment in the 
temperature range 35-110 oC, implying a high melting temperature than 110 oC. The 
formation of this structure thus was confirmed by the CD scan, which exhibits a 
positive peak at 260 nm and negative peak at 240 nm, consistent with the reported 
result (106) (Figure 4.19). ITC titration of neomycin with this tetraplex also yields two 
types of independent binding sites, one around 2 drugs per tetraplex, the other around 
12 drugs per tetraplex at pH 7.0 (see appendix). Fitting with two binding sites model 
yields the binding affinity of (8.8±2.8)×107 M-1 for first binding event and 
(9.9±0.9)×105 M-1 for second binding event under 150 mM Na+ (see appendix). 
Comparison of neomycin binding with G10T4G10 and d(T2G20T2)4 found that (1) the 
binding affinities obtained in both systems are very similar for the first binding event. 
For second binding site, the binding affinity of neomycin for G10T4G10 tetraplex is 
higher than for d(T2G20T2)4 tetraplex (see appendix); (2) in both systems, the binding 
site size is ~2 for first one and ~12 for second one; (3) similar binding enthalpy was 
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observed here, which is -4.3~-4.7 kcal/mol for first binding site and -2.7~-2.8 kcal/mol 
for second binding site. These similar thermodynamic parameters observed for 
neomycin binding with G10T4G10 and d(T2G20T2)4 implies that the binding mode for 
both systems may be same. As discussed previously, one binding site may lie at the 
termini of the tetraplex, while the second one being at the broad grooves of the 
tetraplex. 
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Figure 4.19. CD scan of G10T4G10 tetraplex alone (continuous line) and drug-
saturated complex (dashed line) in 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM 
Na2EDTA, 150 mM Na+,  pH 7.0. T=20oC. 
 
i-motif: poly(dC) 
 Cytosine-rich polynucleotides or oligodeoxynucleotides can adopt a non-B form 
structure, called an i-motif, under slightly acidic or neutual pH. This i-motif DNA is a 
tetramer of equivalent strands, containing two duplexes zipped together in an 
antiparallel fashion, with the individual parallel stranded duplexes having their 
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hemiprotonated C•C+ base pair face-to-face in the right handed and unwound manner 
(285) (Figure 4.20). This structure contains two wide and two narrow grooves.  
 
 
Figure 4.20. Structure of i-motif DNA.  
 
 The cytosine-rich sequence is found at the 5’ end of the telomere in the 
eukaryotic chromosomes (286) and some non-coding regions of eukaryotic DNA such 
as promoter site and introns. Some RNA in the genomes of various cardioviruses and 
encephalomyocarditis viruses contain many stretches composed of more than 75% 
cytosine (286). Lacroix has reported that two proteins from human cell extracts bind to 
the i-motif DNA specifically, in two orders of magnitude greater than to duplex DNA 
(287). Minisatellite, the mutational hot spots in the germ cells consisting of various 
numbers of tandem repeat sequences, are related to the genetic predisposition of human 
diseases such as cancer (287). Therefore, the formation and stability of this unusual 
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DNA conformation can have a significant biological impact, such as a mutation 
contributing to the final damages associated with these sequences.  
 As shown in Figure 4.21a, the CD scan of the poly(dC) sequence exhibits a 
strong positive band at 285 nm and  a negative band at 265 nm, both characteristic of 
the i-motif conformation. It is not yet known what type of conformation change is 
induced by neomycin; however, this change at least increases the thermal stability of 
the i-motif DNA, about 4 degree increase in the melting temperature (50 oC → 53.5 oC) 
as shown in Figure 4.21b. The binding affinity is further calculated using the ∆Tm 
method, yielding a value of (1.0±0.1)×106 M-1, which is only one order higher than B-
form DNA, but lower than all the other types of nucleic acids. The i-motif DNA, which 
contains three hydrogen bonds formed between every base pair, apparently lacks the 
structural property and hydrogen acceptor favoring the neomycin binding, explaining 
the lower binding affinity observed here.  
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Figure 4.21. (a) CD titration of neomycin into i-motif DNA. The spectrum with solid 
circle represents the one of DNA alone. The insert is the CD spectra of DNA alone 
(continuous line) and drug-saturated complex (dashed line). (b) UV melting profiles 
of i-motif DNA in the absence (1) and presence (2) neomycin at rbd of 4. Buffer 
condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl, pH 6.8. T=20 
oC. 
 
Comparison of neomycin-nucleic acid interaction at pH 5.5 and 6.8 
 The advantage of study at physiological pH 6.8 is that all the conformations 
adopted by nucleic acids, binding site size, melting enthalpy of nucleic acids and 
stabilization effect of neomycin reflect the real properties in organisms. At pH 5.5, 
neomycin is fully protonated, thus the observed binding enthalpy, binding entropy and 
binding constant reflect the intrinsic interaction between the drug and nucleic acids. 
However, study at such a low pH leads to practical problems since the neomycin-triplex 
interaction becomes entropy-driven, thereby, the ITC signal intensity and derived 
binding enthalpy decreases dramatically (Table 4.4). Furthermore, nucleic acid stability 
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at a low pH may become another concern due to the possible charge repulsion between 
multiple strands. However, the destabilization of selected nucleic acids at a low pH of 
5.5 is not significant, with approximately a 1-5 degree decrease in the melting 
temperatures of structures studied. 
 The electronegative potential of the nucleic acid backbone is smaller at pH 5.5 
compared to the one at pH 6.8, due to the neutralization of phosphodiester by free 
protons; as a result, the electrostatic interaction between the protonated neomycin and 
the nucleic acid sequences are not so strong at pH 5.5 as the one at pH 6.8. This, as a 
consequence, partially contributes to the lower binding constants observed at pH 5.5 as 
compared to the ones at pH 6.8. 
 At pH 6.8, the observed binding enthalpy contains the intrinsic binding enthalpy 
between neomycin and nucleic acid, the binding linked protonation heat of neomycin, 
and dilution heat of ligand. The dilution heat can be obtained experimentally by 
titrating the ligand solution into buffer only.  The protonation heat of neomycin differs 
from system to system, depending on the extent of binding linked protonation, thus 
contributing differently to the observed ∆Cp and binding constants.  The overestimated 
binding enthalpy and ∆Cp obtained from ITC at pH 6.8 leads to an overestimated 
binding constant by ∆Tm-based method, a model requiring the intrinsic thermodynamic 
parameters in the calculation. 
 Negative ∆Cp was observed for neomycin-nucleic acid interactions at both pH 
5.5 and 6.8. The negative ∆Cp is thought to be a distinctive feature of site-specific 
binding in protein-DNA interactions, and the negative sign partially results from the 
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removal of large amounts of nonpolar surface from the water on complex formation 
(172, 173). Solvent-accessible surface area change (∆SASA) has an impact on the value 
of ∆Cp  as well (37, 168).   Spolar has defined the following relationship between ∆Cp 
and  ∆SASA, ∆Cp= 0.32(±0.04)∆Anp - 0.14(±0.04)∆Ap, where ∆Anp represents the 
binding-induced changes in the nonpolar surface area and ∆Ap represents the binding-
induced changes in the polar surface  area (174). This relationship implies that the 
removal of nonpolar surface causes the ∆Cp value to be more negative while the 
removal of polar surface leads to a more positive ∆Cp value. In addition to the removal 
of nonpolar solvent accessible surface area, generally, changes of vibrational modes of 
macromolecules and water molecules (175), and involvement of conformational 
equilibrium of macromolecules or some other coupled binding reaction (176, 177) are 
the other two main factors contributing to the negative sign of ∆Cp value. However, in 
our system, the conformational equilibrium of nucleic acid does not exist at the 
temperature range studied here since those temperatures were carefully determined 
based on the thermal denaturation profiles from either UV or DSC. Binding coupled 
protonation of drug molecule was believed to contribute to the observed negative ∆Cp 
value at pH 6.8 since it has been found that drug protonation is associated with a 
negative ∆Cp (178). While at pH 5.5, the contribution of drug protonation to ∆Cp does 
not exist any more. Recently, Lohman also reported the effect of anion to the ∆Cp value 
in the protein-nucleic acid interaction, with the magnitude of ∆Cp being larger when salt 
type switches from NaF, NaCl to NaBr (179). The effect of anions such as Cl- and 
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SO42- to the ∆Cp may also exist in the small molecule-nucleic acid interaction system by 
interacting weakly with the positively charged neomycin, but not significant given the 
reason that such type of interactions are likely to be weak in solution. The heat capacity 
change, thus, not only is linked to the changes between nonpolar and polar surface area 
change upon complexation, but also is dependent on the solution conditions.  
 Table 4.3 and 4.4 show the thermodynamic parameters obtained for neomycin 
interaction with a variety of nucleic acids at both pH 6.8 and 5.5, respectively. Several 
conclusions can be drawn from the results: (1) In the absence of neomycin protonation 
heat, the observed binding enthalpies at pH 5.5 are all smaller than the ones observed at 
pH 6.8 [except poly(dA)•2poly(dT)], reflecting the intrinsic binding enthalpies; (2) all 
heat capacity changes at pH 5.5 are much smaller than the values at pH 6.8, suggesting 
that at pH 6.8 the heat capacity changes of protonation also contributes to the observed 
heat capacity changes of interaction; (3) Heat capacity changes were determined by 
observed binding enthalpies obtained from two or three temperatures which were at 
least 10 degrees apart. Theoretically, at least three data points are needed to accurately 
determine a slope of a linear-related plot. However, our study has found that ITC is a 
technique that measures the binding enthalpies so accurately that two points of those 
values are sufficient to calculate the heat capacity changes (see ITC excess titrations in 
supporting information); (4) the lower binding constants of neomycin were observed at 
pH 5.5, with about 2-30 times decrease for different nucleic acids when compared to 
the values at pH 6.8. As mentioned above, one reason is due to the decreased 
electronegative potential of nucleic acids backbones at pH 5.5, which can decrease the 
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electrostatic interacting forces between neomycin and backbone if compared to the 
same forces at pH 6.8. Another reason is attributed to the observed binding enthalpies 
and heat capacity changes at pH 5.5 that reflect intrinsic values, and are much smaller 
than the ones obtained at pH 6.8. The decrease of magnitudes of these two terms leads 
to the decrease of calculated binding constants; (5) the melting enthalpy for each 
nucleic acid sequence is lower at pH 5.5 than those at pH 6.8, implying the number of 
hydrogen bonds formed at low pH are most likely decreased; (6) at both pH 6.8 and 5.5, 
CD titration studies of neomycin into various nucleic acids reveals similar binding site 
size, with a discrepancy less than l. This result indicates that different pH values do not 
affect the binding sites and modes, but only the tightness of drug-nucleic acid 
complexation; (7) it seems that the systems with higher neomycin binding constant at 
pH 6.8 exhibit large overestimation of binding constant by ∆Tm method, specifically, ~ 
10 times for 16S A site rRNA, ~30 times for poly(rA)•poly(rU), ~20 times for 
poly(dA)•poly(rU)  and ~5 times for d(A2G15C15T2)2 duplex. For those systems with 
lower binding affinities, the discrepancies of neomycin binding constants at pH 6.8 and 
5.5 are not significant, usually less than 3 times. Thus, the higher the binding constant 
is, the greater the contribution of neomycin protonation is; (8) neomycin has been 
known to increase poly(dA)•2poly(dT) thermal stability significantly. However, the 
stabilization effect at pH 5.5 is not potent, with only six degree increase in melting 
temperature. Contradicting to this observation, the binding enthalpy of neomycin with 
this DNA triplex is significantly higher than the value at pH 6.8, implying that 
neomycin induced arrangement of triplex conformation may exist at pH 5.5; (9) 
 173 
tetraplex DNA T2G20T2, surprisingly, reveals the highest binding affinity (~108 M-1) 
among all tetraplex-binding small ligands studied up to date. The observation not only 
enlarges the list of DNA that aminoglycosides bind to, but also increases the potential 
for the successful treatment of tumors.   
 Even though neomycin protonation is involved in its interaction with nucleic 
acids at pH 6.8, the preference of neomycin to nucleic acid structures is same as what 
was observed at pH 5.5, which is RNAs > poly(dA)•poly(rU)  and G-tetraplex > GC-
rich 34 mer and T•A-T triplex > poly(rA)•poly(dT)  > B-form AT-rich or GC-rich 
DNA sequences. Apparently, the more A-like the nucleic acid conformation is, the 
higher the binding affinity of neomycin is. Although studies at pH 6.8 overestimate the 
binding affinities and binding enthalpies of aminoglycosides interaction with nucleic 
acids, this nucleic acid survey under same condition still provides valuable information 
when investigating the selectivity and specificity of aminoglycosides in the therapeutic 
application, and sometimes this comparison is even more important than the absolute 
binding affinity.  
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Table 4.3. Thermodynamic profiles of neomycin interaction with a variety of nucleic 
acids. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl, pH 6.8. 
 
∆Hwca 
 
Tm0b  Tmb  
∆T  
nc 
∆Hd
 
(10oC) 
∆H d
 
(20oC) 
∆H d
 
(30oC) ∆Cp
e          KT(20oC)f 
(M-1) 
poly(rA) - - - - - - - - - - 
poly(rU) - <10 - - - - - - - - 
poly(dA-dT) 
•poly(dA-dT) 5.20 61.7 62.2 0.5 8.0 -3.4±0.1 -3.7±0.2 - -26±24 (1.9±0.4)×10
5
 
poly(dA)• 
poly(dT) 4.04 69.3 69.7 0.4 9.0 -7.7±0.2 -7.2±0.8 - -58±25 (2.7±0.7)×10
5
 
poly(dG-dC) 
•poly(dG-dC) 6.10 
111.
7 
112.
1 0.4 9.8 -2.7±0.1 -3.0±0.1 - -28±22 (5.0±2.5)×10
5
 
Calf thymus 5.12  84.4 84.9 0.5 6.0 -3.7±0.1 -4.9±0.1 - -120±16 (4.8±3.3)×105 
poly(dA)• 
2poly(dT)  1.00 23.4 50.0 26.6 7.0 
-6.6±0.1 
(10oC) 
-7.9±0.1 
(15oC) 
-8.7±0.1 
(18oC) -264±23 
(1.2±0.1)×107 
(15oC)g 
poly(rA)• 
poly(dT) 9.21 65.2 67.3 2.1 8.0 -2.5±0.1 -3.9±0.1 -5.7±0.1 -159±5 (8.5±0.1)×10
6
 
poly(dA)• 
poly(rU) 5.27 48.4 65.2 16.8 6.0 -2.8±0.1 -6.3±0.1 -9.0±0.1 -311±15 (2.3±0.4)×10
8
 
poly(rA)• 
poly(rU) 6.75 59.0 73.1 14.1 7.0 -4.2±0.1 -7.6±0.1 -9.8±0.1 -279±11 (1.0±0.2)×10
9
 
poly(rA)• 
2poly(rU)  
12.21   
(3->1) 59.0 - - 8.5 -4.6±0.2 -7.0±0.1 -9.4±0.1 -238±22 - 
d(A2G15C15T2)
2 
3.40 93.8 95.2 1.4 10.0 -7.2±0.1 -9.5±0.2 -11.9±0.1 235±10 (9.1±0.1)×107 
16S A-site 
RNA 78.82 71.6 75.4 3.8 1.0 -9.7±0.1 -13.0±0.1 -16.7±0.1 -350±20 (1.2±0.4)×10
9
 
d(T2G20T2)4  1.48 81.7 83.2 1.5 - -6.3±0.1 -7.5±0.1 - -135±10 (3.6±1.6)×108 
i-motif 4.25 50.0 53.5 3.5 4.0 -6.4±0.2 -7.9±0.1 - -151±32 (5.2±0.1)×106 
   a Obtained from DSC melting experiments. b obtained from UV or DSC melting 
experiments. c obtained from CD titration. d obtained from ITC excess site titration 
experiments. e Calculated with equation 
T
HC p ∂
∂
=∆ . f Calculated with equation (5) and 
(6) from chapter 5.  g Binding constant determined at 15 oC. The units are Celsius 
degree for temperature, kcal/mol for binding enthalpy, cal/mol.K for heat capacity 
change, and M-1 for binding constant.  
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Table 4.4. Thermodynamic profiles of neomycin interaction with a variety of 
nucleic acids. Buffer: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM NaCl, 
pH 5.5. 
 
∆Hwca 
 
Tm0b Tm b  ∆T  nc ∆H(T1)
 d
 
 
∆H(T2) d 
 
∆Cpe 
 
KT(20oC) f 
(M-1) 
poly(dA-dT) 
•poly(dA-dT) 3.90 62.4 63.2 0.8 7.3 
-2.1±0.1 
(40oC) 
-2.3±0.1 
(53oC) -16±10 (1.2±0.1)×10
5
 
poly(dA)•  
2poly(dT) 1.21 23.5 30.6 7.1 6.0 
-14.6±0.2 
(5oC) 
-16.9±0.1 
(15oC) -232±33 
(1.1±0.1)×106 
(15oC)g 
poly(rA)•      
poly(dT) 7.12 64.7 68.1 3.4 8.0 
-4.5±0.1 
(35oC) 
-5.0±0.2 
(45oC) -50±20 (3.4±0.4)×10
6
 
poly(rA-rA) 4.05 44.0 61.5 17.5 6.5 -1.8±0.1 (5oC) 
-2.1±0.1 
(10oC) -60±25 (1.7±0.2)×10
7
 
poly(dA)•       
poly(rU) 3.84 43.6 65.5 21.9 6.5 
3.6±0.1 
(15oC) 
2.8±0.1 
(20oC) -160±18 (9.4±0.1)×10
6
 
poly(rA)•      
poly(rU) 6.34 53.4 64.6 11.2 8.0 
1.7±0.1 
(15oC) 
-0.7±0.1 
(25oC) -245±7 (2.9±0.1)×10
7
 
poly(rA)•    
2poly(rU) 1.40 45.5 - - - 
-
2.42±0.02
(15oC) 
-
0.02±0.01 
(25oC) 
-240±3 - 
d(A2G15C15T2)2 3.00 93.7 101.1 7.4 10.0 
-0.7±0.1 
(20oC) 
-2.5±0.2 
(30oC) -173±23 (1.8±0.6)×10
7
 
16S A-site RNA 96.64 71.7 79.9 8.2 1.0 -0.9±0.1 (10oC) 
-2.4±0.1 
(20oC) -151±12 (8.7±0.9)×10
7
 
d(T2G20T2)4 2.38 84.7 - - 10.0 
-
1.06±0.02
(10oC) 
-
1.45±0.01
(20oC) 
-40±4 (1.1±0.5)×108 
a Obtained from DSC melting experiments. b obtained from UV or DSC melting 
experiments. c obtained from CD titration. d obtained from ITC excess site titration 
experiments. e Calculated with equation 
T
HC p ∂
∂
=∆ . f Calculated with equation (5) and 
(6) from chapter 5.  g Binding constant determined at 15 oC. The units are Celsius 
degree for temperature, kcal/mol for binding enthalpy, cal/mol.K for heat capacity 
change, and M-1 for binding constant.  
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Comparison of binding preference of neomycin between competition dialysis and ∆Tm 
method derived binding constants 
 When comparing the binding preference of neomycin, we calculated the 
apparent binding constant Kapp with the equation (1) (288):  
 
Kapp=Cb/{Cf-([NA]total-Cb)}  (1) 
 
where Cb and Cf are the bound and free drug concentrations, respectively, [NA]total is 
the total nucleic acid concentration used in the competition dialysis.   
 Table 4.5 shows the binding affinities of neomycin for most of nucleic acids 
calculated from equation (5) for competition dialysis and ∆Tm-based method. DNA 
triplex poly(dA)•2poly(dT) and poly(rA)•poly(rA) were not used in competition 
dialysis since these structures are not existing at pH 6.8. Poly(rA)•2poly(rU) triplex-
neomycin binding affinity cannot be derived from the ∆Tm method due to the reason 
mentioned previously, thereby not shown in table as well. d(A2G15C15T2)2 was used in 
∆Tm method as the model to represent poly(dG)•poly(dC) since latter is not applied for 
∆Tm method in calculating the binding affinity, as mentioned above. 
 The binding preference of neomycin observed from competition dialysis is 16S 
rRNA A site > RNA triplex poly(rA)•2poly(rU) > RNA duplex poly(rA)•poly(rU) > 
poly(dG)•poly(dC) and poly(dA)•poly(rU) > T2G20T2 > poly(rA)•poly(dT) > poly(dA-
dT)2. The trend observed from ∆Tm derived binding affinities is almost same except for 
G-tetraplex T2G20T2. T2G20T2 exhibits the highest binding affinity (1.1±0.5×108 M-1) 
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with neomycin at pH 5.5 among all sequences studied, while in competition dialysis its 
binding constant is only slightly higher than poly(rA)•poly(dT)  and poly(dA-dT)2. The 
large discrepancy in the binding preference of neomycin for tetraplex may be explained 
as steric hindrance when neomycin binds to the tetraplex. In competition dialysis, the 
fluorescein-neomycin conjugate was used. Even though fluorescein does not contribute 
to the binding, the large size of the conjugate may prevent the neomycin from 
effectively binding to the first specific binding site, the termini G-tetrad of tetraplex 
which contains eight thymidines tail at each end.  Thereby, the observed amount of 
bound neomycin for first binding site in competition dialysis is dramatically decreased.  
 Even though both methods exhibits the almost same binding preference of 
neomycin over the nucleic acids studied here,  one significant discrepancy between 
competition dialysis and ∆Tm method is that the binding constants obtained from 
competition dialysis are also at least 30 times smaller than one observed in the ∆Tm-
based method. This can be explained as the following reasons: (1) in ∆Tm method, the 
binding constants were calculated at 20 oC, while in competition dialysis, the 
experiment was operated at room temperature which was around 24 oC. However, the 
binding affinities difference resulted from the temperature difference should be small; 
(2) fluorescein-neomycin was used in competition dialysis while neomycin was used in 
∆Tm method. Even though the binding of fluorescein to nucleic acids studied is 
negligible, it could affect the binding of neomycin to nucleic acids sequences when it 
was conjugated to neomycin. Fluorescein’s unfavorable effect on neomycin’s binding 
could include its restriction on neomycin’s freedom at binding site and possible 
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formation of intramolecular or intermolecular hydrogen bonds within or between 
conjugates. Based on those possible factors, the efficient amount of neomycin for 
binding with nucleic acids is decreased dramatically, observed as the much lower 
binding affinities.  This hypothesis was also supported by the direct ITC titration of 
fluorescein-neomycin conjugate into d(T2G20T2)4 tetraplex and d(A2G15C15T2)2 (see 
appendix). There are two binding sites observed in neomycin--d(A2G15C15T2)2 
interaction, while only one is observed when fluorescein-neomycin was used. The first 
binding event, observed as a specific binding site with high binding affinity of 
(8.0±3.1)×107 M-1 in the neomycin--d(A2G15C15T2)2 interaction, was not observed in the 
fluorescein-neomycin--d(A2G15C15T2)2 interaction which yielded only one binding 
constant of (3.1±0.1)×105 M-1 (see appendix). This binding constant is close to the one 
from second binding event in neomycin--d(A2G15C15T2)2 interaction, most likely due to 
the nonspecific binding. For the fluorescein-neomycin--d(T2G20T2)4 interaction, the 
binding constant for the specific first binding site was found to be (4.6±2.0)×106 M-1, 
about two orders of magnitude smaller than the one of (1.3±0.3)×108 M-1 obtained from 
neomycin-d(T2G20T2)4-interaction (see appendix).Thus, it has clearly shown that 
fluorescein-neomycin significantly affects the specific binding of neomycin to nucleic 
acids.  
 However, even though competition dialysis does not quantitatively produce the 
true binding affinities here, it still can be used qualitatively as an efficient technique to 
compare the binding preference of neomycin with various nucleic acids, which has 
been confirmed by the result obtained from ∆Tm-based method. 
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Table 4.5. Comparison of binding preference of neomycin between competition 
dialysis and ∆Tm method derived binding constants. 
 KA (20 oC) (×105M-1) 
(∆Tm method)  
Kapp (~24 oC) (×105M-1) 
Competition dialysis  
AT rich duplexes 1.2±0.1 [poly(dA-dT)2] 0.08 ±0.02 [poly(dA) •poly(dT)] 
poly(dA)•2poly(dT) 11±1 (15oC) - 
poly(rA)•poly(dT) 34±4 0.17 ±0.09 
poly(rA)•poly(rA) 120±20 - 
poly(dA)•poly(rU) 94±1 0.32±0.04 
poly(rA)•poly(rU) 290±10 0.35 ±0.07 
poly(rA)•2poly(rU) - 1.00 ±0.04 
GC-rich duplex 180±30 {d(A2G15C15T2)2} 0.21 ±0.06 {poly(dG)•poly(dC)} 
16S A-site RNA 870±90 17.0 ±0.5 
d(T2G20T2)4 1100±500a  0.21 ±0.02 
G10T4G10 880±280b 1.89 ±0.05 
a
 Obtained from ITC data fitting using a two binding site model. b Obtained from ITC 
data fitting using a two binding site model under BPES buffer, 150 mM Na+ and pH 
7.0. 
  
Conclusion 
 
 Since the discovery that neomycin is able to stabilize DNA triplexes 
significantly and selectively, the list of nucleic acid structures that neomycin binds has 
been extended to DNA. A comprehensive study of neomycin binding to different 
structures is required to evaluate its selectivity and specificity in the organism being 
treated, information that may at least partially help explain the side effects and 
toxicities induced by its use. The study conducted here investigates a variety of nucleic 
acid structures, to determine the ones neomycin prefers. Results suggest that neomycin 
prefers to bind to the more A-like structures, gradually becoming less favorable as 
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nucleic acid structure moves toward the B-form. This report, the first involving a 
nucleic acid screen by neomycin from a thermodynamic perspective, can function as a 
database for comparing other nucleic acid sequences or nucleic acid-binding ligands 
such as modified aminoglycosides. 
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CHAPTER 5 
EXPERIMENTAL SECTION 
 
Materials  
Chemicals 
 Neomycin B sulfate form and ribostamycin were purchased from ICN 
Biomedicals Inc.. Paromomycin sulfate was purchased from Sigma. Cacodylic acid, 
sodium form was purchased from Fisher Scientific, Inc.. Na2EDTA, DNAase and 
RNAase free, was purchased from Acros. Sodium chloride and potassium chloride were 
purchased from Acros.  All the chemicals were used without further purification. Water 
was obtained from a Millipore Milli-Q water purification system. 
 
Nucleic Acids 
 The biotinylated dT30 single stand and the intramolecular triplex (5'-dA12-x-
dT12-x-dT12-3') were purchased from Integrated DNA Technology with HPLC 
purification.  The intramolecular triplex (5'-dA12-x-dT12-x-dT12-3'), dT30 and dA30 were 
also synthesized by us using Expedite Nucleic Acid Synthesis System (8909) with 
standard phosphoramidite chemistry. The oligomer was purified on an anion exchange 
HPLC column (Water Gen-Pak FAX, 4.6×100 mm) with Tris·HCl buffer. Buffer A: 25 
mM Tris·HCl, 1 mM of EDTA, and 10% of MeCN (v/v%); Buffer B: Buffer A + 1M 
NaCl. Conditions: 2-60% buffer B over buffer A during 0-16 min at a flow rate of 0.75 
mL/min. The concentration of 5′-dA12-x-dT12-x-dT12-3' was determined with molar 
extinction coefficient, ε260  = 341,100. 
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 All the polynucleotides were purchased from GE Healthcare Amersham 
Bioscience. The concentrations of all the polymer solutions were determined 
spectrophotometrically using the following extinction coefficients (in units of mol of 
nucleotide or bp/L-1cm-1):  ε264  = 8520 for poly(dT),  ε 260 = 6000 for 
poly(dA)•poly(dT), ε262  = 6600 for poly(dA-dT)•poly(dA-dT), ε254  = 8400 for 
poly(dG-dC)•poly(dG-dC), ε258  = 9800 for poly(A), ε260 = 9350 for poly(U), ε274  = 
7400 for poly(dC); d(A2G15T15T2) was purchased from Integrated DNA technologies, 
ε260  = 301,200. 16S A-site rRNA was purchased from Dharmacon RNA technologies, 
and further deprotected before use, ε260  = 253,300. Calf thymus DNA was purchased 
from Sigma, ε260  = 12,824. d(T2G20T2) was purchased from Invitrogen life 
technologies, ε260  = 39,267 in tetrad.  
 
Biophysical and Bioanalytical Experimental Section 
Competition Dialysis 
 For each competition dialysis assay, 200 µl of different nucleic acids in the 
remade mini dialysis units were placed in a MINI dialysis flotation device (Pierce 
Chemical Company; www.percenet.com) and then dialyzed with 400 ml of 1 µM or 0.1 
µM ligand BPES buffer solution within 72 hrs at ambient temperature (20-22°C).  At 
the end of the experiment, 180 µl nucleic acids samples were carefully removed to 
microfuge tubes, and were taken to a final concentration of 1% (w/v) sodium dodecyl 
sulfate (SDS). Each mixture was allowed to equilibrate for 2 hours. The concentration 
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of ligand after dialysis was determined by fluorescence (Fluoromax-3, Jobin Yvon, 
Inc.) An appropriate correction was made due to volume changes. The amount of bound 
drug was determined by difference, Cb=Ct-Cf. Where Cf is the concentration if bulk 
drug solution, Ct is total concentration of drug solution that penetrates into the 
membrane, and Cb is the concentration of drug bound to the nucleic acids. Data were 
plotted as a bar graph using Kaleidagraph Software (Version 3.5, Synergy Software). A 
calibration curve is made before each experiment via plotting the fluorescence 
intensities at ligand characteristic wavelength to a series of corresponding ligand 
concentrations. Ct and Cf are determined based on the calibration curve.  
 
UV spectrophotometry 
 All UV absorbance experiments were conducted on a Cary 1E UV/vis 
spectrophotometer equipped with temperature programming. Quartz cells with a 1 cm 
path length were used for all the absorbance studies. For the triplex preparation, all 
samples were heated at 95 ºC for 5min, then cooled slowly to room temperature and 
allowed to incubate for 16 hours at 4 ºC prior to use. Absorbance vs. temperature 
profiles were recorded at 260 nm and 280 nm. The samples were heated from 5 ºC to 95 
ºC at a rate of 0.2 ºC/min, then they were cooled to 10 ºC at a rate of 5.0 ºC/min. Data 
was recorded at 1 degree increments. For melting temperature (Tm) determination, two 
baselines (upper and lower) were drawn, corresponding to folded and unfolded forms, 
respectively. Thereafter a median line between the two baselines was drawn, and the 
crossing point between the experimental curve and median line was used for Tm. For all 
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the thermal denaturation experiments, DNA concentrations were 1 µM in strand for 
intramolecular triplex and 15 µM for poly(dA)•2poly(dT) triplex.   
 
Surface plasmon resonance (SPR) 
 All the SPR experiments were carried out on a BIAcoreX instrument (Biacore 
Inc., Upsaala, Sweden) at 20 ○C. The biosensor chip (SA chip, Biacore Inc., Upsaala, 
Sweden) was precoated with streptavidin. Three consecutive 1-min pulses of 1 M NaCl 
in 50 mM NaOH were performed in the flow rate of 25 µL/min to activate the chip 
surface prior to use. After flowing the running buffer for at least 10 min, the flow 
channel 1(control channel) was closed and 2 µM/strand of the biotinylated-dT30 was 
manually injected onto the flow channel 2 for the capture by streptavidin. After 6 
minutes flowing, ~1500 RU of the 5′-biotinylated dT30 was immobilized on the surface. 
Corresponding double helix and triple helix were formed by injecting 30 µL of 
complementary dA30 and dT30 with the concentration of 2 µM/strand (see supporting 
information). The flow rate was 5 µL/min for double helix or triple helix formation in 
this report. Because triple helix is not stable enough and it will dissociate from the 
surface slowly after injection, the drug solution was immediately introduced after triple 
helix was formed (see supporting information). Thus, we didn’t observe any 
dissociation of triple helix from surface before the drug solution arrived the surface. 
Subsequent to the drug injection, a 15 µL injection of 5 mM aqueous sodium hydroxide 
was used to remove the third strand of triplex by breading the Hoogsteen hydrogen 
bonds formed between purine strand (dA30) and triplex-formed pyrimidine strand 
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(dT30), and also partially remove the duplex-formed strand (dA30). A 15 µL injection of 
2 µM/strand dA30 solutions was introduced to regenerate the duplex bt-dT30-dA30 on the 
surface for storage for next experiment. In all experiments, a serial of drug solution 
were introduced from low concentration to high concentration for 2 min flowing at flow 
rate of 10 µL/min. After each experiment, the chip was regenerated by forming the 
double helix bt-dT30-dA30 and stored at 4 ○C in the conical tube with very small amount 
of nanopure water to moister the chip. The mass transfer limitation, a factor needed to 
take into account when conducting a SPR experiment, was not observed in our 
experiments. 
The SPR sensorgrams were analyzed using BIAevaluation 3.1 software. The 
corrected sensorgrams were obtained by subtracting the control signal (flow channel 1) 
from sample signal (flow channel 2). To obtain the binding affinity, steady state 
analysis was used by making a binding isotherm of steady state response vs. 
corresponding drug concentration. The resulting binding isotherms then were fitted 
with Origin 7.0 for nonlinear least squares optimization using a single binding site 
model, which is listed below (208): 
 






+
=
C*1K1
C*1K
*maxRUssRU         (1)  
 
where K1 is dissociation equilibrium constant, C is the free drug concentration which is 
fixed by the drug concentration in the flow solution, RUss is the steady state response in 
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RU corresponding to every drug concentration, RUmax is the maximum binding 
response in RU for binding one ligand per binding site (201).  
Kinetic parameters were obtained by fitting the dissociation and association phases 
of SPR sensorgram separately or globally using BIA evaluation 3.1. Generally, global 
fitting was used if the goodness of fits was satisfactory by visual inspection. However, 
when global analysis did not yield good fits, separate fitting of kinetic data was carried 
out. For ligand dissociation from DNA triplex on the surface, the dissociation kinetics 
can be described by a single-exponential decay for single site binding (209, 210) with 
equation (2): 
 
offR
)0tt(*1dk
e*)0t(1R)t(R +
−−
=        (2) 
 
where kd1 is dissociation rate constants, R1 is the amplitude of the dissociation with a 
rate constant kd1, t0 is the starting time of the fitted data, R(t) is the response at time t, 
and Roff is the residual response at infinite time.  With the aid of dissociation rate 
constants derived from equation (2), the association rate constants for one binding site 
is fitted with equation (3) (209, 210), 
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where ka1 and kd1 are the rate constants describing one interaction with maximal 
response of Rmax1, and ka2 and kd2 are the rate constants describing another interaction 
with maximal response of Rmax2, Rt0 is the fitting parameter equivalent to the signal at 
the injection time (t=0), t0 is the starting time of injection, and the R(t) is the binding 
response at time t. 
 
Isothermal Titration Calorimetry (ITC) 
 All isothermal calorimetric measurements were performed on a MicroCal VP-
ITC (MicroCal, Inc., Northampton, MA) at various temperatures. In ITC studies, DNA 
concentrations were varied to obtain reliable signal intensity. In every titration, 5 - 10 
µL aliquots of aminoglycoside solution were injected into a sample cell containing 1.42 
mL of DNA triplex solution. After each experiment, a corresponding control 
experiment was performed by titrating the same drug solution into experimental buffer. 
The injection spacing was either 240s or 300s, syringe rotation rate was 260 rmp, and 
duration of each injection was 20s. The resulting data were processed by Origin version 
5.0. Every heat burst curve was due to every drug injection. Integrating the area under 
each heat curve yielded the heat given off upon each injection, from which the 
corresponding control data was subsequently subtracted to obtain the ITC binding 
profile associated with the drug-DNA binding.  
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Differential Scanning Calorimetry (DSC) 
 The DNA melting temperature and melting enthalpy changes in the absence of 
drug were obtained using a MicroCal VP-DSC (MicroCal, Inc., Northampton, MA).  
The scan rate was 1 ºC/min, and the operating temperature range was 5 ºC - 95 ºC.  
After each DSC experiment, a corresponding control experiment was conducted with 
only sample buffer in the sample cell.  The corrected DSC profile was obtained by 
subtracting the control data from the sample data.  The enthalpy changes for the melting 
of either triplex or duplex in the absence of drug (∆HHS) were calculated by integrating 
the area under the heat capacity curves using Origin version 5.0. 
 
Circular Dichroism Spectropolarimetry (CD) 
 All CD experiments were conducted at 10 °C on a JASCO J-810 
spectropolarimeter equipped with a thermoelectrically controlled cell holder.  A quartz 
cell with a 1 cm path length was used in all CD studies.  CD spectra were recorded as 
an average of 3 scans from 300 nm to 200 nm in 0.1 nm increments.  In isothermal CD 
titration experiments, small aliquots of concentrated drug solutions were added to a 
solution of DNA, inverted twice, and allowed to equilibrate for at least 10 minutes prior 
to scanning.  In each CD titration, small aliquots (0.6-40 µL) of a concentrated 
aminoglycoside solution (500 µM) were added to a 2 mL solution of nucleic acid 
solution. The initial DNA solution was allowed to equilibrate for at least thirty minutes 
prior to the first addition of drug. 
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Fluorescence Intercalator Displacement Assay (FID) 
 FID assay was done using a Photon Technology International instrument 
(Lawrenceville, NJ) at 10oC. A 2 ml solution with 4 µM/base triplet was prepared and 
incubated for 16 hours at 4 oC prior to use. Thiazole orange was added to DNA solution 
until final concentration was 2 uM. After incubation at 10 oC for 30 min, the solution 
was excited at 503 nm at its λmax (slits = 2 nm) and resulting emission curves (from 
515-555 nm) were recorded after serial quantitative additions of a concentrated 
neomycin solution. Before each scan, the solution was allowed to stir and equilibrate 
for 30 min. ∆F was calculated by taking the difference of fluorescence emission at 533 
nm between each scan and the one of DNA-thiazole orange only. ∆F was plotted vs. the 
molar concentration of neomycin after each corresponding addition and the resulted 
data was fit using two binding sites model in Origin 5.0 according to the equation 
below (289):  
 
)2]drug[2K1K]drug[1K1/(])drug[2K5.0(]drug[1KF ××+×+×+××∑ ×Φ=    (4) 
 
Where F is the fluorescence of the solution after each neomycin addition, ∑Φ is the 
fluorescence of DNA saturated with neomycin, K1, K2 is the binding constant for first 
and second binding events, respectively. [Drug] is the concentration of neomycin after 
each quantitative titration. 
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Molecular Modeling 
 The structures of the dA10•2dT10 triplex, neomycin, and paromomycin structure 
have been built and optimized with MacroModel program (290)  using the AMBER* 
force field (291, 292). The all atom AMBER* force field was used since it reproduces 
x-ray and NMR derived DNA structures.  The continuum GB/SA model of water (293, 
294), as implemented in MacroModel, has been used in all calculations. The force field 
atomic charges were used for triplex. The ligands were built and optimized in 
MacroModel and the RESP charges were derived using ab initio calculations with 6-
31G* basis set in Jaguar program (290). The structure of the dA10•2dT10 triplex was 
built starting from the experimental (NMR), solution structure of related DNA triplex 
(295, 296). Twenty seven sodium ions were added to neutralize the initial structure.  
The sodium ions were removed and the structure was reoptimized to within a gradient 
of 0.05 kJ/(mol·Å). Only the movement of atoms of external bases was restricted during 
minimization. The structure of neomycin was built by MacroModel and submitted to 
conformational searching in order to find the global minimum structure and the other 
low energy conformations.  For conformational searching, the Monte Carlo (MC) 
routine (297, 298) from MacroModel was used.  Three MC runs (for all single bond 
torsional angles and 1000 steps each) starting from different initial conformations were 
performed, yielding the same global minimum conformation. All the flexible bonds 
were selected.   
 Several of the lowest conformations of neomycin were manually docked to the 
DNA triplex groove in different orientations. The conformations of the molecules were 
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adjusted to allow maximum base-ligand, and phosphate-ligand H-bond formation with 
no significant unfavorable van der Waals interactions.  Neomycin was manually docked 
into the triplex grooves avoiding any unfavorable steric clashes, and positioned 
approximately central in the entrance to the grooves. For a more detailed analysis of 
ligand groove interactions, appropriate contacts between protonated amines and 
phosphate oxygens on the backbone were selected. The minimized complexes were 
then re-minimized with the distance constraints removed to a RMS gradient of 0.08 
kcal/(mol·Å) to eliminate unfavorable contacts. In the next step, all the restrictions were 
removed except the movement of ring atoms of the terminal bases, and the structure 
was optimized to a gradient of 0.05 kJ/(mol· Å) or lower. To test the stability of the 
complex, the low energy complexes were submitted to 500 ps MD simulation using 
reported procedures (stochastic dynamics, constant temperature of 300 K, with 
coupling constant of 0.2 ps, and a time step of 1.0 fs) (152). The SHAKE procedure 
was used for all bonds.   Electrostatic potential was generated from viewerLite 5.0 for 
windows (Accelrys Inc., CA, USA) using Gasteiger charges.  
 
∆Tm Method 
 The following equation has been used to calculate association constants at the 
corresponding melting temperatures where the triplex is complexed with drug (163):  
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∆
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Tmo is the melting temperature of drug-free DNA triplex; Tm is the melting temperature 
of drug bound DNA triplex; ∆HHS is enthalpy change corresponding to Hoogsteen base 
pair melting in the absence of drug, determined from a DSC measurement; L is free 
drug concentration at Tm (estimated by one-half the total drug concentration), and n is 
the binding site size as determined by CD experiments. After obtaining the association 
constants at Tm, the integrated van’t Hoff equation (6) is used to calculate the 
association constants at 10 ºC (164): 
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where ∆Hobs is the observed binding enthalpy of drug to triplex as derived from ITC 
excess site binding experiments at 10 ºC; R is the gas constant, and ∆Cp is the heat 
capacity change, which can be determined from equation (7) by using binding 
enthalpies at various temperatures.  
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GLOSSARY OF ABBREVIATIONS 
 
W-C Watson-Crick 
W-H Watson-Hoogsteen 
HS Hoogsteen 
MOPS 3-[N-Morpholino] propanesulfonic acid 
NMR Nuclear magnetic resonance 
CD Circular dichroism 
HPLC High performance liquid chromatography 
SPR Surface plasmon resonance 
DSC Differential scanning calorimetry 
ITC Isothermal titration calorimetry 
FID Fluorescence intercalator displacement 
SDS Sodium dodecyl sulfate 
TFO Triplex formation oligonucleotide 
mRNA Messenger RNA 
tRNA Transfer RNA 
rbd Ration of [DNA]/[Drug] 
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APPENDIX 
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Figure 1. (a) UV melting profiles of the 5'-dA12-x-dT12-x-dT12-3' triplex in the 
absence of drug at 260 nm.  (b) UV melting profiles of the 5'-dA12-x-dT12-x-dT12-
3' triplex in the absence of drug at 280 nm. From left to right, the salt concentration 
was 0, 50, 100, 150, 250, 500, 800 mM, pH 7.2. (c) Plots of the ∆Tm3→2 and 
∆Tm2→1 of the 5'-dA12-x-dT12-x-dT12-3' triplex as a function of [KCl]. (d) Plots 
of the ∆Tm3→2 and ∆Tm2→1 of  poly(dA)•2poly(dT) triplex as a function of increasing 
pH value. The Tm for the triplex was picked up from the profiles at 280 nm.  All the 
buffer solutions contain 10 mM sodium Cacodylate, 0.5 mM EDTA and 100 mM 
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Figure 2. CD titration curves of paromomycin(a) and neomycin (c) with 5′-dA12-x-
dT12-x-dT12-3′ triplex. The insert is an expanded spectrum from 242 nm to 252 nm. 
For clarity, not all the CD spectra are shown. Plots of normalized molar ellipticity 
vs 1/rdb for CD titration of 5′-dA12-x-dT12-x-dT12-3′ triplex with paromomycin (b) 
and neomycin (d) were drawn. The continuous lines in the right plot reflect the 
linear least-squares fits of each apparent linear domain of the experimental data. 
Buffer conditions: 10 mM sodium cacodylate, 0.5 mM EDTA, 150 mM KCl, and 
pH 6.8. T=10 °C. DNA triplex concentration was 4 µM in strand.  
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Figure 3.  Sample ITC excess site titration of neomycin with 5'-dA12-x-dT12-x-dT12-3' 
at 5oC (a), 10 oC (b) and 15 oC (c). (d) A plot of observed binding enthalpies vs 
corresponding temperatures. The slope reflects the heat capacity change ∆Cp.  Buffer 
condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 6.8. 
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Figure 4.  Sample ITC excess site titration of paromomycin with 5'-dA12-x-dT12-x-
dT12-3' at 5oC (a), 10 oC (b) and 15 oC (c). (d) A plot of observed binding enthalpies vs 
corresponding temperatures. The slope reflects the heat capacity change ∆Cp.  Buffer 
condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 6.8. 
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Table 1: ITC derived binding constants and binding enthalpy for the neomycin 
binding to 5'-dA12-x-dT12-x-dT12-3' triple helix at pH 5.5, 6.8 and 7.4 in 10 mM 
sodium cacodylate, 0.5 mM EDTA and 150 mM KCl. T=10 oC. 
pH 5.5 6.8 7.4 
Kobs1 (M-1) (9.1 ± 4.5) × 106 (3.8 ± 0.4) × 105 (2.7 ± 0.81) × 105 
∆Hobs1 (kcal/mol) - 0.15 ± 0.01 -5.9 ± 0.20 -6.0 ± 1.9 
T∆S1 (kcal /mol) 9.7 1.1 1.0 
∆G1 (kcal /mol) -9.8 ± 0.01 -7.1 ± 0.2 -7.0± 0.2 
n1 (drug/triplex) 2.0 ± 0.3 1.1 ± 0.0 1.0 ± 0.0 
Kobs2 (M-1) (6.1 ± 1.4) × 105 (8.6 ± 2.4) × 104 (7.3 ± 0.7) × 104 
∆Hobs2 (kcal/mol) - 0.34 ± 0.03 -6.9 ± 0.2 -6.8 ± 1.5 
T∆S2 (kcal /mol) 7.2 -0.5 -0.5 
∆G2 (kcal /mol) -7.5 ± 0.03 -6.4 ± 0.3 -6.3 ± 0.1 
n2 (drug/triplex) 1.9 ± 0.3 1.1 ± 0.0 1.0 ± 0.0 
All the data are derived from ITC experiments. The values of Ka, ∆H and ∆S were 
determined from fits of ITC profile by the model with two sets of binding sites. ∆G 
were determined by the equation ∆G=-RTlnK.  
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Figure 5. ITC studies of intramolecular triplex 5'-dA12-x-dT12-x-dT12-3' with 
neomycin (a) and paromomycin (b) in 10 mM MOPS, 0.5 mM EDTA, 150 mM KCl, 
pH 6.8; T=10 ºC. [DNA] = 6 µM/strand, [Drug] = 700 µM. (c-d) Corrected injection 
heat as a function of [drug]/[triplex] ratio. The data points represent the experimental 
injection heat and the solid lines correspond to the calculated fits of the data by using a 
model with two sets of binding sites (Origin 5.0). 
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Table 2: Heat capacity changes of neomycin and paromomycin binding with 5'-dA12-
x-dT12-x-dT12-3' triplex at four salt concentrations in 10 mM sodium cacodylate, 0.5 
mM EDTA, and pH 6.8.  
[KCl]        
(mM) 
Drug 
Hb(5 °C) 
(kcal/mol) 
Hb(10 °C) 
(kcal/mol) 
Hb(15 °C)  
(kcal/mol) 
Cp   
(cal/mol·K) 
100 Neomycin -6.9±0.1 -8.4±0.1 -10.0±0.3 -310±43 
150 Neomycin -4.8±0.1 -5.5±0.1 -6.3±0.2 -158±30 
200 Neomycin -3.6±0.0 -4.1±0.1 -4.5±0.0 -84±12 
250 Neomycin - -2.7±0.0 -2.8±0.1 -17±22 
100 Paromomycin -3.8±0.1 -5.0±0.10 -6.1±0.1 -229±36 
150 Paromomycin -3.2±0.0 -3.7±0.1 -4.1±0.1 -96±24 
200 Paromomycin - -2.2±0.0 -2.3±0.1 -26±18 
250 Paromomycin - -1.2±0.0 -1.2±0.0 -13±6 
100 Ribostamycin - -3.0±0.1 -3.4±0.1 -76±30 
∆Hb were obtained from the ITC excess sites binding experiments.  
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Figure 6. (left) UV melting profiles of poly(dA)•2poly(dT) triplex in 10 mM sodium 
cacodylate, 0.5 mM EDTA, pH 6.8 and various  KCl concentrations. (right) DSC 
melting profile of poly(dA)•2poly(dT) in 10 mM sodium cacodylate, 0.5 mM EDTA, 
pH 6.8, and various KCl concentration. [DNA]=100 µM/bp. 
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Figure 7. UV melting profiles of poly(dA)•2poly(dT) triplex at absence and saturated 
amount of neomycin in 10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, and 
various KCl concentrations as indicated in profiles. 
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Figure 8. UV melting profiles of poly(dA)•2poly(dT) triplex at absence and saturated 
amount of paromomycin in 10 mM sodium cacodylate, 0.5 mM EDTA, pH 6.8, and 
various KCl concentrations as indicated in profiles. 
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Figure 9. CD spectra of poly(dA)•2poly(dT) with increasing neomycin in (a)100 mM, 
(b) 150 mM, (c) 200 mM KCl.  rbd plots were shown at bottom panel (d,e,f). Buffer 
conditions: 10 mM sodium cacodylate, 0.5 mM EDTA, and pH 6.8. T=10 °C. [DNA]= 
50 µM/bp. 
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Figure 10. CD spectra of poly(dA)•2poly(dT) triplex with increasing paromomycin in 
(a)100 mM, (b) 150 mM, (c) 200 mM KCl.  CD signals at 247nm plotted vs 
corresponding rbd values were shown at bottom panel (d,e,f). Buffer conditions: 10 mM 
sodium cacodylate, 0.5 mM EDTA, and pH 6.8. T=10 °C. [DNA]= 50 µM/bp. 
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Figure 11. ITC excess site titration of neomycin with poly(dA)•2poly(dT) at 5oC (a), 
10 oC (b) and 15 oC (c). (d) A plot of observed binding enthalpies vs corresponding 
temperatures. The slope reflects the heat capacity change ∆Cp.  Buffer condition: 10 
mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 6.8. 
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Figure 12. (a) UV melting profiles of poly(dA)•2poly(dT) triplex at absence and 
saturated amount of ribostamycin. (b) A plot of observed binding enthalpies vs 
corresponding temperatures. The slope reflects the heat capacity change ∆Cp. (c) CD 
spectra of poly(dA)•2poly(dT) triplex with increasing ribostamycin. (d) CD signals at 
247nm plotted vs corresponding rbd values. The continuous lines in the right plot 
reflect the linear least-squares fits of each apparent linear domain of the experimental 
data. Buffer condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and 
pH 6.8. 
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Figure 13. (a) CD spectra of poly(dA)•2poly(dT) triplex with increasing neomycin. 
(b) CD signals at 247nm plotted vs. corresponding rbd values. The continuous lines in 
the right plot reflect the linear least-squares fits of each apparent linear domain of the 
experimental data. Buffer condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 
mM KCl, and pH 5.5. 
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Figure 14.  ITC excess site titration of neomycin with poly(dA)•2poly(dT) at 5oC 
(a), 10 oC (b) and 15 oC (c). (d) A plot of observed binding enthalpies vs 
corresponding temperatures. The slope reflects the heat capacity change ∆Cp.  
Buffer condition: 10 mM sodium cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 
5.5. 
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Table 3. Thermodynamic profiles of poly(dA)•2poly(dT) and 5'-dA12-x-dT12-x-dT12-
3' interaction with aminoglycosides in 10 mM sodium cacodylate, 0.5 mM EDTA,  
100 mM KCl and various pH. T = 10 oC. 
Drug pH ∆Hwc Tm0 Tm n ∆Cp(cal/mol.K) Ka(10oC) (M-1) 
Neo 6.8 1.20 22.7 54.2 6.2 
-218±15 (3.5±0.7)×10
Neo 6.2 1.05 22.4 28.4 7.3 
-140±14 (7.1±0.1)×10
Neo 5.5 1.157 22.4 28.6 8.8 
-98±13 (6.2±0.5)×10
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Figure 15. ITC excess site titration of neomycin with poly(dA)•2poly(dT) at 5oC (a), 
10 oC (b) and 15 oC (c). (d) A plot of observed binding enthalpies vs corresponding 
temperatures. The slope reflects the heat capacity change ∆Cp.  Buffer condition: 10 
mM MOPS, 0.5 mM EDTA, 100 mM KCl, and pH 6.8. 
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Figure 16. UV melting profile of poly(dA)•poly(dT) at different rbd ratios of 
neomycin. (b) UV melting profile of poly(dA)•2poly(dT) at different pH values in 
the presence of neomycin at rbd ratios of 6.8. Buffer condtion: 10 mM sodium 
cacodylate, 0.5 mM EDTA, 100 mM KCl, and pH 5.5. 
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Figure 17. Immobilization of biotinylated T30 (t = 0) and subsequent duplex (t = 
2000 s) and triplex (t  = 2750 s) formation. All DNA concentrations were 2 
µM/strand. Running buffer and sample buffer: 40 mM Tris acetate, 5 mM MgCl2, 
and pH =7.0.  T = 20oC; Flow rate: 5 µl/min.   
 
 
Figure 18. Sample drug interaction with triplex formed on the chip. Running buffer 
and sample buffer: 40 mM Tris acetate, 5 mM MgCl2, and pH =7.0. T = 20 oC. Flow 
rate: 5 µl/min.   
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Figure 19. Global fits of neomycin (a), paromomyin (b) and ribostamycin (c) 
interactiong with bt-T30-A30 duplex by 1:1 langmiur model. The solid colorful lines 
are corresponding to experimental data and the black solid lines represent calculated 
data. 
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Figure 20. (a) DSC melting profile of poly(rA)•poly(rA) duplex. (b) UV melting 
profiles of RNA duplex in the absence (1) and presence (2) of neomycin at rbd of 6.5. 
(c,d) ITC titration of neomycin into poly(rA)•poly(rA) at 5 oC (c) and 10 oC (d). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 21. CD melting profiles of poly(U) in the absence (a) and presence (b) of 
neomycin at rbd of 8.5 at pH 6.8. (c) CD scan of poly(rU) at different temperatures at 
pH 6.8. (d) UV melting profile of poly(U) at pH 5.5. 10 mM sodium cacodylate, 100 
mM NaCl, 0.5 mM EDTA. 
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Figure 22. (a,b) DSC melting profiles of poly(dA)•poly(dT) in the absence (a) and 
presence (b) of neomycin at rbd of 9. (c) CD scans of neomycin titration with 
poly(dA)•poly(dT) duplex. The scan with solid circle is the one of DNA alone. The 
insert is the CD spectra of DNA alone (continuous line) and drug-saturated complex 
(dashed line). (d) A plot of CD signals at 247 nm vs. corresponding rbd values. The 
cross of two apparent linear portions reveals binding site sites. (e,f) ITC titration of 
neomycin into poly(dA)•poly(dT) at 10 oC (e) and 20 oC (f). Buffer: 10 mM sodium 
cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 23. (a,b) DSC melting profiles of poly(dA-dT)2 in the absence (a) and 
presence (b) of neomycin. (c) CD scans of neomycin titration with poly(dA-dT)2 
duplex. The scan with solid circle is the one of DNA alone. The insert is the CD 
spectra of DNA alone (continuous line) and drug-saturated complex (dashed line). 
(d) A plot of CD signals at 247 nm vs. corresponding rbd values. The cross of two 
apparent linear portions reveals binding site sites. (e,f) ITC titration of neomycin 
into poly(dA-dT)2 at 10 oC (e) and 20 oC (f). Buffer: 10 mM sodium cacodylate, 100 
mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 24. (a) DSC of poly(dA-dT)2 in the absence of neomycin. (b) UV melting 
profiles of duplex in the absence (1) and presence (2) of neomycin at rbd of 7.3. (c) 
CD scans of neomycin titration with poly(dA-dT)2 duplex. The insert is the CD 
spectra of DNA alone (continuous line) and drug-saturated complex (dashed line). (d) 
A plot of CD246 sgnals vs. rbd values. The cross of two apparent linear portions 
reveals binding site sites. (e,f) ITC of neomycin into poly(dA-dT)2 at 40 oC (e) and 
53 oC (f). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 25. DSC melting profiles of poly(dG-dC)2 in the absence (a) and presence (b) 
of neomycin. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 
6.8. 
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Figure 26. (a) An extended CD scan of poly(dG-dC)2 duplex from 350 nm to 200 
nm. (b,c) ITC titration of neomycin into poly(dA-dT)2 at 10 oC (b) and 20 oC (c). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 27. (a) DSC of calf thymus in the absence of neomycin. (b) UV melting 
profiles of duplex in the absence (1) and presence (2) of neomycin at rbd of 6. (c) CD 
scans of neomycin titration with calf thymus duplex. The insert is the CD spectra of 
DNA alone (continuous line) and drug-saturated complex (dashed line). (d) A plot of 
CD signals at 247 nm vs. corresponding rbd values. The cross of two apparent linear 
portions reveals binding site sites. (e,f) ITC of neomycin into DNA at 10 oC (e) and 
20 oC (f). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 28. (a)CD scans of neomycin titration with DNA duplex. The scan with solid 
circle is the one of DNA alone. The insert is the CD spectra of DNA alone 
(continuous line) and drug-saturated complex (dashed line).  (b A plot of CD signals 
at 270 nm vs. corresponding rbd values. The cross of two apparent linear portions 
reveals binding site sites. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. 
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Figure 29. (a,b) ITC titration of neomycin into DNA at 20 oC (a) and 30 oC (b). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
 
 224 
-0.6
-0.4
-0.2
0.0
10 20
Time (min)
µc
a
l/s
e
c
-10
-8
-6
-4
(a)
10
o
C
∆H = -7.2+0.1 kcal/mol
Molar Ratio
kc
a
l/m
ol
e
 
o
f i
n
jec
ta
n
t
 
-0.6
-0.4
-0.2
0.0
10 20
Time (min)
µc
a
l/s
e
c
2
-12
-10
-8
-6
(b)20
o
C
∆H = -9.5+0.2 kcl/mol
Molar Ratio
kc
a
l/m
o
le
 
o
f i
n
jec
ta
n
t
 
-0.5
0.0
10 20
Time (min)
µc
a
l/s
e
c
0.0 0.5 1.0 1.5
-14
-12
-10
(c)30
o
C
∆H=-11.88+0.07 kcal/mol
Molar Ratio
kc
a
l/m
ol
e 
o
f i
n
jec
ta
n
t
 
-12
-11
-10
-9
-8
-7
5 10 15 20 25 30 35
∆∆ ∆∆H
o
bs
 
(kc
al
/m
o
l)
T (oC)
∆Cp=-235+10cal/(mol.K)
(d)
 
Figure 30. ITC titration of neomycin into d(A2G15C15T2)2 at 10 oC (a), 20 oC (b), and 
30 oC (c). (d) A plot of observed binding enthalpy vs. temperature. Slope reveals the 
heat capacity changes. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. 
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Figure 31. (a,b) DSC melting profiles of poly(dA)•poly(rU) in the absence (a) and 
presence (b) of neomycin. (c) CD scans of neomycin titration with hybrid duplex. 
The scan with solid circle is the one of DNA alone. The insert is the CD spectra of 
hybrid alone (continuous line) and drug-saturated complex (dashed line). (d) A plot 
of CD signals at 261 nm vs. corresponding rbd values. The cross of two apparent 
linear portions reveals binding site sites. Buffer: 10 mM sodium cacodylate, 100 mM 
NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 32. ITC titration of neomycin into poly(dA)•poly(rU)
 
at 10 oC (a), 20 oC (b), 
and 30 oC (c). (d) A plot of observed binding enthalpy vs. temperature. Slope reveals 
the heat capacity changes. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. 
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Figure 33. (a) DSC of poly(dA)•poly(rU)
 
in the absence of neomycin. (b) UV of 
duplex in the absence (1) and presence (2) of neomycin at rbd of 6.5. (c) CD scans of 
neomycin titration with poly(dA)•poly(rU). The insert is the CD spectra of hybrid 
alone (continuous line) and drug-saturated complex (dashed line). (d) A plot of CD243 
vs. rbd values. The cross of two apparent linear portions reveals binding site sites. 
(e,f) ITC titration of neomycin into DNA at 10 oC (e) and 20 oC (f). Buffer: 10 mM 
sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 34. (a,b) DSC of poly(rA)•poly(dT) in the absence (a) and presence (b) of 
neomycin at rbd of 8. (c) CD scans of neomycin titration with hybrid duplex. CD 
scans of neomycin titration with poly(rA)•poly(dT). The insert is the CD spectra of 
hybrid alone (continuous line) and drug-saturated complex (dashed line). (d) A plot 
of CD260 vs. rbd values. The cross of two linear portions reveals binding site sites. (e) 
A plot of observed binding enthalpy vs. temperature. Slope reveals the heat capacity 
changes. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 35. (a) DSC melting profiles of poly(rA)•poly(dT)
 
in the absence of 
neomycin. (b) UV melting profiles of duplex in the absence (1) and presence (2) of 
neomycin at rbd of 8. (c,d) ITC titration of neomycin into DNA at 35 oC (c) and 45 oC 
(d). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 36. (a,b) DSC melting profiles of poly(rA)•poly(rU)
 
in the absence (a) and 
presence (b) of neomycin. (c) CD scans of neomycin titration with poly(rA)•poly(rU). 
The scan with solid circle is the one of RNA alone. The insert is the CD spectra of 
RNA alone (continuous line) and drug-saturated complex (dashed line). (d) A plot of 
CD signals at 243 nm vs. corresponding rbd values. The cross of two apparent linear 
portions reveals binding site sites. (e) A plot of ITC derived ∆H vs. temperatures. The 
slope is the heat capacity changes. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 
0.5 mM EDTA, pH 6.8. 
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Figure 37. (a) DSC of poly(rA)•poly(rU)
 
in the absence of neomycin. (b) Thermal 
stability of RNA induced by neomycin at rbd of 8. (c) CD scans of neomycin titration 
with poly(rA)•poly(rU). The insert is the CD spectra of RNA alone (continuous line) 
and drug-saturated complex (dashed line). (d) A plot of CD signals at 244 nm vs. 
corresponding rbd values. The cross of two apparent linear portions reveals binding 
site sites. (e,f) ITC of neomycin into DNA at 15 oC (e) and 20 oC (f). Buffer: 10 mM 
sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 38. (a) DSC melting profiles of 16S A site rRNA
 
in the absence of neomycin. 
(b) Thermal stability of A site rRNA induced by neomycin at rsd of 1 and 2. (c) CD 
scans of neomycin titration with rRNA. The scan with solid circle is the one of RNA 
alone. The insert is the CD spectra of RNA alone (continuous line) and drug-
saturated complex (dashed line). (d) A plot of CD signals at 210 nm vs. 
corresponding rbd values. The cross of two apparent linear portions reveals binding 
site sites. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 39. ITC titration of neomycin into 16S A site rRNA
 
at 10 oC (a), 20 oC (b) 
and 30 oC (c). (d) A plot of ITC derived ∆H vs. temperatures. Buffer: 10 mM sodium 
cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 40. (a,b) ITC titration of neomycin into 16S A site rRNA at 10 oC (e) and 20 
oC (f). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 41. (a) CD scans of neomycin titration with poly(dA)•2poly(dT). The scan 
with solid circle is the one of DNA alone. The insert is the CD spectra of DNA alone 
(continuous line) and drug-saturated complex (dashed line). (b) A plot of CD signals 
at 247 nm vs. corresponding rbd values. The cross of two apparent linear portions 
reveals binding site sites. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. 
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Figure 42. ITC titration of neomycin into poly(dA)•2poly(dT)
 
at 10 oC (a), 15 oC (b) 
and 18 oC (c). (d) A plot of ITC derived ∆H vs. temperatures. Buffer: 10 mM sodium 
cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 43. (a) CD scans of neomycin titration with DNA. The scan with solid circle 
is the one of DNA alone. The insert is the CD spectra of DNA alone (continuous 
line) and drug-saturated complex (dashed line). (b) A plot of CD signals at 246 nm 
vs. corresponding rbd values. The cross of two apparent linear portions reveals 
binding site sites. (c,d) ITC titration of neomycin into DNA at 5 oC (c) and 15 oC (d). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 44. (a) CD scans of neomycin titration with poly(rA)•2poly(rU). The scan 
with solid circle is the one of RNA alone. The insert is the CD spectra of RNA alone 
(continuous line) and drug-saturated complex (dashed line). (b) A plot of CD signals 
at 260 nm vs. corresponding rbd values. The cross of two apparent linear portions 
reveals binding site sites. (c) DSC melting profile of RNA triplex. (d) A plot of ITC 
derived ∆Hobs vs. temperatures. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 
0.5 mM EDTA, pH 6.8. 
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Figure 45. (a,b) ITC titration of neomycin into RNA at 15 oC (a) and 25 oC (b). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 46. (a) ITC titration of neomycin into d(T2G20T2)4. (b) DSC of d(T2G20T2)4. 
(c,d) ITC excess titration of neomycin into d(T2G20T2)4 at 10oC (c) and 20oC (d). (e) 
DSC of d(T2G20T2)4 with neo. (f) UV of tetraplex without (1) and with (2) neo at rbt 
of 3. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 47. (a) ITC titration of neomycin into d(T2G20T2)4. (b) DSC of d(T2G20T2)4. 
(c,d) ITC excess titration of neomycin into d(T2G20T2)4 at 10oC (c) and 20oC (d). 
Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 5.5. 
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Figure 48. ITC titration of neomycin into d(T2G20T2)4 tetraplex in 100mM Na+ (a), 
150 mM Na+ (b), and 200 mM Na+ (c). Buffer condition: 6 mM Na2HPO4, 2 mM 
NaH2PO4, 1 mM Na2EDTA, pH 7.0. T =20oC. In each curve, the upper panel is the 
raw titration curve, the bottom panel is the integrated data points and the red line is 
the result of data fitting with two binding sites model.  
 
 
 
 
 
 
 
 
 
 
 242 
Table 4. Thermodynamic profile of d(T2G20T2)4 tetraplex interaction with neomycin 
in 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, pH 7.0 and various Na+ 
concentrations. T=20oC. 
[Na+] 
mM 
Binding 
site 
n 
drug/tetraplex 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
First ~3.5 -5.0±0.1 5.9 -10.9 ±0.1 (1.3±0.3)×108 
100 
Second ~10 -9.0±0.1 -0.4 -8.6±0.1 (2.5±0.2)×106 
First ~2 -4.3±0.1 6.4 -10.7 ±0.1 (8.4±4.6)×107 
150 
Second ~12 -2.8±0.1 4.9 -7.7±0.1 (6.0±0.6)×105 
First ~2 -4.1±0.1 6.4 -10.5 ±0.1 (7.5±4.0)×107 
200 
Second ~15 -2.8±0.1 4.6 -7.4±0.1 (3.6±0.3)×105 
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Figure 49. (a) ITC titration of neomycin into G10T4G10. (b) DSC melting profile of 
G10T4G10 tetraplex. Buffer: 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, 150 
mM Na+, pH 7.0. T=20oC. 
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Table 5. Thermodynamic profile of G10T4G10 tetraplex interaction with neomycin in 
6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, 150 mM Na+, pH 7.0 . T=20 oC. 
[Na+] 
mM 
Binding 
site 
n 
drug/tetraplex 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
First ~2 -4.7±0.1 6.0 -10.7 ±0.1 (8.8±2.8)×107 
150 
Second ~12 -2.8±0.1 5.2 -8.0±0.1 (9.9±0.9)×105 
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Figure 50. (a) DSC of i-motif DNA in the absence of neomycin. (b) UV of DNA in 
the absence (1) and presence of (2) neomycin at rbd of 4. (c,d) ITC titration of 
neomycin into DNA at 10 oC (c) and 20 oC (d). Buffer: 10 mM sodium cacodylate, 
100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
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Figure 51. Comparison of binding site sizes obtained from ITC titration (top panel) 
and CD titration (bottom panel) for some selected sequences. Buffer: 10 mM sodium 
cacodylate, 100 mM NaCl, 0.5 mM EDTA, and pH 6.8. 
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Figure 52. (a,b) ITC titration of d(T2G20T2)4 interaction with neomycin (a) and 
fluorescein-neomycin (b) in 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, 100 
mM Na+, pH 7.0. (c,d) ITC titration of d(A2G15C15T2)2 with neomycin (c) and 
fluorescein-neomycin (d) in 10 mM sodium cacodylate buffer, 100 mM NaCl, pH 
6.8.T= 20 oC. 
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Table 6. Thermodynamic profiles of d(T2G20T2)4 interaction with neomycin and 
fluorescein-neomycin in 6 mM Na2HPO4, 2 mM NaH2PO4, 1 mM Na2EDTA, 100 mM 
Na+, pH 7.0 . T=20 oC. 
Binding site 
n 
drug/tetraplex 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
Fluorescein-neomycin 
First ~3 -3.0±0.8 5.9  -8.9 ±0.8 (4.6±2.0)×106 
Second ~10 -7.1±1.8 1.3 -8.4±1.8 (1.8±0.6)×106 
Neomycin 
First ~3.5 -5.0±0.1 5.9 -10.9 ±0.1 (1.3±0.3)×108 
Second ~10 -9.0±0.1 -0.4 -8.6±0.1 (2.5±0.2)×106 
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Table 7. Thermodynamic profile of d(A2G15C15T2)2 interaction with neomycin and 
fluorescein-neomycin in 10 mM sodium cacodylate,0.5 mM EDTA,100 mM NaCl, 
pH 6.8. T=20 oC.  
Fluorescein-neomycin 
Binding site 
n 
drug/tetraplex 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
First ~8 -11.5±0.1 -4.08  -7.4 ±0.1 (3.1±0.1)×105 
Neomycin 
Binding site 
n 
drug/tetraplex 
∆H 
kcal/mol 
T∆S 
kcal/mol 
∆G 
kcal/mol 
K 
M-1 
First ~3.1 -9.5±0.1 1.07 -10.6 (8.0±3.1)×107 
Second ~3.8 -8.6±0.3 -1.1 -7.5 (5.9±0.4)×105 
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Table 8. Dilution heat for neomycin interacting with each nucleic acid at different 
temperatures. The value listed after each nucleic acid is the neomycin concentration 
applied in the dilution experiment. Buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 100 mM NaCl and pH 6.8. 
Nucleic Acid ∆H(10
o
C) 
(kcal/mol) 
∆H(20oC) 
(kcal/mol) 
∆H(30oC) 
(kcal/mol) 
poly(rA) - - - 
poly(rU) - - - 
poly(dA-dT)•poly(dA-dT) 
(80 µM) -0.80±0.03 -0.70±0.06 - 
poly(dA)•poly(dT) 
(80 µM) -0.80±0.03 -0.70±0.06 - 
poly(dG-dC)•poly(dG-dC) 
(75 µM) -0.75±0.02 -0.60±0.03 - 
Calf thymus 
(90 µM) -0.70±0.15 -0.48±0.05 - 
d(A2G15C15T2)2  
(200 µM) -0.29±0.06 0.30±0.04 0.80±0.04 
poly(rA)•poly(dT) 
(150 µM) -0.55±0.02 -0.25±0.04 0.15±0.03 
poly(dA)•poly(rU) 
(100 µM) -0.70±0.12 -0.42±0.07 0.10±0.03 
poly(rA)•poly(rU)  
(150 µM) -0.55±0.02 -0.25±0.04 0.15±0.03 
16S A-site rRNA  
(100 µM) -0.70±0.12 -0.42±0.03 - 
poly(dA)•2poly(dT)a 
(80 µM) 
-0.80±0.03a 
(10 oC) 
-0.76±0.05a 
(15 oC) 
-0.72±0.03a     
(18 oC) 
poly(rA)•2poly(rU) 
(150 µM) -0.55±0.02 -0.25±0.04 0.15±0.03 
d(T2G20T2)4  
(250 µM) 0.14±0.04 0.36±0.02 - 
i-motif  
(80 µM) -0.80±0.03 -0.70±0.06 - 
a ITC titrations of neomycin with poly(dA)•2poly(dT) were operated at 10 oC, 15 oC 
and 18 oC which are below the Tm of  poly(dA)•2poly(dT)  triplex around 23 oC.  
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Table 9. Dilution heat for neomycin interacting with each nucleic acid at different 
temperatures. The value listed after each nucleic acid is the neomycin concentration 
applied in the dilution experiment. Buffer: 10 mM sodium cacodylate, 0.5 mM 
EDTA, 100 mM NaCl and pH 5.5. 
Nucleic Acid ∆H(T1) (kcal/mol) 
∆H(T2) 
(kcal/mol) 
poly(rA-rA)  
(150 µM) -0.46±0.01 (5 
oC) -0.47±0.03 (10 oC) 
poly(dA-dT)•poly(dA-dT) 
(200 µM) 0.15±0.03 (40 
oC) 1.02±0.13 (53 oC) 
d(A2G15C15T2)2  
(400 µM) -0.14±0.01 (20 
oC) 0.17±0.03 (30 oC) 
poly(rA)•poly(dT)  
(150 µM) 0.07±0.02 (35 
oC) 0.36±0.15 (45 oC) 
poly(dA)•poly(rU)  
(100 µM) -0.88±0.03 (15 
oC) 0.45±0.03 (20 oC) 
poly(rA)•poly(rU)  
(150 µM) -0.42±0.02 (15 
oC) -0.20±0.03 (25 oC) 
16S A-site rRNA  
(80 µM) -0.92±0.08 (10 
oC) -0.61±0.05 (20 oC) 
poly(dA)•2poly(dT) 
(25 µM) -1.35±0.13 (5 
oC) -1.09±0.06 (15 oC) 
poly(rA)•2poly(rU)  
(150 µM) -0.42±0.02 (15 
oC) -0.20±0.03 (25 oC) 
d(T2G20T2)4  
 (200 µM) -0.43±0.01 (10 
oC) -0.30±0.02 (20 oC) 
Note: ITC temperatures were selected about 10 ~ 20 oC below the melting temperature 
of nucleic acid. 
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Figure 53. ITC dilution titration of neomycin into poly(dA)•poly(dT) buffer at 10 oC 
and 20 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
[neomycin]=80 µM. 
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Figure 54. ITC dilution titration of neomycin into poly(dA-dT)•poly(dA-dT) buffer at 
40 oC  and 53 oC (f). Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 5.5. [neomycin]=200 µM. 
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Figure 55. ITC dilution titration of neomycin into poly(dG-dC)•poly(dG-dC) buffer 
at 10 oC and 20 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. [neomycin]=75 µM. 
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Figure 56. ITC dilution titration of neomycin into d(A2G15C15T2)2buffer at 10 oC , 20 
oC and 30 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 
6.8. [neomycin]=200 µM. 
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Figure 57. ITC dilution titration of neomycin into poly(dA)•poly(rU) buffer at 10 oC 
, 20 oC and 30 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, 
pH 6.8. [neomycin]=100 µM. 
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Figure 58. ITC dilution titration of neomycin into poly(rA)•poly(dT) buffer at 10 oC, 
20oC and 30 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, 
pH 6.8. [neomycin]=150 µM. 
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Figure 59. ITC dilution titration of neomycin into poly(rA)•poly(dT) buffer at 35 oC  
and 45 oC . Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 
5.5. [neomycin]=150 µM. 
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Figure 60. ITC dilution titration of neomycin into poly(rA)•poly(rU) buffer at 10 oC, 
20 oC and 30 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, 
pH 6.8. [neomycin]=200 µM. 
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Figure 61. ITC dilution titration of neomycin into 16S A-site rRNA buffer at 10 oC 
and 20 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 
6.8. [neomycin]=100 µM. 
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Figure 62. ITC dilution titration of neomycin into poly(dA)•2poy(dT) buffer at 
10 oC and 18 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM 
EDTA, pH 6.8. [neomycin]=80 µM. 
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Figure 63. ITC dilution titration of neomycin into poly(dA)•2poy(dT) buffer at 5 oC 
and 15 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 
5.5. [neomycin]=25 µM. 
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Figure 64. ITC dilution titration of neomycin into d(T2G20T2)4 buffer at 10 oC and 
20 oC. Buffer: 10 mM sodium cacodylate, 100 mM NaCl, 0.5 mM EDTA, pH 6.8. 
[neomycin]=250 µM. 
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